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Abstract 
Recent advances in single-cell technologies have permitted the investigation of 
heterogeneous cell populations at previously unattainable resolution. In this thesis 
single-cell approaches are applied to resolve the molecular mechanisms driving disease 
in mouse haematopoietic stem cells (HSCs), using JAK2 V617F mutant 
myeloproliferative neoplasms (MPNs) as a model. This study utilises single-cell gene 
expression and functional assays to identify a subset of JAK2 V617F mutant HSCs that 
display defective self-renewal. This defect is rescued by crossing JAK2 V617F mice 
with mice lacking TET2, the most commonly co-mutated gene in patients with MPN. 
Single-cell gene expression profiling of JAK2 V617F-mutant HSCs revealed reduced 
expression of specific self-renewal regulator genes, some of which were restored to 
normal levels in single TET2/JAK2 mutant HSCs. Of these, Bmi1 and, to a lesser 
extent, Pbx1 and Meis1 overexpression in JAK2-mutant HSCs could improve stem cell 
self-renewal, allowing development of a disease phenotype in functional assays. 
Together, these findings refine the molecules involved in clonal expansion of MPNs, 
and highlight the power of single cell approaches in deconstructing the functional 
characteristics and molecular network of normal and malignant stem cells. 
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1.1 Haematopoiesis and HSCs 
Blood is a complex and multifaceted tissue: circulating through the body, it transports 
oxygen, nutrients and hormones; removes waste; regulates body temperature and pH; 
and provides a crucial defence from pathogens, viruses and injury. The blood is made 
up of an aqueous component (plasma), and a cellular component; the cellular 
component of blood contains a diverse array of cell types which reflect the blood’s 
many functions. For example, erythrocytes carry oxygen to, and carbon dioxide from, 
tissues. Platelets play a key role in blood clotting in response to vessel damage. B and 
T lymphoid cells are the primary players in the adaptive immune system responsible 
for acquired defence against pathogens. While the innate immune system – 
encompassing lymphoid cells such as natural killer and mast cells, and phagocytic cells 
such as macrophages and neutrophils – is involved in non-specific pathogen defence.1  
 
A sufficient number and balance of each blood cell type needs to be maintained to 
efficiently fulfil the blood’s numerous functions. However, as the mature cells of the 
blood have relatively short life spans,1 and cannot self-renew, they need to be 
continually replaced by more potent progenitor cells. The process of blood cell 
production is termed haematopoiesis, and it begins with the haematopoietic stem cell 
(HSC). HSCs are a rare cell population that sit at the top of the haematopoietic 
hierarchy, the most potent cell in the blood. HSCs are defined by two fundamental 
characteristics: the ability to differentiate into multiple mature blood cell lineages (via 
a series of progenitors and substantial amplification in cell number), and the ability to 
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self-renew to create equally potent daughter HSCs, to sustain the population of 
immature multipotent stem cells. As a population, HSCs must undergo a number of fate 
decisions on a cell-by-cell basis, such as whether or not to self-renew or differentiate, 
divide by symmetric or asymmetric division, or to undergo cell death. All of these fate 
decisions are coordinated by molecular changes and are balanced within the population 
of HSCs to ensure equilibrium between all mature blood lineages and a sufficient 
population of HSCs to sustain haematopoiesis for the lifetime of the organism.2  
 
Understanding the haematopoietic system has been a longstanding goal of the scientific 
and medical community for several reasons. Firstly, the use of blood and blood 
fractions, like platelets, plasma or red blood cells, are in common use in the clinical 
setting, for example for blood transfusions in surgery or after childbirth, or treatment 
of anaemias, cancer and blood disorders. The current source of blood and blood 
fractions is from healthy volunteer donors and is often insufficient for the demand. HSC 
transplantation is the only curative option for many diseases, but the availability of 
donor HSCs is limited. The ability to generate these products in vitro would allow for 
a larger and more homogenous source of blood cells, which could be generated to fit 
demand and tailored to the required cell and histocompatibility types. Likewise, by 
gaining a deeper understanding of blood diseases such as leukaemia, new therapies 
could be generated, either for diseases that respond poorly to current therapies, or to 
replace therapies that are poorly tolerated in patients. Finally, by understanding how 
the blood carries out its functions, like immune control, blood cells could be 
manipulated to allow new and highly specific therapies, such as chimeric antigen 
receptor T (CAR-T) cells.3 By understanding HSCs more fully, and especially the 
process by which they self-renew, options such as expansion for transplantation and 
gene therapy could become a real clinical option.  
 
 1.2 Identification of HSCs 
The HSC was first alluded to experimentally during studies on the effects of ionizing 
radiation. Jacobsen et al. (1949) found that shielding the spleen (or femur) of mice with 
lead protected them from the lethality of irradiation.4 This led Lorenz et al. (1951) to 
discover that transplantation of bone marrow (BM) post-irradiation could protect 
against irradiation lethality.5 It was revealed that this protection was due to cells (rather 
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than injection stimulation), by Barnes and Loutit (1954)6, and Main and Prehn (1955),7 
thereby setting the stage for the study of the cells of the BM. 
 
Till and McCulloch made the first functional description of the haematopoietic stem 
cell – the first adult stem cell functionally demonstrated to exist – in 1961.8 They 
discovered that when BM is transplanted from one mouse to an irradiated recipient 
‘nodules’ of rapidly dividing haematopoietic tissue appeared on the spleen. Mature cells 
could be identified within these nodules and some colonies contained multiple lineages. 
The authors found that the number of nodules that appeared on the spleen was directly 
proportional to the number of cells transplanted and referred to these cells with the 
capacity to produce colonies as colony-forming units – spleen (CFU-S).8 These 
colonies were proven to be of single cell origin by inducing mutations in the initiating 
cells via low level irradiation and studying the karyotype of the resulting colonies.9 The 
full capacity of a single HSC - completely on its own -  to repopulate a mouse was 
recognised in 1996 when the first single cell transplantations of functional HSCs was 
published,10 formally demonstrating that a single cell (CD34-/low, c-Kit+, Sca1+, Lin-) 
could successfully repopulate the BM of 21% of recipients, with reconstitution in the 
lymphoid and myeloid compartment in 85% of successful transplants. 
 
Following the early HSC experiments of the 1960s, focus moved quickly to isolating 
these cells, to permit the unique and defining characteristics of HSCs to be studied. 
Isolation strategies ranged across research groups, with some opting to isolate HSCs 
based on their functional properties, for example Rhodamine 12311 or Hoescht 33342 
dye exclusion,12 resistance to 5-fluorouracil,13 or resistance to gamma-irradiation.14 
Others sought to isolate stem cells based upon various antibodies binding to cell surface 
proteins. Neither antibody binding nor dye exclusion methods for HSC isolation would 
have been possible without the popularisation of fluorescence activated cell sorting. 
The first HSC sorting strategy that utilised cell surface marker properties was published 
by Visser et al. (1984).15 This group first performed density gradient centrifugation and 
sorted the low-density cells for WGA (wheat germ agglutinin) binding positivity, then 
resorted for high expression of H-2K (histocompatibility antigen). When assessed in a 
CFU-S assay the group reported an 135 fold enrichment of HSCs over non-purified 
BM.  
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In 1988 Spangrude, Heimfield and Weissman16 improved upon the HSC sorting 
strategy. By isolating Lin-Thy1loSca1+ cells the group were able to increase the 
efficiency of spleen or thymic colony formation by 1000-fold over non-purified BM.16 
Subsequently a number of additional HSC and progenitor markers have been identified 
the most notable of which being c-Kit,17 Endothelial protein C receptor (EPCR),18 
cluster of differentiation (CD)49b,19 the SLAM markers20 and CD34/Flk2.21 A number 
of different flow cytometric sorting strategies have been developed allowing the 
isolation of populations from fresh BM of young adult mice with HSC frequencies of 
>50%.20,22–25 Currently techniques like index sorting are being used to refine these 
sorting strategies further to obtain even higher HSC purities; flow cytometric index 
sorting records the fluorescence intensity of each immunophenotypic marker, thereby 
allowing the retrospective coupling of markers and functional output. This has been 
combined with single cell functional in vitro26 and in vivo27 assays to refine the 
effectiveness of sort panels. 
 
Index sorting is also used in the refinement of human HSCs sorting panels,28 which 
remain less well optimised that murine HSC isolation. Currently the best human HSC 
sorting strategy isolates HSCs at a frequency of ~1 in 10 from cord blood (with lower 
frequencies in BM and peripheral blood).29 This, in combination with the variability 
between human individuals’ genetic, clinical and lifestyle factors, and mutation status 
varying between cells, mean that mouse models continue to be heavily relied upon for 
the study of HSC biology.  
 
1.3 The changing properties of HSCs 
1.3.1 HSCs throughout life   
In mice, HSCs can first be detected at embryonic day (E)10.5 in the aorta-gonads-
mesonephros (AGM) and aorta associated vessels (vitelline vessels and umbilical 
vessels).30 HSCs form in the AGM from a specialised endothelium on the ventral side 
of the dorsal aorta called the haemogenic endothelium, in a process termed endothelial-
to-haematopoietic transition.30 The AGM is the site of de novo HSC production in the 
developing embryo, but it is not the site of HSC expansion or differentiation. The 
primary site of HSC expansion and differentiation in the developing foetus is the foetal 
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liver (FL). As soon as HSCs emerge, they colonise this site, before migrating to the BM 
prior to birth.31 
 
The properties of HSCs in the FL differ from those of the adult BM in their proliferation 
rate, self-renewal capacity and lineage output. Foetal HSCs are in active cell cycle and 
have a substantially increased capacity for self-renewal compared to adult HSCs, a trait 
that persists until 3-4 weeks after birth when a more quiescent adult phenotype is 
established.32 The foetal HSC properties of increased proliferation rate and increased 
self-renewal capacity are the same properties that must be activated for clonal 
expansion in the cancer setting, it is therefore understandable that some of the molecular 
regulators involved in developing HSCs have also been implicated in cancer, some of 
these will be discussed later (in section 1.4.2). 
 
During adult life it is important for the HSC population to maintain a balance between 
differentiation and self-renewal. Excessive differentiation or defective self-renewal 
leads to depletion of the HSC pool, whereas unrestrained self-renewal or lack of 
differentiation can result in cancer. Control of this delicate balance is regulated by a 
number of intrinsic factors (e.g. transcription factors and epigenetic regulators) and 
extrinsic factors (e.g. BM microenvironment: cytokines, cell:cell interactions etc).33  
 
With age the balance between differentiation and self-renewal becomes is disrupted, 
leading to a decline in regenerative capacity.34 In mouse, two major changes occur with 
age in the haematopoietic system: depletion of the stem cell pool, and lineage skewing 
of HSC progeny. As mice age the number of phenotypic HSCs increases,35–37 however 
the long-term functional capacity of these cells, as measured by serial transplantation, 
decreases.35,36 With regard to lineage output, in young mice a strict balance of cell types 
is maintained, however aged mouse HSCs tend to have a myeloid bias due to a reduced 
capacity to give rise to lymphoid cells.36,38 
 
Numerous factors have been suggested as the cause of stem cell aging, such as genetic 
mutations, epigenetic changes, and changes in the microenvironment and stem cell 
niche.37 The majority of the aged phenotype has been linked to intrinsic cell changes,39 
as demonstrated when aged HSCs are transplanted into a young microenvironment 
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resulting in expansion of the HSC population and reduced lymphoid capacity in young 
recipients.40 
 
With the reduction in HSC self-renewal that aging brings, and the subsequent 
exhaustion of clones, the diversity of clones within the stem cell compartment 
decreases. This reduction in polyclonality has been observed though viral barcoding of 
HSCs; ‘tagging’ HSCs with a genetic barcode which is passed on to all the cells 
progeny, allowing the clonal dynamics of the stem cell compartment to be observed. 
This approach has shown that if young cells are transplanted and followed over time, 
grafts begin as very polyclonal but progressively decrease in the number of clones 
contributing to blood production as the mice age.41 Barcoded tracking also highlights 
the heterogeneity of the HSC population in terms of cellular output, time to 
contribution, length of clone life, and number of cells produced.  
1.3.2 Clonal Haematopoiesis  
Defining a clone is a difficult task; with “a population of cells of single cell origin” 
representing a common definition. However, this could in fact refer to every organism 
- emerging from the single cell that is the fertilised egg.42 In the cancer setting it is 
somewhat easier to define the clone where all cells share the same genetic aberration 
that was acquired in a single cell. Similarly, a clone is easily defined in cellular 
barcoding studies where a single cell is infected with a unique barcode. In the normal 
haematopoietic setting, as HSCs give rise, though significant progenitor amplification, 
to large numbers of mature cells, HSC “clones” are often referred to as the progeny of 
an HSC. These clones are very hard to define due to the fact that HSCs are giving rise 
to more HSCs and clones form inside clones, the line between these clones is 
impossible to draw. Clonal haematopoiesis refers to the relative over-representation of 
one clone within the mature cell output.  
 
Clonal haematopoiesis can occur as a result of neutral drift; random chance leading to 
the expansion or exhaustion of clones. A analogy can be drawn between the expansion 
or disappearance of haematopoietic clones and family surnames in Western cultures 
where children retain the male surname; if one assumes an even distribution of family 
names within a town, through chance, some families will have sons carrying on the 
family names, others will have daughters who give up their family name. Over time 
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some family names will expand while others will diminish or disappear altogether 
without any sort of “selective pressure”. The same is true of haematopoietic clones; the 
balance between differentiation and self-renewal will cause some clones to expand over 
time while others decrease in size, this is not due to outcompeting of one clone over 
another but neutral drift. However positive selection, and not neutral drift, has been 
shown to be the major driving force in clonal haematopoiesis,43 there are a number of 
ways in which a clone can make up a larger proportion of the haematopoietic 
compartment beyond the levels of neutral drift (Figure 1)44; 
 
1. The clone expands.  
If a clone gains an advantage that results in the dramatic growth the clone, leaving the 
rest of the haematopoietic cells unaffected, the overall size of the population is 
increased, the clone making up a large proportion of the population. The clone has not 
compromised the fitness of other clones but established its proportion of the 
haematopoietic population by expanding the population size.  
 
2. The clone outcompetes the other HSCs.  
The population size of the haematopoietic population remains stable but an increasing 
proportion of it is made up of the clone as it outcompetes and displaces the other HSCs. 
It is important to remember that in this case the clone only needs to be more competitive 
than the other HSCs, in the case of aging HSC are less competitive and therefore a 
mutation that may be insufficient to outcompete young HSCs may be sufficient to 
outcompete aged HSCs.  
 
3. Population decrease.  
With aging HSCs become less competitive and the population size decreases. With the 
reduction in size of other clones, one clone can take up an increasing amount of the 
haematopoietic space. This clone may not have any particular advantage, but as a 
consequence of decreasing population size it artificially appears to grow.  
 
The presence of clonal haematopoiesis in human individuals increases with age; in 
individuals under 50 only 1% have clonal haematopoiesis as measured by whole exome 
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sequencing, however, in individuals over 65 10% have observable clonal 
haematopoiesis.45 Certain mutations, commonly found in myeloid malignancies, are 
associated with clonal haematopoiesis without clinical features, these mutations 
provide an advantage to the clone, allowing clonal expansion46. Age-related clonal 
haematopoiesis (ARCH) is defined as the expansion of HSPC clones, harbouring 
specific disruptive genetic variants, in individuals without a diagnosis of 
haematological malignancies.47  The most commonly mutated genes in ARCH are 
DNMT3A, ASXL1, TET2, JAK2, PPM1D, and SF3B1.45 (DNMT3A, ASXL1, TET2, and 
 
Figure 1 Means of acquiring clonal haematopoiesis. 
As clonal haematopoiesis is measured as a proportion of the overall haematopoietic 
stem cell clone population there are a number of ways in which clonal haematopoiesis 
can occur; the clone can expand enlarging the population size, the clone can 
outcompete other clones keeping a stable population size, or the population itself can 
shrink.  
Expansion of clone (increasing population size)
Clone outcompeting (stable popultation size)
Normal population decrease (shrinking popultation size)
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JAK2 are also commonly mutated in myeloproliferative neoplasms (MPNs) and are 
covered in sections 1.10.1 and 1.10.2.) The majority of individuals with ARCH do not 
go on to develop any clinical features, however ARCH does increase the risk of 
developing myelodysplastic syndrome (MDS) and other blood cancers, as well as the 
increased risk of heart disease. 
 
1.4 Molecular regulators of HSCs   
1.4.1 Gene expression assays 
Many approaches have been taken to try to discover what underpins stem-cell self-
renewal, including extensive molecular profiling, and murine mutation 
characterisation. Gene expression analysis has made up a large proportion of these 
studies. In the cell, active genes are transcribed to produce messenger ribonucleic acid 
(mRNA), by measuring mRNA level a picture of the ‘future proteome’ can be 
generated, giving insight into cellular functions and processes. In malignancy, 
molecular profiling allows the effects of specific mutations to be determined and 
mechanisms of action, leading to disease, to be hypothesised.  
 
The first widely used method of studying gene expression of multiple genes 
simultaneously was gene expression microarrays. Microarray chips have a number of 
microscopic spots containing nucleic acid probes specific to the mRNAs of interest. To 
determine the presence of specific mRNAs of interest, sample mRNAs are extracted, 
converted to complementary deoxyribonucleic acid (cDNA) by reverse transcription, 
and fluorescently labelled, when they hybridise to the target spots they fluoresce which 
can be detected by an imaging step that measures relative signal to noise. However, this 
technology lacks the ability to be reliably scaled to the single cell level, it is only 
suitable for use on bulk samples. For a more sensitive and specific approach, 
researchers turned to multiplexed quantitative Polymerase Chain Reaction (qPCR). By 
using targeted amplification of specific genes smaller starting amounts of mRNA can 
be used.  
 
The development of microfluidic technology allowed the miniaturisation of the reaction 
to nL volumes to generate gene expression profiles of a set number of target genes in 
small cell numbers (including at the single cell level). Generally, these technologies use 
  Introduction  
 24 
sequence specific reporter probes which have a fluorophore bound at one end and 
quencher at the other. While the quencher is in close proximity the fluorophore will not 
fluoresce, but when polymerisation of the new strand degrades the probe and liberates 
the fluorophore from the quencher, it does fluoresce. This fluorescence can be measured 
by the real-time PCR machine and related to the quantity of mRNA in the sample. The 
most commonly used commercial technologies for these applications is the Fluidigm 
integrated fluidics chip (IFC) and the Biomark analyser.  
 
A more recently developed method for assessing gene expression is RNA sequencing 
(RNAseq). As with microarrays cDNAs are generated from the sample mRNAs, but 
instead of hybridising to probes, RNAseq uses next generation sequencing to sequence 
the nucleic acids of the cDNAs rather than look for specific genes of interest. The 
benefits of RNAseq over microarray and qPCR-based approaches include not biasing 
sampling by looking for specific genes and being able to detect subtle changes in gene 
sequences like single nucleotide polymorphisms, gene fusions and splice variants. 
However, when looking for expression of specific genes with low expression levels, 
for example transcription factors, qPCR based systems are more sensitive as RNAseq 
approaches often have high dropout rates for genes with low levels of expression.48 
qPCR also allows the analysing of a greater number of biological samples at a 
substantially lower cost, although recent advances in droplet sequencing technology 
(e.g. 10X genomics) has lowered the costs of RNAseq even further, although this comes 
at the expense of sequencing depth and transcriptome coverage per cell. 
 
As qPCR and RNAseq both measure mRNA presence to report gene expression, they 
share the same disadvantages. As the cellular transcriptome is continually changing, 
and RNA is taken at a snapshot in time, temporal events can be missed, leaving a 2D 
image of gene expression. Additionally, not all mRNA is translated to protein, and it is 
impossible to determine which mRNAs would meet alternate fates e.g. degradation. It 
is also important when examining gene expression data to correlate findings with 
functional data, i.e. do the functional properties of the cell differ with varying gene 
expression? By combining gene expression with functional assessment of mutant HSCs 
the molecular mechanisms driving malignancy can be resolved.  
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 1.4.2 Key genes in HSCs 
Maintaining HSC quiescence is a combination of repressing differentiation and division 
while also actively promoting the hibernating state (avoiding apoptosis, maintaining 
multilineage capacity, avoiding differentiation, drug efflux etc.). Differentiation and 
division are multifactorial processes that require precise spatial and temporal control of 
expression of a myriad of genes. It is therefore unsurprising that many genes associated 
with regulation of HSCs are involved with gene expression control, these can be 
broadly categorised into transcription factors, epigenetic regulators, chromatin 
regulators. 
 
Transcription factors influence gene expression by directly binding and influencing the 
activation or repression of genes. Epigenetic regulators cause transcriptional changes 
by modifications to the DNA structure, for example methylation of cytosine bases, this 
alters the accessibility of promoters for transcription factors. Chromatin is the complex 
of DNA wrapped around histones. Chromatin regulators modify histones by 
methylation, acetylation, phosphorylation, or ubiquitination to alter the condensation 
of chromatin into a more accessibility open (active) or closed (inactive) state. Histone 
modifications affect interactions between histone subunits and with non-histone 
proteins. Generally, methylation is associated with a closed state while acetylation is 
associated with a more active state.49  
 
Given the complex and interconnected network of genes involved in maintaining HSC 
self-renewal it is impossible to catalogue all of the genes involved, but the summary 
table below (Table 1) gives an overview of 45 key self-renewal genes with strong 
functional data or association with malignancy.  
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Gene  Function Family/complex/ 
interactions  





Loss of BMI1 induces a defect in self-renewal, while over-
expression promotes self-renewal.  
Overexpression correlates with poor 
prognosis in MDS, AML, CML, ALL, 






Knock-out mice show that BPTF is essential for maintaining the 
HSPC populations and their repopulating capacity 










Corepressor in complex 
with TAL1 
Enhances the expression of self-renewal and survival genes while 
reducing the expression of growth arrest and pro-inflammatory 
genes 





Overexpression increases multi-lineage long term engraftment. 
Repression in AML cells results in terminal differentiation 




p19Arf )  
Mediates cell cycle 
arrest and apoptosis 
Retinoblastoma p53 
pathways. Expression 
repressed by BMI1. 
Individually deletion of p19Arf or p16Ink4a does not alter HSC 
engraftment or repopulation when transplanted, but triple knock-
out of p16Ink4a, p19Arf and p53 have a 10-fold increase in cells able 
to reconstitute the blood long term. 
Common in non-haem cancers including 
skin, lung and colorectal  
58–60 
Csf1r Colony stimulating 





platelet derived growth 
factor family 
M-CSF, a myeloid cytokine released during infection and 
inflammation, can directly induce the myeloid master regulator 
PU.1 and instruct myeloid cell fate change in HSC, independently 
of selective survival or proliferation 
Therapeutic target in AML  61–63 
 
Dnmt3a DNA methylation de novo DNA 
methyltransferases 
Loss of DNMT3A increases self-renewal, HSCs can be serially 
transplanted up to 12 times (normal 4), differentiation block  
Mutated in AML, MPN, MDS 64,65 
 
Egfl7 Interacts with 
b3integrin to 




EGFL7 induces HSCs to enter cell cycle and undergo myelo-
megakaryocytic differentiation  
Increased expression in AML  66,67 
Erg TF ETS family of TFs Loss or ERG accelerates differentiation, leading to depletion of 
HSCs 
Frequently overexpressed (and associated 
with poor outcome) in AML and T-ALL  
68  
Ezh2 Histone methylation 
and deacetylation 
PRC2 complex Overexpression causes increased HSC self-renewal (serial 
transplantation of does not exhaust) 
Mutated in AML, MDS, MPN 69  
Fli1 TF ETS family of TFs. Essential in haematopoietic development. FLI1 knock-out BM 
transplantation recipients have reduced chimerism compared with 
WT.  
High expression in AML is an adverse 
prognostic factor. 
70–72 
Foxo3a TF Downstream of the 
PTEN/PI3K/AKT 
pathway 
FOXO3A knock-out mice have reduced numbers of HSC, these 
HSCs are less competitive by long-term transplantation. 
High expression associated with poor 
prognosis in AML 
 
73,74 
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Gata1 TF GATA family of TFs Overexpression causes loss of self-renewal in HSCs and pushes 
erythroid/megakaryocyte differentiation.  
Not normally expressed in HSCs. 
Mutations in Diamond-Blackfan anemia, 
acute megakaryoblastic leukaemia, 
transient myeloproliferative disorder 
75,76 
 
Gata2 TF GATA family of TFs. 
 
Required for HSC generation in the AGM and continues to be 
required for HSC survival. 
Mutations in MDS, AML, and in blast 
crisis transformation of CML 
76,77 
Gata3 TF GATA family of TFs Required for the maintenance of a normal number of HSCs and for 
their entry into the cell cycle 
required for T-cell development  




Gfi1 Recruitment of 
histone deacetylases 
and (de)methylases 
Zinc finger protein Represses the expression of genes implicated in cell survival, 
proliferation and differentiation. Restrains proliferation of HSCs 
and thereby regulates their self-renewal. GFI1 knock-out mouse 
has reduced number of HSCs and impaired competitiveness when 
transplanted. 
Low expression is associated with poor 
prognosis in AML patients  
80–82 
Gfi1b Recruitment of 
histone deacetylases 
and (de)methylases 
Zinc finger protein Essential for megakaryopoiesis and erythropoiesis 
Loss of Gfi1b increases the frequency of HSCs in BM, still able to 
self-renew but no longer quiescent  
Role in CML (Gfi1b silencing inhibits 
imatinib-induced apoptosis). High 




Hhex Loss of HHEX 
leads to expression 
of Cdkn2a 
Interacts with PRC2 Dispensable for maintenance of HSCs and myeloid lineages but 
essential for the commitment of common lymphoid progenitors to 
lymphoid lineages 
Overexpressed in AML 85,86 
Hoxa5 TF Hox family Involved in cell cycle control. Overexpression pushes erythroid 
differentiation and reduction in HSC population size. The 
remaining HSCs still have self-renewal and multilineage 
differentiation capacity.  
Suppressed in AML 87 
Hoxa9 TF Hox family. Interacts with 
MEIS1 and PBX1 
Over expression of HOXA9 leads to expansion of HSCs and early 
progenitors, leading to myeloproliferative phenotypes in mice. 
Cannot progress to AML without increased expression of cofactors 
e.g. MEIS1/PBX1 
Overexpressed in over 50% of AMLs and 




Hoxb4 TF Hox family Strong positive regulator of HSC self-renewal. Overexpression 
leads to HSC population expansion. 
Higher HOXB4 expression linked with 
better prognosis in AML  
89,90 
Ikzf1 TF Zinc finger Involved in the early lymphoid development and in governing the 
developmental pathway of lymphoid or myeloid lineage from 
multipotent progenitors 
Mutated in ALL and CML 91 
Itga2b (aka 
CD41) 
Integrin subunit of receptor 
complex integrin aIIbb3 
Up regulated during megakaryopoiesis. CD41 has been reported to 
mark myeloid and megakaryocyte progenitors within the HSC 
compartment.  
Mutated in blood clotting disorder 







tyrosine kinase  
SCF receptor  Cell surface marker for HSCs. Mutant (W41) have reduced HSC 
competitiveness and number  
Activation mutations are associated with 
sporadic adult human mastocytosis and 
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Lmo2 Transcriptional co 
factor 
TAL1/LMO2/LDB1 
complex. Also bind 
LYL1. 
Essential role in HSC development. Lmo2−/− mice die at E10.5 due 
to the lack of erythropoiesis. 
Frequently deregulated gene in human T-
ALL, overexpressed caused by diverse 




Lyl1 TF Basic-helix-loop-helix 
TFs. Like TAL1. Binds 
LMO1 and 2 and E2A 
LYL1 is essential for maintaining normal HSC function in the 
absence of SCL. 
Translocation reported in T-ALL.  









Evi1 zinc finger 
proteins 
 
Acts via PU.1 to push 
HSPCs towards the 
myeloid lineage 
EVI1 knock-out results in the absence of functional haematopoietic 
precursors in embryos. ME-deficient mice lack quiescent, long-
term repopulating cells. EVI1 overexpression expands HSC 
population, suppresses erythropoiesis and lymphopoiesis, and 
creates a myeloid-skewed phenotype. 




Meis1 Hox cofactor Interacts with PBX1 and 
HOXA9 
Required for the maintenance of haematopoiesis under stress and 
over the long term. MEIS1 knock-out mice contained significantly 
fewer numbers of long-term HSCs, which exhibit loss of 
quiescence. MEIS1 knock-out HSCs have reduced colony 
formation capacity. 
Transcriptional target of MLL-fusion 
proteins and in cytogenetically normal 
AML MEIS1 expression is associated 
with poor prognosis.  
101–
103 
Mitf TF Basic-helix-loop-helix TF Controls expression of c-Kit (knock-out loss of c-Kit expression). 
Involved in mast cell differentiation. 
Highly expressed in systemic 




Mpl Cell surface 
cytokine receptor 
THPO receptor MPL is a key regulator of megakaryopoiesis and platelet 
production. Essential role in the early steps of adult 
haematopoiesis, MPL knock-out are unable to compete with 
normal marrow for long-term haematopoietic repopulation 
Mutated in MPNs 106 
Myb TF MYB family In mice knock-out of cMYB causes depletion of HSC pool & 
reduced self-renewal. Also required for thymocyte and B-cell 
development, myelopoiesis and erythropoiesis.  
Translocations in Infant acute basophilic 
leukaemia, and T-ALL. Overexpression 
in AML, ALL, and T-ALL 
107,108 
Nfe2 TF nuclear factor erythroid-
derived 2 (NF-E2) 
(Erythroid transcription 
activator), composed of a 
heterodimer of NFE2 and 
MAFK 
Involved in megakaryocyte and platelet production. Knock-down 
of NF-E2 in HSPCs reduces the formation of megakaryocytes, also 
impairs HSC activity, decreasing engraftment. In mice over 
expression of NF-E2 in vivo causes an MPN phenotype  
Truncation mutations reported in MPNs 
although rare (∼2% of cases) 
109,110 
Pbx1 Hox cofactor Interacts with MEIS1 and 
HOXA9. alters HOX-
DNA binding and 
therefore alters 
transcription 
Conditional inactivation of PBX1 in the haematopoietic 
compartment results in a progressive loss of HSCs that is 
associated with concomitant reduction in their quiescence, leading 
to a defect in the maintenance of self-renewal as assessed by serial 
transplantation. 
Chromosomal translocation causing 
constitutive expression of PBX1 is 
associated with pre-B-cell ALL  
111 
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Prdm16 TF Repressed by HOXB4 but 
upregulated by HOXA9 
and HOXA10 
Critical for the establishment and maintenance of the HSC pool 
during development and after transplantation. PRDM16 deletion 
enhances apoptosis and cycling of HSCs. 








Endothelial protein C 
receptor 
Well established HSC marker. A role has been suggested for EPCR 




TF Interacts with PU.1, 
CEBPA, GATA1, 
GATA2, PAX5, FLI1, 
and ETS1 
Essential in HSC development. RUNX1 deficiency decreases both 
apoptosis and proliferation, conflicting reports on impacts the 
frequency of HSCs – some say minimally effects, others increase, 
others decrease. Cell cycle and p53 pathways that are dysregulated 
in RUNX1 deficient HSCs. 
Point mutations reported in AML, MDS 
and chronic myelomonocytic leukaemia. 
Translocations also common; ETV6-
RUNX1 is the most common fusion gene 
in childhood ALL, AML1-ETO one of 






TF ETS family of TF PU.1 acts by inhibiting genes that promote cell proliferation and 
activates those encoding cell-cycle inhibitors. Thus PU.1 is 
required to maintain HSC quiescence and prevent exhaustion of the 
HSC pool. 
Reduced expression in AML. PU.1 loss-
of-function heterozygous mutations or 




Adaptor protein Negative regulator of 
JAK2 
In mouse loss of LNK causes increased HSC number and self-
renewal capacity in HSCs.  
In human expression is upregulated in CD34+ cells and platelets of 
MPN patients, especially in JAK2 V617F-positive cases 











Increased HSC reconstitution activity (primary transplantation 16 
weeks) with retroviral overexpression of Smarcc1.  










Higher expression in the ESLAM fraction versus the lineage 
negative and CD45+EPCR+CD48−CD150− fractions of BM and FL 
blood cells.  









TAL1 is essential for the formation but not maintenance of adult 
HSCs. TAL1 null adult HSCs have impaired short-term 
repopulating ability, predominantly of the myeloid lineage, but no 
defects in long-term repopulation or self-renewal.  
TAL1 is ectopically overexpressed in 40–
60% of T-ALL cases via chromosomal 
translocation, intrachromosomal 





TF, also chromatin 
remodelling  
TCF/LEF family of 
transcription factors 
TCF7 down regulated in switch from CD34+ to CD34- in human, 
involved in self-renewal and differentiation. RUNX1 and TCF7 
bind each other’s promotor regions, TCF7 is necessary for the 
production of the short isoforms of RUNX1.  
Knock-out mice develop T-cell 
lymphomas, but no patient mutations 
126,127 
Tet2 DNA methylation TET family Loss of TET2 increases HSC self-renewal as demonstrated by 
serial transplantation from TET2 knock-out mice.  
Loss of function mutations in MPN, 
MDS, CMML, AML 
128 
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Trib3 Pseudokinase Endoplasmic reticulum 
stress modulator 
Trib3 expression is high in the HSC population. 
TRIB3 knock-out mice have abnormal differentiation towards mast 
cells. TRIB3 knock-out HSCs express mast cell genes such as 
Cpa3 prematurely, poor long-term engraftment in transplantation. 
TRIB3 expression associates positively 
with acute promyelocytic leukaemia 




Vwf Glycoprotein Mediates platelet 
adhesion to damaged 
blood vessels, and platelet 
aggregation.  
Vwf expression can be used to stratify the HSC compartment by 
lineage priming; platelet-biased and platelet-myeloid-biased HSCs 
are enriched in the VWF+ subset.  Elevated VWF expression is 
associated with HSCs possessing durable self-renewal potential. 
Mutations cause von Willebrand disease 24,132 
Table 1 Overview of 45 key self-renewal genes, their roles in HSCs and links with haematological malignancy 
Maintenance of self-renewal involves the correct expression of many genes, some positively and some negatively regulating self-renewal capacity. 
Many of these genes listed in this table have strong functional data that associates them with self-renewal, and/or have been shown through 
malignancy to play a key role in HSCs. ALL; Acute lymphoblastic leukaemia, AML; Acute myeloid leukaemia, CLL; chronic lymphocytic 
leukaemia, CML; Chronic myelogenous leukaemia, CMML; Chronic myelomonocytic leukaemia, ECM; Extracellular matrix, FL; Foetal liver, 
MDS; Myelodysplastic syndromes, M-CSF; Macrophage colony-stimulating factor, MPN; Myeloproliferative neoplasms, PRC2; Polycomb 
repressive complex 2, T-ALL; T-cell acute lymphoblastic leukaemia, TF; transcription factor, THPO; Thrombopoietin 
  
1.5 In vitro assays for detecting HSC potential  
The experimental assessment of the functional capacity of HSCs is crucial for 
understanding this cell type, and how it is affected by alterations, for example mutations 
or aging. A number of in vitro and in vivo assays have been developed to assess HSC 
functional characteristics, the most common of which are discussed below.  
1.5.1 CFC 
HSCs can be grown clonally in vitro, and this was initially established in 1966 by 
Bradley and Metcalf, who plated BM cells in agar on feeder layers.133 Now the colony 
forming cell (CFC) assay more commonly involves plating cell populations of cells in 
semi-solid methylcellulose-based media, the viscosity of the media allows cells to be 
spatially separated and grow as clonal units. CFC assays permit differentiation, and the 
cell types produced in the assay are directed by the cytokines present in the media. 
Multilineage clones can be grown, which can be assessed visually or by flow cytometry, 
CFU assays determine the myeloid, erythroid or megakaryocytic differentiation (but 
generally not lymphoid without specialised co-culture systems134). Both stem and 
progenitor cells are able to form colonies in a CFC assay as it does not measure self-
renewal but proliferative potential. Serial re-plating CFCs can be used to allude to self-
renewal potential of HSCs, for this CFCs are collected and replated weekly, wild-type 
BM can sustain (on average) three re-platings, while mutations which enhance HSC 
self-renewal (e.g. TET2 135 and DNMT3A 136) have been shown to be able to perform 
more serial re-platings.  
1.5.2 Liquid culture  
Individual HSCs can also be grown in liquid culture assays. In these assays single cells 
are sorted into, and cultured in, individual wells in medium supplemented with 
cytokines, this allows clones to be grown and the lineage output assessed by flow 
cytometry. As in CFCs, the cell types produced will be influenced by the cytokines 
added to the medium. Single cell liquid culture permits assessment of multilineage 
potential, cell cycle kinetics and proliferative capacity, however it does not assess long-
term self-renewal, as HSCs and progenitors can both form colonies. Single cell liquid 
culture has the benefit over CFC assays of ensuring that resultant clones are indeed 
clonal; since in CFC assay colonies can overlap due to high plating density and colony 
picking can result in clones being mixed. In single cell liquid culture, cells are plated 
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in separate wells ensuring clones cannot be mixed. Single cell liquid culture has the 
additional benefit that the functional output can be linked with index sorting data, which 
allows coupling of functional output with cell surface marker expression.  
1.5.3 CAFC and LTC-IC 
The cobblestone area–forming cell (CAFC) assay involves culturing HSCs on a pre-
established stromal layer. Unlike CFC and liquid culture which primarily assess 
proliferative potential, CAFCs are an in vitro assay for self-renewal potential. In 
CAFCs test cells are cultured on a stromal cell line for more than 5 weeks and assessed 
for the presence of haematopoietic  colonies with ‘cobblestone’ morphology.137 HSCs 
with less durable self-renewal tend to form colonies at early times while HSCs with 
more durable self-renewal from colonies at later time points.37 Like the CAFC assay, 
the long-term culture-initiating cell (LTC-IC) assay involves growing HSCs on stromal 
cell layers for >5 weeks, and cells produced after this period cells are harvested and 
plated in CFCs. The logic is that progenitors from the original test suspension will not 
survive for 5 weeks before re-plating and thus the CFUs must be the progeny of HSCs. 
Neither the CAFC or LTC-IC are very commonly used due to disputes around their 
effectiveness/relatability, and high inter-lab variability.138  
 
The influence of media components and additional cytokines is a feature of all in vitro 
assays – it is impossible to completely mimic the in vivo niche, and so the full potential 
of the cells can be under-reported. Consequently in vivo assessment of HSCs is often 
performed to formally demonstrate the full potential of a particular cell.  
 
1.6 In vivo assays of HSC potential  
1.6.1 In vivo multilineage assays  
Both multilineage potential and self-renewal of HSC can be assessed in in vivo assays. 
Like in vitro assays, in order to resolve whether an individual HSC has multilineage 
output capacity it must be spatially separated from other HSCs – bulk assays cannot 
determine multilineage output. 
 
As mentioned earlier (section 1.2), the first stem cell assay was the transplantation of 
BM cells which formed colonies (nodules) within the spleen of recipient animals,8 these 
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nodules were of single cell origin (as determined by karyotyping studies post low dose 
radiation9) and some colonies contained multiple blood lineages – proving for the first 
time the multilineage capacity of HSCs on the single cell level.  
 
Since the popularisation of single cell transplantation, it is now more common to assess 
the cellular output of individual HSCs in vivo by single cell transplantation into 
myeloablated recipients (alongside helper cells). The benefit of transplantation 
compared with in vitro assays is that the assay is not limited in cell type output by 
addition of cytokines – the clone will be able to make all cell types it can. The downside 
of transplantation is that it is a fairly lengthy assay and the cost and ethical 
considerations associated with keeping large numbers of animals is restrictive. 
Alternatively, HSC output can be tracked by genetic barcoding, this allows many HSCs 
to be assessed in the same mouse, reducing the number of recipient mice required, and 
permitting the studying of HSC clonal dynamics. HSCs can be labelled with a genetic 
barcode either by ex vivo transduction with a lentiviral library,139 or by in vivo 
recombinase-induced or transposon-mediated shuffling of genetic sequences to 
generate unique genomic sequences in each HSC.140 HSC output can be assessed by 
determining the barcode abundance within cell populations from the blood or BM.  
1.6.2 In vivo self-renewal assays  
CFU-S assays can be used to assess self-renewal, as well as multi-lineage potential, by 
harvesting and re-transplanting the colonies. In this way the ability of the stem cells to 
produce more equally potent stem cells able of sustained engraftment and blood 
production can be assessed. However, this assay is now uncommon, with most groups 
preferring serial BM or sorted cell transplantation assays. Currently, serial 
transplantation assays represent the gold standard to formally demonstrate HSC 
function by assessing their long-term multi-lineage reconstitution capacity (>16 weeks) 
in primary recipients and their self-renewal ability in secondary recipients.138 When 
undertaking a secondary transplantation, a number of considerations must be made; 
 
Whole BM or sorted population? 
Transplantation of whole BM provides the recipient mouse with terminally 
differentiated cells and progenitors, in addition to the more primitive HSCs. These 
additional mature cells protect the recipient mouse from irradiation complications. In 
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order to enumerate HSCs in a test cell suspension, different doses of BM cells can be 
transplanted into recipient mice and the frequency of HSCs estimated using limiting 
dilution analysis.1  However, a sub-optimal whole BM transplantation can be the result 
of the donor having a reduced number of HSCs or if the HSCs have reduced function.  
  
Flow cytometric cell sorting has led to the isolation of purified populations of HSCs – 
allowing HSCs from two different conditions to be directly compared. However, flow 
cytometric sorting strategies are not completely generalisable across developmental 
stages, activation states (i.e., post-transplantation), or in mutant animals, and caution 
must be exercised when interpreting phenotypic populations in the absence of 
functional assays.  A nice example of this issue is outlined by Santaguida et al. (2009)141 
where a reconstitution defect was observed upon transplantation of whole BM or 
HSPCs from a JunB-deficient mouse model. When the group went on to look at a more 
purified population of HSCs they found that these cells had enhanced repopulating 
capacity compared to control cells. The reconstitution defects observed in whole BM 
and HSPC fractions resulted from a dilution of HSCs as a result of progenitor 
expansion.  
 
Another example requiring care is the interpretation of transplantation data from sorted 
populations as evidenced by Lundberg et al. (2014)142. Here, a purified population of 
phenotypic HSCs from their JAK2 V617F mutant mouse were transplanted, but the 
same increase in HSC activity that was observed in whole BM transplantations was not 
seen. When subsets of the progenitor compartments were assessed in transplantation 
assays, a percentage of cells expressing lineage markers – populations normally not 
considered to contain HSCs - were able to initiate a sustainable disease. This study 
highlights a key challenge when transplanting purified populations of cells – the cells 
you wish to study may not be present in your purified population. When assessing 
purified HSCs from genetically modified mouse models, it is important to undertake 
new functional assays if HSCs are to be studied since a genetic mutation may affect the 
cell surface phenotype.  
 
Overall, therefore, depending on the research question being asked, it may be necessary 
to undertake new baseline functional assays in settings where haematopoiesis has been 
disrupted (e.g., genetic models of malignancy).  This becomes especially important 
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when comparing the molecular profiles of cells at the single cell level. Neither the 
whole BM nor sorted population strategy is perfect; the challenge is to select the most 
appropriate approach for the question being investigated.   
 
To compete or not to compete?  
Transplantation can be competitive or non-competitive. A non-competitive 
transplantation assesses whether a population containing HSCs, transplanted alone, has 
the capacity to engraft in an irradiated host. It can also be useful for demonstrating 
whether any haematopoietic phenotypes are present in the test cell suspension (e.g., a 
genetic mutation that results in increased red cell production) 
 
Competitive transplant, by contrast, requires test and wild type (WT) HSCs to compete 
against each other to give sustained engraftment. This more accurately measures a test 
cell suspension’s ability to outcompete normal healthy WT cells (a key property of 
cancer). Competitive transplantation is semi-quantitative when transplanted alongside 
known numbers of cells with an established repopulation capacity (e.g., 500,000 whole 
BM cells). Moreover, the competitor cells act as an internal technical control, 
controlling for such variables as the differential impact of irradiation across recipients 
or the technical success of an injection procedure.  
 
1.7 Functional Heterogeneity of HSCs 
The existence of heterogeneity in HSCs has been well documented from a functional 
standpoint. From the first CFU-S stem cell assays the cellular heterogeneity of HSCs 
has been alluded to; showing variability in the output of haematopoietic progenitors, 
variation in clone size, composition (the numbers and types of mature and primitive 
cells), time to detection and the number of secondary colonies they could give rise to.9 
These differences were the first hint that heterogeneity was a feature of mammalian 
blood stem cells. Key experiments in the 1980s tracking HSCs using retroviral inserts 
as genetic marks for their progeny, provided the first formal evidence of variations in 
self-renewal durability and also reaffirmed differences in mature cell production, 
prompting the eventual description of lineage-biased HSCs.143–146 
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As mentioned earlier, one of the greatest advances in deciphering the functional 
heterogeneity of HSCs was the introduction of multi-parameter florescence activated 
cell sorting for HSC purification,16 which lead to single HSC sorting and transplantation 
assays.10 Single cell transplantation provided clear evidence of the heterogeneity of 
HSCs, in their lineage output, longevity of graft, and graft size. However, single cell 
transplantations have two key limitations. The first of these is that it assesses what an 
HSC can do in a stressed environment, as opposed to what it does do under homeostatic 
conditions. The second is that it does not test how HSCs interact as a population to 
maintain the balance of cellular outputs. These issues are at least partially overcome by 
lenti- or retro-viral genetic barcoding studies where bulk HSPCs can be transplanted 
together and tracked individually.147 However, these assays are still transplantation-
based and are further limited by needing an in vitro culture period, meaning that the 
culture itself (or integration site of the barcode) could add bias to the population. 
Moreover, sequence detection limits could also add bias, as it cannot conclusively 
determine absence of contribution or disappearance of a clone in longitudinal studies.  
More advanced endogenous barcoding approaches have now been undertaken where 
HSCs are traced using reporter mice140 or genetic recombination is used to mark cells 
in vivo without any additional manipulation.42,148  
 
1.8 Molecular heterogeneity of HSCs 
Single cell molecular profiling of HSC and progenitors has already revealed a number 
of findings that were previously unattainable using bulk populations. Unbiased 
approaches such as RNAseq have identified new genes (and associated pathways) 
involved in stem cell function and lineage commitment.149,150 These same techniques 
have unveiled the heterogeneity within various progenitor compartments,150 and 
confirmed that the molecular process by which stem cells differentiate is a gradual 
process (i.e., a continuum) rather than a stepwise progression though progressively 
more differentiated progenitors.151 Importantly, studies that have profiled HSCs all 
converge on the description of significant heterogeneity within the population, but the 
utility of such a finding is unclear. 
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An important factor when considering “heterogeneity” is the difference between 
informative heterogeneity (biologically driven variations that result in functional 
differences), and generic heterogeneity (differences driven by processes occurring in 
all cell types e.g., cell cycle).152 Another consideration is the extent of heterogeneity 
that is actually driven by technical noise: if it were possible to sequence the same cell 
many times, there would be technical drop-out of genes and this would differ between 
experiments, adding an artificial “heterogeneity” to the population. Finally, there is yet 
another type of heterogeneity hidden amongst molecular studies of purified HSCs – 
that of non-HSC contaminants. Unlike transplantation assays, where non-HSCs do not 
read out and are therefore not able to confuse the description of heterogeneity, 
molecular assays will generate 100 gene expression profiles from 100 cells.  When 
populations are of a low purity, for example 5 or 10%, and single cell molecular studies 
are undertaken, it becomes incredibly difficult to assign a specific molecular 
 
Figure 2 Selectivity of functional assays reduces experimental noise in the 
description of HSC heterogeneity 
Depicted on the left is a single cell functional assay where 5 input cells are each 
transplanted into a single recipient mouse and analysed for the presence of an HSC.  
In this case, 3 cells do not read out and a “red” HSC subtype and a “blue” HSC 
subtype are easily compared.  On the right are a similar set of 5 input cells where each 
cell is subjected to single cell gene expression profiling – all 5 cells generate a 
molecular profile that is unique, but it is unclear which profiles belong to HSCs and 
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programme to a specific cell function. The reality in such cases is that 90-95% of the 
molecular programmes are not the cell of interest and, unlike long term cell biological 
assays where non-HSCs are no longer represented, these represent a significant 
confounder for single cell molecular biology studies (Figure 2).   
 
One of the main reasons for studying HSCs is to understand how single cells are mis-
directed to drive a leukaemia. The study of ‘normal’ HSCs sets the stage for how 
‘normal’ is subverted to drive malignancy and we are now in a position technically 
where we can start to figure that out how the molecular mechanisms of HSCs are 
altered, at the single cell level, by oncogenic mutations. 
 
1.9 Myeloproliferative Neoplasms  
The myeloproliferative neoplasms (MPNs) are a set of clonal, stem cell derived 
diseases that cause overproduction of mature myeloid cells.153 The most well-known 
mutation in MPNs is the BCR-ABL fusion (first discovered in 1960154), CML is defined 
by the BCR-ABL fusion; detectable in 100% of CML patients (occasionally patients 
have CML symptoms without BCR-ABL, this represents a separate disease, atypical 
CML).155  
 
The BCR-ABL fusion has been well characterised and an understanding of the mutation 
and molecular consequences has led to development of a potent targeted therapy in the 
form of Tyrosine Kinase Inhibitors (TKIs), the first of which was imatinib. Prior to 
TKIs, CML life expectancy was a few years (less than 20% 8 year survival156) and the 
only treatment was allogeneic stem cell transplant, since the introduction of TKIs the 
life expectancy for CML patients is essentially normal. TKIs are the poster child for 
targeted therapy; they have revolutionised treatment of this previously fatal disease. 
BCR-ABL and its targeted therapy highlights the power of having a comprehensive 
understanding of a genetic mutation and is a goal for the field in BCR-ABL-negative 
chronic MPNs. There are three BCR-ABL negative MPNs; polycythaemia vera, 
essential thrombocythaemia, and myelofibrosis.157  
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1.9.1 Polycythaemia vera 
Polycythaemia vera (PV) is characterised by an overproduction of red blood cells and 
is diagnosed by an increased erythrocyte volume; haemoglobin level greater than 
16.0g/dL in women or 16.5 g/dL in men, or haematocrit greater than 48 percent in 
women or greater than 49 percent in men. Low erythropoietin (EPO) levels in 
combination with high red cell count is indicative of PV, as it suggests cytokine 
independent activation of the JAK/STAT signalling pathway. In almost all PV patients 
this activation is caused by JAK2 mutations, either V617F or exon 12. The incidence 
of PV is approximately 0.4 - 2.8 individuals per 100,000 per year,158 with slight male 
preponderance (1.2:1).159 The median age at diagnosis is 60,159 and the median survival 
14 years.160  
 
The greatest risk for PV patients is thrombosis. PV patients can be treated with 
venesection to reduce the number of circulating erythrocytes and thus the viscosity of 
the blood, thereby reducing the risk of thrombosis.161 With the application of 
venesection, mean survival for PV patients increased from 2 to 10 years.162  Patients 
can also be treated with low-dose aspirin to reduce the risk of thrombosis, hydroxyurea 
to suppress blood cell production,163 or interferon (IFN)-a  to induce differentiation in 
JAK2 V617F mutant HSCs.164  
1.9.2 Essential thrombocythaemia 
Essential thrombocythaemia (ET) is characterised by overproduction of platelets and 
diagnosed on high platelet count - above 450,000 platelets per microliter of blood (with 
exclusion of reactive thrombocytosis causes, such as infections, iron deficiency and 
other haematological or non-haematological neoplasms). The incidence rate of ET is 
0.38 – 1.7 individuals per 100,000 /year, with a 2:1 female bias.158 The median age at 
diagnosis is 65-70,165 and the median survival is 20 years.160  ET patients are at risk of 
thrombosis and haemorrhage as well as transformation to AML (2% risk at 15 years), 
and MF (9% risk at 15 years). Like PV patients the main risk for ET patients is of 
thrombosis. Patients can be risk stratified by age (high risk aged over 60), presence of 
previous thrombosis, and platelet count >1500x109/ul.  High risk ET patients can be 
treated with hydroxyurea or IFN-a to reduce thrombotic risk.166  
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1.9.3 Myelofibrosis 
Myelofibrosis (MF) is the most severe of the BCR-ABL negative MPNs and is 
characterised by fibrosis of the BM. MF can occur as the primary disease (pMF), or ET 
or PV can transform to MF (secondary MF, sMF). MF is diagnosed by BM 
morphology; collagen and/or reticulin fibrosis, with increased megakaryocyte 
proliferation and atypical megakaryocytes (large with atypical nuclear:cytoplasmic 
ratio and irregularly folded nuclei).157 This fibrosis is thought to be the result of the 
MPN clone producing cytokines (e.g. fibroblast growth factor), which stimulate the 
growth of connective tissue in the BM. This overproduction of fibrotic tissue replaces 
the haematopoietic cells within the BM, leading to progressive pancytopaenia.  
 
The incidence rate of pMF is 0.1 to 1 per 100,000 individuals per year,158 with patients 
presenting at a median age of 64. The median survival is 6 years.160 Of the BCR-ABL 
negative MPNs, MF has the highest risk of transformation to AML of 5-30%.167 
Currently the only curative treatment for MF is stem cell transplantation, however the 
risk of transplant-related death or morbidity is very high (over 50%). Other treatments, 
like JAK2 inhibitors, are palliative and have not been shown to be disease modifying.157  
 
1.10 Mutations in MPNs 
The development of a cancer is a multi-step process in which acquired genetic 
mutations confer an advantage to cells, allowing them to outcompete normal cells. All 
haematological malignancies can trace their origins to single stem or progenitor cells 
in the blood system.168 In order for these clones to evolve from a single cell - and expand 
to the extent where clinical features become apparent - the population of cells must 
have a significant clonal advantage over non-mutant blood HSCs. To achieve such a 
clonal advantage, two functional properties must be operative: 1) increased 
proliferation: one cell needs to expand to billions, and 2) HSC self-renewal: the clone 
must be continually sustained by newly created daughter HSCs.  Whether a single 
mutation can drive both properties, however, remains unclear.  
 
The BCR-ABL fusion protein is defining of CML, and consequently is present in all 
patients,155 most often alone.169 Despite its prevalence, it has been suggested that this 
mutation alone is insufficient to drive CML, as BCR-ABL HSCs have been reported to 
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have a decreased probability of self-renewal divisions and a bias towards 
differentiation.170 Indeed BCR-ABL has been detected in healthy individuals,171,172 
suggesting the presence of this mutation alone is insufficient to drive disease. This is 
supported by a mouse model of BCR-ABL lacking the capacity to repopulate a 
secondary mouse on serial transplantation.  
 
Koschmieder et al. (2005)173 generated a BCR-ABL transgenic model expressing BCR-
ABL (under the control of the SCL promoter) in primitive haematopoietic cells. These 
animals developed a myeloproliferative disease that resembled human CML - with 
neutrophilia, leucocytosis and myeloid cell infiltration of extramedullary organs. 
Primary BM transplantation or sorted Lin-, Sca1+, c-Kit+ cells (LSK; less than 10% 
HSCs138) resulted in a marked decrease in chimerism over the 5-month follow up 
period, indicating a failure of long-term reconstitution, this was accompanied by a lack 
of disease phenotype. A follow-up study174 transplanted whole BM or LSK cells from 
the same BCR-ABL mouse line into a different strain of recipient (FVB/N) and were 
able to recreate the disease phenotype. However, cells from primary recipients failed to 
initiate a leukaemic phenotype in secondary mice, due to low chimerism. Moreover, 
leukaemic mice show a significant reduction in BM HSCs (LSK, CD34-, FLK3-) and 
increased multipotent progenitor (MPP; LSK, CD34+, FLK3+) number compared to 
controls, leading to the idea that BCR-ABL mutation might be responsible of increased 
differentiation of HSCs. 
 
Since the majority of cancers are highly mutated, resulting in a large degree of genetic 
heterogeneity, it can be challenging to accurately assess the impact of an individual or 
a small number of mutations on a particular disease.175 By contrast, MPNs are relatively 
simple in terms of their genetics175 and therefore are a highly tractable set of diseases 
in which to study the individual contributions of a given mutation on the biology of the 
clone. MPNs provide a window into the very earliest stages of tumorigenesis, typically 
carrying fewer than 3 genetic driver mutations.176  In this thesis I primarily focus on 
two of the most common genetic drivers in MPNs, the most commonly commutated 
pair, JAK2 V617F and TET2 loss of function, investigating their properties individually 
and in combination. The next section describes a wider range of mutations in MPNs. 
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1.10.1 Signalling mutations in MPNs 
The vast majority of MPN patients have mutations in one of three genes; JAK2, MPL 
or CALR. Mutations in these 3 genes are nearly always mutually exclusive and all lead 
to hyperactivation of the JAK/STAT signalling pathway.177 Across the 3 MPN subtypes 
there is a different prevalence of these 3 mutations. In PV the vast majority of patients 
have a JAK2 mutation (95%) with CALR and MPL mutations virtually absent (0%). In 
ET approximately 60% of patients have a JAK2 mutation, 20% have a CALR mutation 
and 3% a MPL mutation. In pMF JAK2 mutations are found in approximately 60% of 
patients, 25% of patients have a CALR mutations, and 7% have a MPL mutation.157 
Patients who do not have mutations in any of these 3 genes are referred to as triple-
negative. Approximately 17% of ET and pMF patients, and 7% of PV patients are triple 
negative.177  
 
Most cytokine receptors lack intrinsic kinase activity and therefore employ the Janus 
kinase (JAK) family of proteins to carry out phosphorylation of downstream proteins. 
Under normal physiological conditions, cytokines such as EPO, THPO and 
Granulocyte colony-stimulating factor (G-CSF) bind to their monomeric receptor 
(EPOR, MPL or G-CSFR), ligand binding induces receptor dimerization and 
 
Figure 3 Activation of JAK/STAT signalling pathway under normal conditions and 
with MPN mutations 
Under normal conditions THPO binds MPL causing a conformational change, leading 
to dimerization, and cross activation of intracellularly bound JAK2. This causes 
activation of downstream JAK/STAT signalling pathway and other signalling targets. 
In MPNs, when JAK2 is mutated (V617F) it is hyperactivated and does not require 
cytokine stimulation to induce receptor dimerization and activate downstream 
signalling pathways. Likewise, when MPL is mutated it dimerises without cytokine 
stimulation, causing inappropriate downstream signalling. When CALR is mutated it 
binds to the MPL extracellular domain resulting in activation of MPL and the 
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activation,178 this dimerization brings the intracellular bound JAK2 into proximity to 
allows cross-phosphorylation (Figure 3). Phosphorylated JAK2 is able to phosphorylate 
signal transducers and activators of transcription (STAT) family transcription factors, 
which are then able to translocate to the nucleus and initiate transcription.179  
 
JAK2  
The most common mutation in BCR-ABL negative MPNs is JAK2 V617F. This 
mutation was first reported in 2005 180–184 and is present in 95% in PVs, and ~50% in 
ET and MFs.180 The JAK2 V617F mutation has also been reported at lower frequencies 
in other myeloid malignancies including CMML (6%), BCR-ABL-negative CML 
(19%), and MDS (3%).182,185,186  
 
JAK2 V617F is a gain-of-function point mutation (a G to T substitution that causes a 
valine to phenylalanine switch) in the pseudokinase domain of JAK2.187 This mutation 
disrupts the inhibitory function of this domain and results in a hyper-activation of JAK2 
and consequently the downstream JAK/STAT signalling pathway and other signalling 
targets 181 (Figure 3). Most PV patients who lack a JAK2 V617F mutation have a JAK2 
exon 12 mutation, exon 12 is the linker between Src homology 2 domain (SH2) and the 
pseudokinase domain. These mutations are mostly in-frame small insertions or 
deletions. 
 
Since its discovery, many studies have been undertaken to resolve the molecular effects 
of JAK2 V617F as it is unclear how the same mutation can be associated with three 
distinct diseases. A number of theories exist to account for how the same mutation 
could be associated with three phenotypes. The gene-dosage hypothesis suggests the 
number of copies of JAK2 V617F (hetero- or homozygous) and allele burden (ratio of 
mutant to non-mutant cell) correlates with different disease phenotypes; homozygous 
clones and high allele burden are associated with PV. Homozygous clones are rarely 
seen in ET patients, these patients also tend to have lower allele burden.188 
Microenvironmental factors, such as serum erythropoietin levels, have also been 
proposed as a factor driving distinction between diseases phenotype.189 Genetic factors 
have been suggested to predispose individuals to the development of MPNs and 
contribute to phenotypic diversity. Having a first-degree relative with an MPN has been 
reported to increase the risk of developing an MPN by 5-7 fold.179 Another genetic 
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factor reported to increase predisposition to MPN is the 46/1 haplotype block. This 
haplotype block contains the JAK2 gene and increases the odds of developing an MPN 
by 3-4 fold.179 As JAK2 V617F is commonly co-mutated, many groups have suggested 
that the co-mutated genes, and even the order they arise in,190 contribute to MPN 
progressions and phenotype. It has also been suggested that JAK2 V617F alone is 
insufficient to drive disease.191  This idea is supported by a study of ~4,000 individuals 
attending outpatient clinics carried out in China, where it was found that nearly 1% of 
patients have a JAK2 V617F mutation without presenting an MPN phenotype.192  
 
These concepts about MPN progression are not mutually exclusive. Other theories 
explore the ways in which genetic factors and collaborating mutations interact. It has 
been suggested the 46/1 haplotype block could contribute to MPN disease progression 
in two ways: either the block increases occurrence of JAK2 mutation (hypermutability 
hypothesis) or, as the fertile ground hypothesis posits, the block provides a selective 




MPL is the receptor for the cytokine THPO. MPL has no intrinsic tyrosine kinase 
activity, instead JAK2 is bound to MPLs intracellular domain. When THPO binds MPL 
it dimerises, and a conformation change occurs resulting in rapid the phosphorylation 
and activation of JAK2. This then phosphorylates MPL and activates downstream 
signalling pathways (STATs, AKT and ERK).194,195 
 
A number of activating mutations in MPL have been found in ET and pMF patients, 
the 2 most common locations being W515 (W to L, K or less commonly R, A, or G) 
and S505 (S505N). Tryptophan W515 is located at the junction between the 
transmembrane and cytosolic domains of the receptor and is involved in dimerization 
and activation.196 While serine S505 is located in the transmembrane domain, the MPL 
S505N mutation stabilises the receptor in the active, dimerised, form, thus causing 
hyper-activation.197  
 
In order to determine the role of MPL mutation on haematopoietic cells, retrovirally 
expression of MPL W515L in cell lines and BM has been performed.198 In cytokine 
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supplemented conditions expression of MPL W515L in cell lines and BM drove no 
difference in proliferation, however when cultured in cytokine free conditions MPL 
W515L transduced cells exhibited cytokine independent growth. When BM transduced 
with MPL W515L was transplanted, an MF like phenotype was observed; with fibrosis 
of BM, splenomegaly with thrombocytosis and leukocytosis (but no change in 
haematocrit). MPL W515L expressing cells were not serially transplanted so no 
conclusion can be drawn about the self-renewal of these cells.198  
 
CALR 
Calreticulin has 2 main functions under normal conditions; 1. Maintaining calcium 
homeostasis, and 2. As a chaperone within the ER. In the latter, its role is to prevent 
misfolded proteins from being exported from the ER to the golgi apparatus.199 CALR 
does not appear to be directly involved in JAK/STAT signalling, however it has been 
found that mutant CALR binds to, and hyper-activates, the THPO receptor MPL via its 
extracellular domain (not the ligand binding site), but the precise mechanism for this is 
currently unclear. 
 
The two most common CALR mutation in MPN patients are a 52 base-pair deletion 
(commonly known as del52, c.1092_1143del) and a 5 base-pair insertion (ins5, 
c.1154_1155insTTGTC). Both mutations result in an exon 9 (c-terminal) frameshift 
mutation, causing removal of the ER retention motif KDEL (and changing the charge 
of the C terminal domain from negative to positive). It is hypothesised that this mutation 
causes a conformational change which allows the N-terminus of CALR to bind to MPL 
via an N-glycosylation site, causing hyper-activation and as a consequence 
hyperactivation of the down steam JAK/STAT signalling pathway.200  
 
A mutant CALR knock-in mouse model201 has been developed with a conditional 
human CALR c-terminal, with a 52 base pair deletion, induced by polyinosinic-
polycytidylic acid (pIpC) treatment (Mx1-Cre). Heterozygous mice have been reported 
to have an ET-like phenotype (characterised by elevated platelet count), while 
homozygous mutant mice have a MF-like phenotype (displaying elevated platelets, 
splenomegaly, and reduced BM cellularity). Both homozygous and heterozygous mice 
have been reported to have an elevated number of phenotypic HSCs (ESLAM), but 
neither have a competitive advantage upon primary or secondary transplantation. 
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1.10.2 Mutations in epigenetic regulators  
Outside of mutations causing hyper-activation of the JAK/STAT signalling pathway, 
the second most common ‘type’ of mutation in MPNs are mutations in epigenetic 
regulators. Epigenetic mechanisms position DNA in a state that allows expression of 
appropriate genes for that cell type. Disruption in epigenetic regulators can lead to an 
overly restrictive or permissive gene expression landscape. A restrictive epigenetic 
pattern could prevent turning off of proliferation or self-renewal pathways, or prevent 
activation of differentiation or apoptotic programmes, while a permissive landscape 
could allow expression of oncogenes.202 A disrupted epigenome can also affect 
telomere maintenance and DNA repair pathways, influencing the rate at which 
mutations arise and are repaired.203 
 
MPN patients commonly have a tyrosine kinase activating mutation alongside a 
mutation in an epigenetic regulator. The most commonly mutated epigenetic regulators 
in MPNs are TET2 (12%), ASXL1 (5%), DNMT3A (5%), EZH2 (~3%), and 
IDH1/2(~1.5%) (Figure 4).204 Mutations in these genes are also commonly found in 
ARCH (section 1.3.2). 
 
Figure 4 The normal role of commonly mutated epigenetic regulators 
DNMT3A is a de novo methyltransferase; catalysing the conversion of cytosine (Cyt) to 
5-methyl-cytosine (5-mCyt). TET2 in turn converts 5-mCyt to 5-hydroxymethyl-cytosine 
(5-hmCyt). For this TET2 requires alpha-ketoglutarate (αKG), the production of which 
is controlled by IDH1/2. Mutations in IDH1/2 result in 2-hydroxyglutarate (2HG) being 
produced instead of αKG, 2HG inhibits TET2. At the histone level, the polycomb 
repressive complex 2 (PRC2) trimethylates histone H3 at lysine 27 (H3K27me3), 
repressing gene expression, H3K27me3 can be stabilised by PRC1. EZH2 is part of the 




















Methylation of the 5-C position of cytosine is a stable epigenetic mark that acts to 
repress gene expression. DNA methylation is crucial for regulation of gene expression 
and is essential for normal development. The DNA methyltransferase (DNMT) family 
is responsible for the methylation of DNA. DNMT1 primarily methylates 
hemimethylated DNA at the replication foci during S phase of the cell cycle, thereby 
maintaining pre-existing DNA methylation patterns.205 DNMT2 is a methyltransferase 
homolog that methylates transfer RNA (tRNA). DNMT3A and B are primarily de novo 
methyltransferases, establishing new methylation patterns during development and 
differentiation. DNMT3L has no catalytic activity but assists DNMT3A and B by 
increasing their ability to bind S-adenosyl-L-methionine, the methyl group donor.205  
 
DNMT3A mutations are common in individuals with AML, MPN, MDS, T-ALL and 
ARCH.206 The most common mutation in DNMT3A is a missense mutation at arginine 
R882, located in the methyltransferase domain, at this location the most common 
mutation is R882H (2/3rds of patients), followed by R882C (1/3rd), and occasionally 
R882S and R882P (3%). The R882 residue is located at the central interface of the 
DNMT3A tetramer where it interacts with the DNA backbone. Mutations at arginine 
R882 effect the function of DNMT3A by altering the flanking sequence preferences for 
DNA binding (altering the CpG locations which are methylated and hence gene 
expression).207  
 
Two types of mouse models have been developed in order to elucidate the role of 
DNMT3A in disease and HSC function; DNMT3A knock-out models, and Dnmt3a 
R878H knock-in models. Dnmt3a R878H (mouse homolog to DNMT3A R882H) mice 
develop AML, and have splenomegaly and enlargement of progenitor (LSK) 
compartment.208 Meanwhile loss of DNMT3a (DNMT3A-/-) has been shown to promote 
self-renewal, leading an expansion in the HSCs population. This increase in self-
renewal is most apparent in serial transplantation experiments; whereas WT HSCs can 
only sustain 4 rounds of serial transplantation before exhausting, DNMT3A-/- HSCs can 
undergo at least 12 rounds of transplantation,64 leading the authors to report that they 
have been ‘immortalised’ in vivo. 
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TET2 
The ten-eleven translocation (TET) family of proteins (TET1-3) are dehydrogenases 
responsible for catalysing the conversion of 5-methyl-cytosine (5-mCyt) to 5-
hydroxymethyl-cytosine (5-hmCyt).128 Unlike 5-mCyt, which is maintained during 
replication by DNMT1, 5-hmCyt is lost during cell division.206 The first TET family 
member identified was TET1 which was found as a fusion partner of MLL in AML (a 
t(10;11)(q22;q23) translocation), TET2 and 3 were subsequently identified as 
homologues. TET1 and 3 have a CXXC and therefore bind DNA directly while TET2 
binds indirectly. In haematopoietic cells TET2 is the highest expressed member of the 
family.128 
 
Loss of function TET2 mutations are present in a range of myeloid malignancies, 
including MPNs, MDS, CMML, and AML, as well as being a frequent mutation in 
ARCH.128 TET2 mutations occur throughout the gene (no hotspots), and are variable; 
small insertions, deletions, and nonsense mutations, have all been reported, the 
commonality between these mutations is that all induce loss of function in the 
protein.209 In MPNs, TET2 is the most commonly co-mutated gene with JAK2 V617. 
Loss of function TET2 mutations give a self-renewal advantage to HSCs as determined 
by numerous TET2 knock-out mouse models;135,210–212 these models all display 
expansion in HSC and progenitor cell compartments and increase in vivo repopulation 
capacity. TET2 knock-out mouse models are discussed in section 3.3.2.  
 
IDH1/2 
TET2 function requires alpha-ketoglutarate (αKG), αKG is produced from isocitrate by 
oxidative decarboxylation, a process that is catalysed by the isocitrate dehydrogenase 
(IDH) family of proteins. IDH1 and 2 are the family members implicated in 
haematopoiesis. In MPNs, mutations in IDH1/2 alter the enzymatic activity of these 
proteins and catalyses the reaction of αKG to 2-hydroxyglutarate (2HG). While TET 
proteins require αKG, 2HG impairs TET2 function. Targeted inhibition of IDH2 can 
restore leukaemic cell differentiation.128 Mutations in IDH1 and IDH2 have been 
described in AMLs (20%) and MDS (5%) patients.213 The most common mutation sites 
in IDH1 is at R132, and in IDH2 is at R140, and R172.213  
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Unlike TET2 knock-out mouse models, which have enhanced HSC self-renewal 
capabilities, IDH1 mutant mice have reduced numbers of HSCs and HSC self-
renewal.214 This is due to IDH proteins’ TET2 independent roles; there are over 80 
other αKG dependent enzymes.215 IDH1/2 mutations have also been shown to affect 
DNA damage by decreasing levels of ataxia telangiectasia mutated (ATM) (via altered 
methylation).214 ATM is recruited to double strands breaks and has a role in cell cycle 
during DNA repair. Reduced ATM levels in IDH1 mutant animals leads to impaired 
DNA repair and as a consequence increased sensitivity to DNA damage and then 




Beyond epigenetic alterations to DNA, epigenetic modifications can also affect gene 
expression through modification of histones. Histones are susceptible to many types of 
modification include acetylation, methylation, phosphorylation, ubiquitination, and 
sumoylation. The polycomb repressive complex 2 (PRC2) trimethylates histone H3 at 
lysine 27 (H3K27), one of the most common forms of histone modification. The 
complex is made up of 3 subunits EZH2, EED, and SUZ12. EZH2 (enhancer of zeste 
2) is the catalytic subunit of PRC2. The trimethylation of H3K27 (H3K27me3) is a 
mark of transcriptional silencing, this mark is stabilised by PRC1, which acts directly 
to silence target genes. Polycomb mediated repression is considered more readily 
revisable that DNA methylation.  
 
Trimethylation of histones (H3 lysine 9 (H3K9), histone H3 lysine 27 (H3K27), and 
histone H4 lysine 20 (H4K20)) has also been suggested as a prerequisite for DNA 
methylation. Components of these methylation systems interact with DNMTs, bringing 
DNMTs into proximity with areas for methylation. EZH2 has been shown to interact 
directly with DNMTs. Overexpression of Ezh2 has been shown to increase CpG 
methylation, and knock-down has been shown to reduce methylation in regions known 
to be targets for EZH2 mediated H3K27 methylation.205  
 
EZH2 has also been reported to have actions outside of its PRC2 histone methylation 
activity; as part of the PRC2 complex EZH2 methylates non-histone protein substrates 
(e.g. STAT3, GATA4, talin, and RORα), influencing transcriptional silencing and 
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activation.216  EZH2 also acts independently of PRC2, as a co-activator for transcription 
factors, such as AR-associated complex, NF-κB signalling, TCF/β-catenin and PCNA, 
and β-catenin and ERα.216 Overexpression, gain of function, and loss-of-function 
mutations in EZH2 have been detected in cancers, suggesting that EZH2 can function 
as a tumour suppressor gene or as an oncogene.216 In MPN and MDS patients, EZH2 
mutations generally are loss of function (numerous mutations have been detected 
through gene including nonsense or frameshift mutations).217 In MPNs, loss-of-
function EZH2 mutations have been found in ~10% of patients, like TET2 these 
mutations are associated with reduced survival and increased transformation risk when 
co-mutated with JAK2 V617F.217  
 
ASXL1 
Additional sex combs like 1 (ASXL1) is involved in chromatin remodelling though 
interactions with polycomb complex proteins (EZH2 and SUZ12), and therefore is 
involved in the placement of the histone repressive mark H3K27me3.218 Inhibition of 
ASXL1 results in loss of the H3K27me3 mark. The exact role of ASXL1 in the 
placement of this repressive mark is not known, but it is though that it may be involved 
in the recruitment of the PRC2 complex to the required loci. ASXL1 has also been 
reported to interact with the heterochromatin repressive component HP1α. HP1α is also 
involved in epigenetic silencing of genes and binds histone H3.218  
 
ASXL1 mutations in myeloid malignancies are most often frameshift or non-sense 
mutations in exon 12 of the gene.218 These mutations result in truncation of the protein 
before the c-terminal plant homeodomain, which is thought to bind methylated 
lysines.218 ASXL1 mutations have been reported in MPN (8% of patients), MDS (10%), 
and CMML (40%).219 Within MPNs ASXL1 mutations are relatively frequent in pMF 
patients (34%) but rare in PV or ET patients.218  
 
In MPN, ASXL1 and JAK2 mutations appear to be mutually exclusive. Both ASXL1 
and JAK2 have been reported to interact with HP1α; JAK2 causes phosphorylation of 
histone H3Y41 and excludes HP1α from chromatin.220 Activating JAK2 mutations and 
loss of function ASXL1 mutations, it can be hypothesised, would both exclude HP1α 
from chromatin. This could provide a functional link between the two mutations, but 
this is yet to be proven.218 
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1.10.3 Patients with only a JAK2 mutation  
There still exists a substantial cohort of JAK2 V617F-positive MPN patients with no 
known additional driver mutation. It must then be considered that if JAK2 V617F does 
not give an intrinsic clonal advantage (as suggested by mouse models below, section 
1.11.1), some additional factor(s) must influence a JAK2-mutant HSC outgrowth 
relative to the other HSCs in the body. Several possible explanations exist including: 
1) additional genetic or epigenetic drivers not yet identified by exome sequencing (e.g., 
long non-coding RNAs, enhancer elements, etc) indeed it has been suggested that, 
across all cancers, half of driver mutations are yet to be discovered;221 2) inherited 
genetic risk factors where some patients are more susceptible to cells gaining a clonal 
advantage (e.g. SNP profiles such as the 46/1 haplotype); and 3) micro-environmental 
factors (the physical niche itself or secreted cytokines) that encourage the outgrowth of 
mutant subclones.222 It is also interesting to note that JAK2 V617F mutations are found 
in a substantial percentage of older individuals with no obvious blood phenotype.222 
This latter finding would be consistent with a low number of poorly competitive JAK2 
V617F HSCs giving rise to more mature cells on a per-HSC basis, but an insufficient 
number to create an observable phenotype in an individual.  
 
1.11 MPN Mouse models  
1.11.1 JAK2 V617F knock-in mouse models 
A number of mouse models have been generated to gain understanding of the effect of 
common MPN mutations on disease initiation and progression. For a comprehensive 
review of more than 15 distinct JAK2 V617F mouse models see Li et al.191, including 
retroviral over-expression, transgenic, and targeted gene knock-in models. The most 
physiologically relevant of these models are the genetic knock-ins where the gene is 
under the control of endogenous elements. While some phenotypic diversity is observed 
between these knock-in JAK2 V617F models, they all recapitulate the main aspects of 
human disease. Although all groups report myeloid expansion from their models, the 
effect of the JAK2 V617F mutation on the self-renewal capacity of HSCs, as 
determined by secondary transplantation, has not been reported on so widely. Currently 
there are three JAK2 V617F knock-in models for which secondary transplantation data 
is available, developed by groups in Boston, Paris and Cambridge.  
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The Boston model (Mullally et al. 2010223) 
Upon competitive primary transplantation of LSK cells from the Boston model (E2A-
Cre/JAK2 V617F heterozygous) the group saw a myeloid expansion with over 80% of 
myeloid cells possessing the JAK2 mutation at 65 weeks post transplantation (223 
followed up in 224), suggesting a strong mutant cell advantage. However, when BM 
cells from the primary LSK transplants (2:1 JAK:WT) were tested in secondary 
transplantation, at 16 weeks post-transplantation164 JAK2 mutant cells did not display 
larger graft size than WT counterparts (Figure 5E164) (primary receipts shown in Figure 
4D,E223, and Figure 2A224). This suggests that, despite their relative advantage in 
primary transplantations, JAK2 mutant HSCs do not have the self-renewal advantage 
required for sustained clonal growth. Supporting this notion, when this mouse was 
crossed to a TET2-deficient mouse, the HSC self-renewal was enhanced, resulting in 
secondary chimerism from double mutant animals being over double of that from JAK2 
mutant alone (in secondary transplantation JAK alone chimerism ~40%, double mutant 
~90%).225  
 
The Paris model (Hasan et al. 2013226) 
Primary transplantation of BM cells from the Paris model (a conditional Vav-Cre/JAK2 
V617F heterozygous model) resulted in an expansion of the JAK2 mutant clone (Figure 
4A226). Here, transplantation experiments were performed using whole BM which 
would control for any potential selection imposed by sorting stem/progenitor cells. 
Mice transplanted with a 30:70 mutant:WT graft resulted in mutant cells representing 
~85% of the total myeloid cells, ~40% of the lymphoid and 99% of the total phenotypic 
LSK SLAM cells. Upon secondary transplantation (from 30% mutant: 70% WT BM 
transplantation primary, vehicle treated, over 75% chimerism by end of primary, Figure 
6A226) declining JAK2 mutant graft size was observed - 45% at 4 weeks falling to ~25% 
at 16 weeks (Figure 6C226), again suggestive of fewer (or less robust) functional HSCs 
being produced in the primary competitive transplant.  
 
The Cambridge model (Li et al. 2010227 and Li et al. 2014228) 
The Cambridge model (heterozygous227 and homozygous228 human JAK2 V617F under 
endogenous promoter) shows the most pronounced effect on the relative 
competitiveness of JAK2 V617F HSCs. When whole BM transplantations were 
performed using the JAK2 V617F heterozygous pIpC inducible model, elevated 
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myeloid lineages were observed, but there was no striking effect on HSC donor 
chimerism (Figure 6C227). In secondary competitive transplantations, a marked self-
renewal disadvantage in JAK2 V617F mutant HSCs was observed (Figure 6D227). 
 
The JAK2 V617F homozygous model also showed an HSC self-renewal defect, with 
some indication already present in the primary whole BM transplantation, as 
represented by a progressive decline in chimerism (Figure 6D228). The earlier 
presentation and exhaustion of functional HSCs may be due to the homozygosity of the 
JAK2 mutation, the fact that this model expresses human JAK2 rather than mouse, or 
as a result of the comparatively lower cell dose used for transplantation (ie. Large 
numbers of donor cells can sustain haematopoiesis in secondary transplantations). To 
assess if reduced chimerism was due to a reduced number of HSCs being transplanted 
(Fig. 6A/B227), purified HSC from JAK2 V617F homozygous, heterozygous and WT 
donors were transplanted and confirmed reduced repopulation in recipients of 
homozygous cells. (Figure 6I228). When secondary transplantation of whole BM from 
the homozygous model was performed,229 the relative loss of functional HSCs was 
more pronounced (Figure 4D229).  
 
Taking the data from these three models together, we can conclude JAK2 V617F drives 
a hyperproliferative advantage, as demonstrated by large myeloid clones in primary 
transplantation recipients, but the long-term self-renewal capacity of HSCs is not 
increased compared to WT HSCs. 
1.11.2 TET2 knock-out mouse models  
Due to the different targeting strategies used to produce the knock-in, JAK2 V617F 
mouse models exhibit considerable variability in their phenotype and HSC properties. 
Conversely mouse models of loss of function TET2 are all very similar, as they all have 
complete loss of TET2 function.  
 
Studies on models of loss of TET2, generated by Ko et al. 2011,210 Moran-Crusio et al. 
2011,135 Li et al. 2011,211 and Quivoron et al. 2011,212 all report an increase in size of 
the LSK compartment (proportion and absolute number), increased serial re-plating 
ability in vitro, and a competitive transplantation advantage. All groups also report an 
abnormal skewing of blood parameter towards a CMML phenotype (Table 2).  
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The TET2 knock-out model used throughout this thesis is the Ko et al. (2011210) model, 
generated by disruption of TET2s catalytic domain (by deletion of exons 8-10, exon 9 
contains HxD motif required for catalytic activity). These mice do not display any 
changes in myeloid, lymphoid, erythroid populations (by flow cytometry) but do have 
increased numbers of LSK and LK populations in their BM and spleens. TET2 knock-
out mice and recipients of TET2 knock-out BM have increased numbers of LSKs. 
Transplantation of BM from TET2 knock-out animals has shown HSCs from these 
animals have an increased repopulating capacity.210 Like other loss of TET2 models, 
this model shows that loss of TET2 leads to an increase in HSC self-renewal.  
 
 Quivoron et al. 
(2011) 212 
Moran-Cruzio 
et al. (2011)135 
Ko et al. 
(2011)210 
Li et al. (2011)211 
Models 











6 bp upstream of 
the transcription 
start 
5-hmC levels Decreased Decreased Decreased Decreased 
BM Lin-, c-Kit+   Increased, serial re-plating Increased Increased 
BM LSK CD150+ 
, CD48− Increased Increased Increased Increased 
BM progenitors Increased CMP, MEP Increased CMP Increased CMP Increased GMP 
Extramedullary 
haematopoiesis Spleen, Liver Spleen, 20 weeks 
Spleen 12 
weeks Spleen, 2–4 months 
Repopulation 
capability in vivo Increased Increased Increased Increased 









transplantability Yes Yes   Yes 
Table 2 Four mouse models of loss of TET2 show very similar features 
Adapted from Solary et al. (2013)128   
1.11.3 JAK2 V617F/TET knock-out double mutant models  
As JAK2 V617F is the most common mutant in MPNs, and a loss of TET2 function is 
its most common co-mutated partner, it is logical to combine these mutations to 
establish how the mutations interact and collaborate to drive disease. Chen et al. 
(2015225) were first to create a cross using the Boston JAK2 V617F knock–in model223 
and the Moran-Crusio et al. TET2 knock-out model135. The resultant JAK2/TET2 
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double mutant mice presented similarly elevated haematocrit and platelets to the JAK2 
V617F mice, alongside an increase in HSC numbers in the spleen and increased 
extramedullary haematopoiesis. The group showed, both in vivo and in vitro, that 
combining these two mutations improved the self-renewal of HSCs compared with 
JAK2 mutation alone.  
 
Chen et al. performed gene expression profiling of bulk stem and progenitor cells (LSK) 
from WT, JAK2 V617F, TET2 knock-out and JAK2 V617F/TET2 knock-out mice by 
microarray. They reported that the individual genotypes had differing gene expression 
patterns, however it was concluded that the genes they identified were unlikely to drive 
the differences in function due to the lack of differentially expressed genes in multiple 
comparisons and minimal fold changes between mutant and WT. They attributed the 
main differences in gene expression to targets of STAT5A signalling (upregulated in 
JAK2 V617F and JAK2 V617F/ TET2 knock-out cells), a consequence of hyper-
activation of the JAK/STAT signalling pathway. As the group performed gene profiling 
on bulk stem and progenitor cells they were unlikely to identify the drivers of this stem 
cell derived disease; less than 10% of the assayed LSK population are HSCs138, and as 
JAK2 V617F has different effects on stem cells and progenitor cells (driving exhaustion 
of HSCs but expansion of progenitors230), it is understandable that the group were 
unable to identify the molecular drivers of the disease at the stem cell level.  
 
Another JAK2 V617F TET2-mutant mouse cross has been performed by Kameda et al. 
(2015)231. This group crossed a JAK2 V617F transgenic model232 (not covered in 
previous section because not a knock-in model) with a TET2 knock-down model233  
(20% TET2 mRNA expression compared to WT). From this cross they obtained JAK2 
V617F TET2 knock-down E14.5 foetuses. FL cells from these animals were 
transplanted into lethally irradiated recipients. The recipients of double mutant cells 
exhibited an MPN-phenotype; splenomegaly, spleen and BM fibrosis, prolonged 
leucocytosis and shortened survival, a pMF-like disease. 
 
The authors observed an increased percentage of LSK cells in the BM of TET2 knock-
down and double mutant recipients, and an increased serial re-plating capacity of BM 
cells from the same mice. In competitive secondary transplantation (primary FL, 
secondary BM), double mutant cells gave rise to similar levels of chimerism to WT at 
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16 weeks post-transplantation, while in recipients of JAK2 V617F alone chimerism 
dropped to 5% (from 80% in primary) (at this point JAK2 recipients exhibited no MPN 
phenotype). The authors thus concluded that TET2 knock-down restores the JAK2 
V617F self-renewal defect, conferring a competitive self-renewal advantage to double 
mutant cells and allowing an MPN phenotype to be sustained long-term.  
 
Like Chen at el.225, Kameda et al.231 went on to do bulk gene expression of BM LSKs 
via microarray (BM from primary transplant). In JAK2 V617F and double mutant cells 
Kameda et al. also saw an enrichment in STAT5 target gene expression, alongside an 
enrichment in pre-erythroid forming colony gene signature. For the same reasons as 
Chen et al. this group were not able to detect the specific self-renewal genes altered in 
the JAK2, TET2 and double mutant HSCs, although they did report a reduction in HSC 
gene signature in JAK2 mutant cells – though this could be due to the reduced 
functionality of JAK HSCs, reduced number of JAK2 HSCs or reduced proportion of 
HSCs in LSK faction (due to increased progenitors).  
 
TET2 is not the only gene that is commonly co-mutated with JAK2 V617F, mutations 
in other epigenetic regulators such as EZH2 have also been found to collaborate with 
JAK2 mutation in MPNs. A JAK2 V617F/EZH2 null double mutant mouse model has 
been developed,234 this mouse is reported to have an MF like phenotype (with fibrosis 
of BM and spleen). Unlike JAK2/TET2 double mutant mouse models, which have 
haematocrit (HCT) and haemoglobin (HGB) elevated to the same extent as JAK2 
mutant alone, JAK2/EZH2 double mutant animals have reduced HCT and RBC count 
compared to JAK alone, causing authors to draw the conclusion that loss of Ezh2 
impairs/inhibits erythropoiesis (JAK2/EZH2 also have reduced spleen sized when 
compared to JAK2 alone). However, like TET2, in the transplantation setting, loss of 
EZH2 enhances the repopulation capacity of JAK2 V617F HSCS. 
 
Likewise, a JAK2 V617F/IDH2 R140Q double mutant mouse has been generated.235 
This mouse has elevated haematocrit, leukocyte count and splenomegaly. Competitive 
transplantation of BM from this double mutant mouse showed that, like loss of TET2, 
IDH2 R140Q leads to higher chimerism when combined with JAK2 V617F than JAK2 
mutation alone. Together these double mutant mouse models show that mutations in 
  Introduction 
 57 
epigenetic regulators combine with JAK2 V617F to enhance the repopulative capacity 
of HSCs. 
 
1.12 Aims of project 
Malignant HSCs share many of the same cellular processes and pathways as normal 
HSCs, but some processes must be hijacked to enable increased proliferation and/or a 
differentiation block. Consequently, it becomes important to not think of malignant 
HSCs as a completely separate cell state to normal HSCs, but rather a very close 
molecular relative. In recent years a number of technical advances have allowed the 
development of single cell approaches, permitting subtle changes in individual 
characteristics to be assessed on a cell by cell basis. This has allowed the study of the 
mechanism by which mutations initiate and sustain disease at previously unobtainable 
resolution.   
 
Since haematological malignancies often have more than one driver,236 and several 
aspects of HSCs can be affected by each mutation (e.g., JAK2 mutations alter cell cycle 
status, proliferation, differentiation and HSC self-renewal), it remains difficult to 
account for the cause of individual properties of disease when studying single mutations 
in isolation. Consequently, numerous groups have developed model models for 
common combinations of mutations.122,237,238 Studying combinations of mutations 
allows a full picture to be built up as to how each mutation influences disease 
characteristics. In studying the molecular effects of specific mutations on HSCs, mouse 
models are particularly useful, largely because it is possible to isolate murine HSCs at 
a much higher frequency compared to human, and additionally mouse models can be 
100% mutant, thereby avoiding complications of intra-patient HSC heterogeneity in 
mutational state.   
 
The aim of this thesis is to use both cellular and molecular single cell techniques to 
explore the functional and molecular consequences of the most common pair of 
mutations in MPN, JAK2 V617F and a loss of TET2, on murine HSCs, focusing on the 









JAK2 V617F knock-in mice228 were crossed with Tet2 knock-out mice from Ko et al., 
(2011).210 HSCs from single mutant mice (for brevity homozygous JAK2 V617F 
termed JAK HOM and homozygous TET2 null termed TET HOM) and double mutant 
(JAK HOM TET HET and JAK HOM TET HOM) animals were compared to wild-
type littermate (for JAK HOM) or age-matched (for TET HOM and double mutant) 
controls.  CALR mutant mice201 were donated by AR Green, loss of CBP mice239 were 
donated by BJP Huntly, NPM1 mutant mice240 were donated by GS Vassiliou, and P53 
knock-out mice241 were donated by KJ Patel. c-Kit mutant C57BL/6W41/W41-Ly5.1 (W41) 
or C57BL/6 mice were used as recipients for transplantation experiments. All recipient 
mice for transplantation were CD45.1, all donors CD45.2, and competitors were 
CD45.1/2 C57Bl/6 mice. All mice were bred and maintained at the University of 
Cambridge in microisolator cages and provided continuously with sterile food, water, 
and bedding. All mice were kept in specified pathogen-free conditions, and all 
procedures performed according to the United Kingdom Home Office regulations. 
 
2.2 Isolation of ESLAM HSCs and SLAM HSPCs 
Suspensions of BM cells were isolated from the femurs, tibiae, and iliac crests of mice. 
Red blood cell lysis was performed by treatment with ammonium chloride 
(STEMCELL Technologies, Vancouver, Canada (STEMCELL)), depletion of mature 
lineage cells was performed using EasySep mouse haematopoietic progenitor cell 
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enrichment kit (STEMCELL). ESLAM cells were isolated as described previously24 
using CD45 FITC (Fluorescein isothiocyanate) (Clone 30-F1,1 BD Biosciences, San 
Jose, CA, USA (BD Biosciences)), EPCR (CD201) PE (Phycoerythrin) (Clone 
RMEPCR1560, STEMCELL), CD150 PE-cy7 (Clone TC15-12F12.2, Biolegend, San 
Diego, USA (Biolegend)), CD48 APC (Allophycocyanin) (Clone HM48-1, Biolegend), 
and 7-Aminoactinomycin D (7AAD) (Thermo Fisher Scientific, Waltham, MA, USA 
(Thermo Fisher)). Although not used in the gating strategy, Sca1 (Ly-6A/E) Brilliant 
Violet (BV) 421 or Pacific Blue (PacB)(Clone D7, both Biolegend), and c-Kit (CD117) 
APC-cy7 (Clone 2B8, Biolegend) were included in some cases for BM analysis.  
Lineage markers (Lin) were, in some cases, stained for using the biotin conjugated 
EasySep Mouse Hematopoietic Progenitor Isolation Cocktail from the EasySep mouse 
haematopoietic progenitor cell enrichment kit (STEMCELL) and a secondary 
streptavidin-BV510 or BV605 (both Biolegend).  
 
Example gating for ESLAM cells (CD48-CD150+CD45+EPCR+) can be seen in Figure 
6 (results section 3.1), a similar strategy was used for HSPC (SLAM) isolation, but both 
EPCR positive and negative populations were sorted (Lin-CD48-CD150+CD45+). The 
cells were sorted on an Influx (BD Biosciences) using the following lasers; 405, 488, 
561, and 640, and filter sets; 530/40 (for FITC), 585/29 (for PE), 750LP (for PE-Cy7 
and APC-cy7), 670/30 (for APC and 7AAD), 460/50 (for PacB and BV421), 520/35 
(for BV510), 610/20 (for BV605). When single ESLAM HSCs were required, the 
single-cell deposition unit of the sorter was used to place 1 cell into the wells of 96 well 
round bottom plates, each well having been preloaded with 50μL medium (described 
below).  
 
2.3 In vitro cultures and clone size calculations 
ESLAM HSCs were sorted and cultured in StemSpan (STEMCELL) containing foetal 
bovine serum (FBS; STEMCELL or Sigma-Aldrich, St. Louis, MO, USA (Sigma-
Aldrich)), 300ng/mL stem cell factor (SCF; STEMCELL or Bio-techne, Abingdon, UK 
(Bio-techne)), 20 ng/mL interleukin (IL)-11 (STEMCELL or Bio-techne), 100 
units/mL Penicillin and 100μg/mL Streptomycin (Sigma-Aldrich), 2mM L-Glutamine 
(Sigma-Aldrich), and 0.1mM 2-Mercaptoethanol (Thermo Fisher) (together HSC 
medium). Cells were cultured at 37°C, 5% CO2. Cell counts were performed daily, and 
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cell cycle kinetics determined for the first and second division by visual inspection, 
manually scoring each well as having 1, 2, or 3-4 cells. At 10 days, clones were 
estimated to be very small (less than 50 cells), small (50–500 cells), medium (500–
10,000 cells), or large (10,000 or more cells). Clone size estimates were previously 
validated using fluorescent counting beads.230  Ten-day clones were stained with Sca1 
(Ly-6A/E) PacB (Clone E13-161.7, Biolegend), Mac1 (CD11b) BV605 (Clone M1/70, 
Biolegend), Gr1 (Ly-6G/Ly-6C) PE-cy7 (Clone RB6-8C5, Biolegend), c-Kit (CD117) 
APC-cy7 (Clone 2B8, Biolegend), CD45.2 FITC (Clone 104, Biolegend), and 7-AAD 
(Thermo Fisher), example gating in results (Figure 6). To enumerate cells, a defined 
number of fluorescent beads (Trucount Control Beads, BD Biosciences) were added to 
each well and each sample was back-calculated to the proportion of the total that were 
run through the cytometer. Small clones were not assessed individually by flow 
cytometry due to low numbers of cells. Flow cytometry was performed on an 
LSRFortessa (BD Biosciences) and all data were analysed using FlowJo (Treestar, 
Ashland, OR, USA). 
 
2.4 Isolation of patient stem and progenitor cells 
Fresh venous blood samples (40-60mL collected in S-Monovette Lithium-Heparin 
tubes (Sarstedt, Nümbrecht, Germany (Sarstedt)) were collected from MPN patients 
with JAK2 and TET2 mutations, diagnosed according to British Committee for 
Standards in Haematology (BCSH) guidelines. The study was approved by the 
Cambridge and Eastern Region Ethics Committee, and was carried out in accordance 
with the principles of the Declaration of Helsinki. Informed written consent was 
obtained from all patients before participating. Mononuclear cells (MNCs) were 
isolated using Lymphoprep (STEMCELL) according to the manufacturer's instructions. 
MNCs were washed with and stored at 4°C overnight in phosphate-buffered saline 
(PBS, Sigma-Aldrich) supplemented with 10% FBS (STEMCELL or Sigma-Aldrich). 
In the morning, cells were washed with PBS (Sigma-Aldrich). For those that were 
grown in vitro and for frozen MNCs, cells were spun at 300xg for 7 minutes and the 
resulting pellets were treated with 50μL of 1 mg/mL DNaseI (STEMCELL) to avoid 
clumping. Cells were then depleted of differentiated haematopoietic cells using the 
EasySep human haematopoietic progenitor enrichment kit (STEMCELL) with the 
following modifications: All samples were processed in 500μL of recommended 
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medium, and the sample was only taken through one round of separation. Cells were 
then stained with antibodies to isolate the various progenitor compartments: CD34 Per-
CpCy5.5 or PE-cy7 (clone 581, both Biolegend), CD38 FITC (clone HIT2, BD 
Biosciences), CD90 APC (clone 5E10, BD Biosciences) and CD45RA Horizon V450 
(clone HI100, BD Biosciences).  
 
CD34+CD38- cells were sorted into microcentrifuge tubes containing 500μL of 
PBS/10%FBS. HSCs were isolated as Lin-CD34+CD38-CD45RA-CD90+ using a BD 
Biosciences Influx sorter equipped with 355nm, 405nm, 488nm, 561nm, and 640nm 
lasers sorted directly into individual wells of a 96-well round bottomed plate. HSCs 
were sorted as single cells into StemSpan medium (STEMCELL) supplemented with 
the cc100 cytokine cocktail (STEMCELL), 100 units/mL Penicillin and 100μg/mL 
Streptomycin (Sigma-Aldrich), 2mM L-Glutamine (Sigma-Aldrich), and 0.1mM 2-
Mercaptoethanol (Thermo Fisher). For proliferation studies HSC derived clones were 
counted visually, on day 10 clones were classified by diameter as very small (<50 cells), 
small (50–500 cells), medium (500–10,000 cells), or large (10,000 or more cells). To 
improve genotyping accuracy, single HSC-derived cultures were harvesting and plated 
into a secondary CFC assay using Methocult 04435 (STEMCELL), the resultant 
colonies were genotyped for TET2 and JAK2 mutation status. 
 
2.5 Bone Marrow Transplantation Assays 
Donor cells were obtained from mice of various genotypes, all donor mice were on a 
C57BL/6J background (CD45.2). For whole BM non-competitive transplantations 
5x105 donor cells were transplanted alone. For limiting dilution transplantations 
100,000, 50,000 or 10,000 WT or JAK HOM TET HOM BM cells were transplanted 
alongside 100,000 competitor cells from WT C57BL/6J (CD45.1/CD45.2) mice. For 
whole BM competitive transplantations 5x105 donor cells were transplanted alongside 
5x105 competitor cells obtained from WT C57BL/6J (CD45.1/CD45.2) mice. 
For whole BM transplantation assays, recipients were adult W41 mice as described 
previously.242,243 Mice were irradiated with a single dose (400 cGy) by Caesium 
irradiation and all transplants were performed by intravenous tail vein injection using a 
29.5G insulin syringe. For competitive transplantation, on average, host cell recovery 
accounted for 30% of the total cells (15-60%) but since a known number of 
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genotypically distinct competitor cells were transplanted, host numbers were not 
required for calculations of relative chimerism between donor and competitor cells 
(donor/(donor+competitor)). For secondary transplantation, whole BM was obtained 
from primary recipients and 1x107 cells, containing a mixture of recipient, (competitor,) 
and donor-derived cells, were transplanted. 
 
2.6 Peripheral Blood and Bone Marrow Analysis 
For all transplantation assays, serial bleeds were performed, for these peripheral blood 
samples were collected in EDTA (Ethylenediaminetetraacetic acid) coated microvette 
tubes (Sarstedt) from the tail vein of mice at regular intervals following transplantation. 
Peripheral blood cell counts were performed using a Woodley ABC blood counter 
(Woodley Equipment, Bolton, UK). Red cell lysis was performed using ammonium 
chloride (STEMCELL) and samples were subsequently analysed for repopulation 
levels by flow cytometry, as described previously.27,242 For flow cytometry the 
following antibodies were used; Gr1 (Ly-6g/Ly6c) PacB or BV421 (Clone RB6-8C5, 
both Biolegend), Mac1 (CD11b) FITC or BV605 (Clone M1/70, both Biolegend), CD3 
PE (Clone 17A2, Biolegend), B220 (CD45R) APC (Clone RS3-6B2, Biolegend), 
CD45.1 AlexaFluor700 (AF700) (Clone A20, Biolegend), and CD45.2 APC-cy7 or 
FITC (Clone 104, both Biolegend). 7-AAD (Thermo Fisher) was used as a live/dead 
stain. Example lineage gating Figure 5. 
 
For transplants for which secondary transplantation was performed (competitive and 
non-competitive whole BM transplantation), at the end of the primary and secondary 
 
Figure 5 Example gating for post-transplantation peripheral blood 
Example of donor population gating from competitive and non-competitive 
transplantation (left), and donor lineages (right). B- and T-cells, granulocytes and 
macrophages are gated from live donor cells (7AAD-, CD45.2+, CD45.1- ). Cells which 
did not fall into any of these lineage gates were termed ‘other’. 
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transplantation time course, mice were sacrificed and BM harvested. BM was analysed 
by flow cytometry for lineage contribution (using the same panel as peripheral blood) 
and stem and progenitor cell contribution. For assessment of stem and progenitor cell 
contribution the following antibodies were used; CD45.1 AF700 (Clone A20, 
Biolegend), CD45.2 APC-cy7 or FITC (Clone 104, both Biolegend), EPCR PE (Clone 
RMEPCR1560, STEMCELL), CD150 PE-cy7 (Clone TC15-12F12.2, Biolegend), 
CD48 APC (Clone HM48-1, Biolegend), Sca1 (Ly-6A/E) BV605 (Clone D7, 
Biolegend), c-Kit (CD117) APC-cy7 (Clone 2B8, Biolegend). As before lineage 
markers were stained for using the biotin conjugated EasySep Mouse Hematopoietic 
Progenitor Isolation Cocktail from the EasySep mouse haematopoietic progenitor cell 
enrichment kit (STEMCELL) and a secondary streptavidin-BV510 (Biolegend), and 7-
AAD (Thermo Fisher) was used as a live/dead stain.  
 
2.7 Gene-expression profiling 
Single-cell gene expression analysis of HSC associated genes (Table 1) was performed 
as described previously.244,245 The 48 TaqMan assays (Thermo Fisher, primer IDs listed 
in Table 3) were pooled to a final concentration of 0.2X (a 1:100 dilution of each assay 
in TE buffer (Thermo Fisher)). Single HSCs were sorted directly into 96-well plates 
containing 5μL CellsDirect 2X reaction mix (Thermo Fisher), 0.1μL SUPERase RNase 
inhibitor (Thermo Fisher), 2.5μL 0.2X assay mix, 1.2μL TE buffer (Thermo Fisher) 
and 1.2μL SuperscriptIII/Platinum Taq (Thermo Fisher). Cell lysis and sequence-
specific reverse transcription were performed at 50°C for 15 minutes. The reverse 
transcriptase was inactivated by heating to 95°C for 2 minutes. Subsequently, in the 
same wells, cDNA went through sequence-specific amplification by denaturing at 95°C 
for 15s and annealing and amplification at 60°C for 4 min for 22 cycles, followed by a 
final 60°C for 4 min, then stored at -80°C. These preamplified products were diluted 
1:5 with TE buffer prior to analysis on the BioMark HD (Fluidigm, San Francisco, CA, 
USA (Fluidigm)). 48.48 dynamic arrays were run; each with 6 no template controls, 1 
positive control well (containing 10 cells) and 41 single cells. 48.48 dynamic arrays 
chips were loaded as per the manufacturer’s instructions using an IFC Controller MX 
(Fluidigm), and run on a BioMark HD (Fluidigm) using the GE 48.48 standard v1 
protocol (95°C for 10 minutes; 40 cycles of 95°C for 15 s and 60°C for 60 s). 
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Table 3 List of genes for which 
expression was analysed by single 
cell multiplex qPCR 
  
Gene  TaqMan order ID  
Bmi1 Mm00776122_gH  
Bptf Mm01251151_m1  
Cbfa2t3h Mm00486780_m1  
Cbx7 Mm00520006_m1  
Cdkn2a Mm00494449_m1  
Csf1r Mm01266652_m1  
Dnmt3a Mm00432881_m1  
Egfl7 Mm00618004_m1  
Eif2b1 (housekeeping) Mm01199614_m1  
Erg Mm01214246_m1  
Ezh2 Mm00468464_m1  
Fli-1 Mm00484409_m1  
Foxo3a Mm01185722_m1  
Gata1 Mm00484678_m1  
Gata2 Mm00492300_m1  
Gata3 Mm00484683_m1  
Gfi1 Mm00515855_m1  
Gfi1b Mm00492318_m1  
Hhex Mm00433954_m1  
Hoxa5 Mm00439362_m1  
Hoxa9 Mm00439364_m1  
Hoxb4 Mm00657964_m1  
Ikzf1 Mm01187882_m1  
Itga2b Mm00439768_m1  
Kit Mm00445212_m1  
Lmo2 Mm01281680_m1  
Lyl1 Mm01247198_m1  
Mecom Mm01289155_m1  
Meis1 Mm00487659_m1  
Mitf Mm01182480_m1  
Mpl Mm00440310_m1  
Myb Mm00501741_m1  
Nfe2 Mm00801891_m1  
Pbx1 Mm04207617_m1  
Polr2a (housekeeping) Mm00839493_m1  
Prdm16 Mm00712556_m1  
Procr Mm00440993_mH  
Runx1 Mm01213405_m1  
Sfpi1 Mm00488142_m1  
Sh2b3 Mm00493156_m1  
Smarcc1 Mm00486224_m1  
Smarcc2 Mm01159912_m1  
Tal1 Mm01187033_m1  
Tcf7 Mm00493445_m1  
Tet2 Mm00524395_m1  
Trib3 Mm00454879_m1  
Ubc (housekeeping) Mm01201237_m1  
Vwf Mm00550376_m1  
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Ct values were obtained from the system's software (BioMark Real-time PCR Analysis; 
Fluidigm). ΔCt values were calculated as previously described245 by cell-wise 
normalisation to the mean expression level of two housekeeping genes (Ubc and 
Polr2a). All housekeepers, Cdkn2a, Eif2b1, Meis1, Tet2, and Egfl7 were removed from 
the dataset for downstream analysis. Cdkn2a was not expressed in any of the cell types, 
Egfl7, Mitf, Cbx7, and Eif2b1 did not pass quality control in any genotype, Meis1 was 
excluded in the TET2 single and double-mutant genotypes due to aberrant signal in no 
template controls, and Tet2 was excluded since the TET2 knock-out cells had no 
expression and clustering would have been unfairly biased. Hierarchical clustering was 
performed in R (http://www.r-project.org) using the hclust package and heatmap.2 from 
the gplots package using Spearman rank correlations and ward linkage. T-distributed 
stochastic neighbour embedding (t-SNE) was performed in R (http://www.rproject.org) 
using the Rtsne package. Principal component analysis (PCA) was performed using the 
prcomp function. 
 
2.8 Lentivirus production  
Lentivirus production was performed with HEK Lenti-X 293T cells (Takara Bio Inc, 
Kusatsu, Japan (Takara)) using TransIT-LT1 (Mirus Bio, Madison, WI, USA). Cells 
were co-transfected with the plasmid of interest in a pCCL-c-MNDUS-X2-PGK-EGFP 
backbone, pMDLg/pRRE (Gag-Pol), pRSV-Rev (Rev), pMD2.G (VSV-G envelope) 
pAdVAntage (Promega, Madison, WI, USA; increases lentirvirus production246) (all 
kindly provided by Priyanka Tibarewal, University of Cambridge).   
HEK Lenti-X 293T cells were cultured in low glucose Dulbecco’s modified Eagle’s 
medium with GlutaMAX and sodium pyruvate (Thermo Fisher), supplemented with 
10% FBS (Sigma-Aldrich), 2mM L-Glutamine (S Sigma-Aldrich), 100 units/mL 
penicillin and 100ug/mL streptomycin/mL (Sigma-Aldrich). 16 hours after liposomal 
transfection, cell culture medium was supplemented with 10-12.5 mM sodium butyrate 
(Sigma-Aldrich). After 6 hours, cells were washed with PBS (Sigma-Aldrich) and cell 
culture medium replaced (Iscove's Modified Dulbecco's Medium (IMDM) with 
GlutaMAX, sodium pyruvate and 25mM HEPES buffer (Thermo Fisher), 
supplemented with 10% FBS (Sigma-Aldrich), 2mM L-Glutamine (Sigma-Aldrich), 
100 units/mL penicillin and 100ug/mL streptomycin/mL (Sigma-Aldrich)). 22 hours 
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later, the virus-containing supernatant was collected and filtered through 0.45μm 
syringe filters. Virus was concentrated by ultracentrifugation (using a Beckman Coulter 
Optima XPN 80K, Beckman Coulter, Brea, CA, USA) at 25,000rpm for 2 hours (with 
breaks off), before being resuspended in IMDM (w 25mM HEPES, STEMCELL) and 
stored at -80oC.  
 
2.9 Overexpression assays  
Small pools (1500-3600 cells) of CD45+Lin-CD150+CD48- haematopoietic stem and 
progenitor cells (HSPCs) were isolated (as described above) and split between wells of 
a 96 well plate coated with RetroNectin (Takara). Following their isolation, cells were 
kept in 50μL of HSC medium (described above) and were supplemented with polybrene 
(Sigma-Aldrich) and a lentivirus equipped with the gene of interest in a pCCL-c-
MNDUS-X2-PGK-EGFP backbone. Plates were centrifuged at 600 x g for 30 minutes, 
30oC, to promote infection, before being transferred to a 37oC incubator. The following 
day, a further 150μL of HSC medium was added to dilute the polybrene and virus. 
Three days after infection, cells were resorted for green fluorescent protein (GFP) 
expression and viability (i.e. GFP+ 7AAD-). Cells (300-2000) were transplanted into 
sublethally irradiated (400cGy) CD45.1 W41 or lethally irradiated (1100cGy) CD45.1 
C57Bl6/J recipient mice and monitored for donor chimerism and disease phenotype as 
described above. At the end of the transplantation time course recipient mice were 
sacrificed and their spleens measured and weighed to assess for splenomegaly.  
 
2.10 Primary patient sample and mouse post-transplantation 
gene expression  
RNA was extracted from sorted human CD34+CD38- cells, and mouse SLAM cells 
(CD45+CD48-CD150+) using the PicoPure RNA isolation kit (Thermo Fisher) as per 
the manufacturer's instructions, with on column DNase treatment using RNase-free 
DNase set (Qiagen, Hilden, Germany), and elution in 11μL. First strand cDNA 
synthesis was performed using SuperScript III First-Strand Synthesis System for RT-
PCR (Thermo Fisher), using Random Hexamers, as per the manufacturer's guidelines; 
10μL of template cDNA was used, with 1.25μL of Random hexamers and 1.25μL dNTP 
mix (as 10μL of cDNA was used, the volumes of components were scaled to 1.25x the 
recommend volumes). qPCR was carried out using TaqMan probes (probe IDs for 
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mouse as listed in Table 3, for human listed in Table 4) and TaqMan universal master 
mix, as per the manufactures instructions, in a 20μL reaction with 2μL of cDNA. qPCR 
assays were run and analysed using the Applied Biosystems ViiA 7 system (Thermo 
Fisher). The expression of individual genes relative to a housekeeping gene (GAPDH) 
was calculated as R = 2-[CT target – CT housekeeping].247  
 






Table 4 List of genes for which expression was analysed in human samples by qPCR 
 
2.11 Statistical Analyses 
For comparison of cell division kinetics and colony size two-tailed Fishers Exact test 
was used, for calculating cluster enrichment scores Chi-squared test was performed 
(two-tailed, yates correction), for both the web based calculator at 
https://www.graphpad.com/quickcalcs/contingency1/ was used. For all other p values 
reported, an unpaired Student’s t-test (Microsoft Excel) was used. For comparison of 
blood parameters t-tests were one-tailed with unequal distribution. For all others two-
tailed with unequal distribution.  
Stem cell frequency from limiting dilution transplantation was calculating using the 









I began this chapter by focusing on the effect of JAK2 and TET2 mutations, both 
individually and in combination, on murine HSCs in culture. I then explored if the 
phenotypes displayed by the JAK2 and TET2 mutant HSCs are shared with other 
common mutations in myeloid malignancy with similar characteristics. Finally, I 
validated the effects of JAK2 and TET2 HSC in vitro using data from the culture of 
human MPN patient stem and progenitor cells. The human data in section 3.3 was from 
work carried out by Christina Ortmann and David Kent 190 
 
The JAK2 mutant and TET2 mutant models used throughout this thesis are a 
homozygous human JAK2 V617F under the control of the mouse endogenous 
promoter,228 and a partial or complete TET2 knock-out.210 For the sake of brevity, 
homozygous JAK2 V617F animals will be termed JAK HOM, homozygous loss of 
TET2 animals TET HOM, heterozygous loss of TET2 TET HET, and double mutant 
animals the appropriate combination of these terms (e.g. JAK HOM TET HOM).  
 
3.1 JAK2 V617F drives increased proliferation and 
differentiation of HSCs in vitro, irrespective of TET2 status  
The study of HSCs often begins with the isolation of purified populations of HSCs. 
Throughout this thesis CD45+EPCR+CD48-CD150+ (ESLAM) sorting strategy (Figure 
6) was used to isolate enriched population of HSCs, this population has been shown to 
be 40%-50% long-term repopulating HSCs by single cell transplantation studies.24  





Figure 6 Schematic of single cell in vitro culture and representative images 
Single CD45+EPCR+CD48-CD150+ (ESLAM) cells (representative gating, yellow box) 
were sorted into individual wells of 96 well plate, cultured for 10 days in StemSpan 
with 10% FCS, 300ng/mL SCF, and 20 ng/mL IL-11, and assessed for proliferation, 
cell cycle kinetics, and differentiation. Representative images very small (VS), small 
(S), medium (M) and large (L) clones at day 10; pink box. Representative gating of a 
day 10 clone (blue box); gating for live cells (7AAD-), differentiated cells (Lin+; Mac1+ 
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Hyperproliferation is a key trait of leukaemic clones, and as discussed in the 
introduction (section 1.6.1) there are a number of assays that can be used to assess 
hyperproliferation in vitro. The single cell liquid culture system was used here; this 
assay allows division kinetics from a single starting HSC to be assessed by daily counts, 
the clone size and lineage composition to be assessed by flow cytometry, and permits 
these functional findings to be coupled with initial HSC cell surface marker expression. 
 
To determine the effect of JAK2 V617F expression and TET2 knock-out on HSCs in 
culture, single ESLAM HSCs were cultured in liquid culture conditions that support 
HSC self-renewal; briefly StemSpan medium supplemented with FBS, L-glutamine, 
penicillin, streptomycin, 300ng/mL SCF, and 20 ng/mL IL-11,248 and daily counts 
performed. After 9-10 days in culture, colony size was assessed visually (representative 
images of clone sizes in Figure 6); clones with fewer than 50 cells were grouped as very 
small clones, clones with between 50 and 500 cells were classified as small clones, 
clones containing between 500 and 10,000 cells were termed medium clones, and 
clones with over 10,000 cells dubbed large clones. The composition of each individual 
clone was assessed by flow cytometry (representative flow cytometry plots, Figure 6), 
and absolute cell numbers determined using Trucount beads (BD Bioscience). 
 
Comparison of the cell division kinetics between WT and JAK HOM ESLAM HSCs 
showed JAK HOM HSCs exited quiescence more quickly (Figure 7). JAK HOM HSCs 
having a shorter time to first cell division; after 2 days in culture 87.67% JAK HOM 
cells had divided vs 60.31% WT cells (Figure 7 top left, p<0.0001). This was followed 
by a shorter time to subsequent cell division, with an increased proportion of JAK HOM 
HSCs (45.5%) having completed their second division after 2 days in culture compared 
with WT controls (16.6%) (Figure 7 top right, p < .0001). Assessment of clonal progeny 
of individual HSCs showed that colonies from JAK HOM HSCs were on average larger 
(Figure 7 bottom left, p VS p<0.0001, S p<0.0001, M p=0.0003, L p<0.0001) and more 
differentiated (Figure 7 bottom middle, p<0.0001) and contained proportionally fewer 
progenitor cells (LSK; Figure 7 bottom right, p<0.0001) than clones grown from HSCs 
obtained from WT littermate controls.  
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When loss of TET2 alone was studied, no change was seen from WT controls in time 
to exit from quiescence (Figure 8 top left, at 2 days p=0.903) or time to subsequent cell 
division (Figure 8 top right, at 3 days p=0.381). Supporting the finding that cell division 
kinetics are unaffected by loss of TET2, there was also no difference between TET 
HOM and WT day 9 clone size (VS p=0.029, S p=0.953, M p=0.020, L p=0.559). 
Likewise, no change was seen in the frequency of lineage positive (p=0.369) or LSK 
(p=0.951) cells within the TET knock-out clones, relative to WT clones (Figure 8).  
 
In order to determine how these two mutations affect HSC proliferation when combined 
- whether double mutant HSCs have a JAK V617F- or TET knock-out -like ‘phenotype’ 
or somewhere in between - HSCs from double mutant mice (homozygous for JAK2 
 
Figure 7 JAK2 V617F alone drives increased proliferation and differentiation of 
HSCs in vitro 
Daily cell counts reveal that JAK HOM HSCs (red line, N=8) have accelerated cell 
cycling when compared with WT HSCs (blue line, N=8) as indicated by a shorter time 
to first and second division, p<0.0001 at 2 days for both. JAK HOM HSCs give rise to 
on average larger clones than WT littermates, p<0.0001. JAK HOM HSCs (red bars) 
give rise to an increased number of differentiated cells (Lin+)(p<0.0001) and a reduced 
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V617F and either heterozygous or homozygous for loss of TET2) were tested in the 
same assay.  
 
When heterozygous loss of TET2 was combined with homozygous JAK2 V617F (JAK 
HOM TET HET), entry into cell cycle was accelerated (Figure 9 top left, at 2 days 
89.7% of JAK HOM TET HET HSCs had divided vs 60% of WT p > 0.0001), cell 
cycle transit time was increased (Figure 9 top right, at day 3 p>0.0001), and average 
clone size was increased (Figure 9 bottom left, VS, S, L all p<0.0001, M p=0.0003), 
similar to the phenotypes observed in JAK2 V617F homozygous HSCs. Clones derived 
from JAK HOM TET HET HSCs also had an increased proportion of mature lineage 
marker-positive cells (Figure 9 bottom middle, p=0.004) and a decreased proportion of 
primitive progenitor (LSK) cells (Figure 9 bottom right, p>0.0001).  
 
 
Figure 8 Loss of TET2 alone does not alter proliferation and differentiation of HSCs 
in vitro 
TET HOM alone HSCs (green line, N=5) do not have altered cell cycling compared to 
WT HSCs (blue line, N=8), for 1st division at day 2 p=0.903, and for 2nd division at 
day 3 p=0.381. TET HOM HSCs do not give rise to more large clones than WT HSCs, 
p=0.559. TET2 clones (green bars) contain similar proportions of Lin+ (p=0.369) and 
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Similarly, when complete loss of TET2 was combined with homozygous JAK2 V617F 
(JAK HOM TET HOM), time to first division was reduced (Figure 10 top left, at day 2 
p>0.0001 at 2), as well as time to second division (Figure 10 top right, at day 3  
p>0.0001). Just as in JAK HOM alone and JAK HOM TET HET, average clone size 
was increased (Figure 10 bottom left, VS p=0.0005, S p<0.0001, M p=0.078, L 
p<0.0001), the proportion of lineage positive cells was increase (Figure 10 bottom 
middle, p=0.018), and proportion of LSK cells decreased relative to WT clones (Figure 
10 bottom right, p=0.001). From these models it can be concluded that compound loss 
of TET2 does not reverse the JAK2 V617F-induced cycling and hyperproliferation 
phenotypes observed in single in vitro HSC functional assays. 
 
 
Figure 9 Homozygous JAK2 V617F combined with heterozygous loss of TET2 
accelerates HSC proliferation in vitro 
JAK HOM TET HET HSCs (yellow line, N=4) have accelerated cell division kinetics 
when compared with WT HSC (blue line N=8) as indicated by a shorter time to first 
(p<0.0001 day 2) and second division (p<0.0001 day 3). JAK HOM TET HET HSCs 
give rise to on average larger clones than WT HSCs, p<0.0001. JAK HOM TET HET 
HSCs (yellow bars) give rise to an increased number of differentiated cells (Lin+, 
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Figure 10 Homozygous JAK2 V617F combined with homozygous loss of TET2 
accelerates HSC proliferation in vitro 
JAK HOM TET HOM HSCs (orange line, N=6) have accelerated cell division kinetics 
when compared with WT HSCs (blue line, N=8) as indicated by a shorter time to first 
(p<0.0001 day 2) and second division (p<0.0001 day 3). JAK HOM TET HOM HSCs 
give rise to on average larger clones than WT HSCs, p<0.0001. JAK HOM TET HOM 
HSCs (orange bars) give rise to an increased number of differentiated cells (Lin+, 
p=0.018) and a reduced number of stem/progenitor cells (LSK, p=0.001). Error bars 
are SEM. 
 
3.2 Impact of myeloid malignancy mutations on murine 
HSC kinetics in vitro   
To assess whether genes commonly found to be mutated in patients with myeloid 
malignancies cause generalised effects on HSCs, for example do all signalling 
mutations accelerate cell cycle? ESLAM HSCs from a number of models of myeloid 
malignancy were cultured in vitro and assessed for their cell cycle kinetics, and 
subsequent day 10 colony size.  
3.2.1 CALR mutant HSCs behave similarly to JAK2 mutant HSCs in 
vitro  
CALR is one of the three genes most commonly mutated in MPNs, alongside JAK2 
























































0 1 2 3 4 5
Days in culture






































































  Results 
 75 
signalling pathway (see introduction section 1.10.1 signalling mutations in MPNs). As 
mentioned in the introduction, a CALR mutant mouse mimicking the CALR del52 
mutation, commonly seen in patients, has been developed.201 Both homozygous and 
heterozygous versions of this model have been reported to have an elevated number of 
ESLAM HSCs, but neither have a competitive advantage upon primary or secondary 
transplantation. To determine the similarity between CALR mutation and JAK2 
mutation on the in vitro capabilities of HSCs, homozygous (CALR HOM) and 
heterozygous (CALR HET) CALR mutant ESLAM HSCs were cultured in the same 
manner as above (Figure 6).  
 
When compared to WT cells, neither CALR HET nor HOM HSCs were significantly 
different in their time to first cell division (at 2 days HET p=0.510, HOM p=0.434, 
Figure 11 left). However, CALR HOM HSCs were substantially accelerated in their 
time to second cell division (98.88% CALR HOM divided vs 88.17% of WT at day 3, 
p=0.005, Figure 11 middle). CALR HET HSCs were not significant different to WT in 
their time to second division (at day 3 p=0.825). After 10 days in culture, compared to 
WT HSCs, CALR HET HSCs had given rise to a larger proportion of large colonies 
(36.36% CALR HET vs 18.28% WT, p=0.007), but the proportion of large colonies 
from CALR HOM HSC was higher still (66.29%, p < 0.0001) (Figure 11 right).  
 
 
Figure 11 Homozygous and heterozygous CALR mutant HSCs give rise to on average 
larger clones after 10 days in culture 
While neither CALR HET (purple line, N=1) or CALR HOM (pink line, N=1) have 
accelerated entry into cell cycle (first cell division, left, at 2 days HET p=0.510, HOM 
p=0.434,) compared with WT HSC (blue line, N=1). CALR HOM HSCs have a reduced 
time to second cell division (day 2 p<0.0001). Both CALR HET and HOM give rise to 
larger clones after 10 days in culture (HET p=0.007, HOM p < 0.0001).  
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3.2.2 CBP null HSCs have delayed cell division kinetics  
Inactivating mutations in Cyclic AMP Response Element Binding (CREB)-binding 
protein (CBP, also known as CREBBP) have been reported in numerous 
haematological malignancies including ALL and B-cell lymphoma.249,250 CBP is a 
protein of many functions and can influence gene expression in a number of ways251; 
firstly, in its role as a molecular scaffold, CBP facilitates the coupling of transcription 
factors with transcriptional machinery. Secondly, CBP remodels chromatin by histone 
acetylation, thereby opening chromatin and facilitating transcription. Thirdly, CBP can 
act to acetylate, and consequently activate, associated proteins including p53 (discussed 
below) and GATA-1, which have well established roles in haematopoietic 
differentiation.251 
 
As inactivating CBP mutations are common in cancers, CBP knock-out mice have been 
developed. Due to CBP having an essential role in the development of HSCs, and 
deletion of CBP being embryonic lethal, conditional CBP knock-out mice have been 
developed to investigate the role of CBP in adult tissues. A conditional CBP model 
(conditional deletion of exon 9252) has been crossed with Mx1-Cre to generate a model 
with conditional ablation of CBP upon pIpC treatment.239 This mouse has been shown 
to have a myeloid (Granulocyte/Macrophage; GM) differentiation bias and self-renewal 
defect, as determined by serial competitive transplantation.239 
 
Unlike the previously described models which have equal or accelerated cell division 
kinetics compared to WT, HSCs from the CBP mutant model have slower entry into 
 
Figure 12 CBP mutation delays HSCs proliferation in vitro 
CBP mutant HSCs (pink line, N=2) had a delayed entry into cell cycle (time to first 
division) compared with WT HSCs (blue line, N=2), (at 2 days p=0.002), and a 
prolonged time to subsequent cell division (at 3 days p=0.0001). After 10 days in 
culture CBP mutant clones were on average smaller than equivalent WT clones (VS, 
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cell cycle compared to WT (Figure 12 left, at 2 days 77.44% of CBP HSCs had divided 
vs 90.48 % of WT HSCs, p=0.002) and delayed time to subsequent cell divisions 
(Figure 12 middle, at 3 days 72.46% of CBP HSCs had completed 2 divisions vs 90 % 
WT, p=0.0001), resulting in smaller average clone sizes after 10 days in culture (Figure 
12 right, VS, M, L p=0.0001, S p=0.217).  
3.2.3 NPM1 mutant HSCs have delayed cell division kinetics  
Nucleophosmin 1 (NPM1) is the most frequently mutated gene in AML, mutated in 
approximately 30% of AML patients and over 50% of cytogenetically normal 
AML.253,254 Under normal conditions NPM1 is a molecular chaperone, and has been 
implicated in facilitating centrosome duplication and ribosome biogenesis, as well as 
regulation of the ARF-p53 tumour suppressor pathway.253 In order to complete these 
many roles NPM1 shuttles between the nucleus and cytoplasm but is predominantly 
found in the nucleus. When mutated in AML patients, the nuclear localisation signal is 
disrupted leading to an accumulation of NPM1 in the cytoplasm (NPM1c).255 These 
mutations are always heterozygous, as a WT copy of NPM1 is required for cell 
survival.256 The most common type of NPM1 mutation is type A, this mutation is a 4 
nucleotide duplication in exon 12, causing a shift in the reading frame, replacing the 
last 7 amino acids of the C-terminus with 11 different amino acids, thereby altering the 
nuclear localisation signal into a nuclear export signal.253  
 
A NPM1 mutant mouse has been created by Vassiliou et al. (2011).240 This mouse is a 
conditional humanised Npm1c knock-in, with a type A NPM1 mutation induced by 
pIpC treatment (Mx1-Cre) (hereafter this mouse will be referred to as NPM1 mutant). 
 
This NPM1 mutant mouse model has an increase in Mac1+ and Gr1+ cells, and 
reduction in B cells (B220+/CD19+), indicating a myeloid expansion/bias. NPM1 
mutant HSC have increased serial re-plating capacity in methylcellulose, a surrogate 
for self-renewal potential. 30% of NPM1 mutant mice develop AML, leading to on 
average shorter life expectancy of NPM1 mutant vs WT animals. The mice that 
developed AML had enlarged spleens and livers, AMLs from these mice were 
transplantable. Additional mutations (induced by transposon mutagenesis using 
sleeping beauty transposon) accelerate AML development, with 80% animals 
developing AML within 1 year, indicating that additional mutations may be required to 
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combine with NPM1 (most common co-mutations in patients are FLT3-ITD and 
DNMT3A).  
 
In vitro, HSCs from NPM1 mutant mice had slower entry into cell cycle, compared to 
WT HSCs (Figure 13 left, after 2 days in culture 87.03% of WT HSCs had divided vs 
70.76% of NPM1 mutant HSCs, p=0.0002), and longer time to subsequent cell 
divisions (Figure 13 middle, after 3 days in culture 88.17% of WT HSCs had completed 
2+ divisions, vs 62.64% of NPM1 HSCs, p=0.0001). This delay in cell division resulted 
in smaller average clone size in NPM1 mutant clones after 10 days in culture (Figure 
13 right, VS, M, L p=0.0001, S p=0.021).  
3.2.4 P53 null HSCs have equivalent cell division kinetics to WT 
HSCs in vitro   
P53 is a transcription factor which, when induced by stress, results in cell cycle arrest, 
apoptosis and senescence.257 TP53, the gene that encodes p53 in humans, is the most 
frequently mutated gene in cancers, it is mutated or deleted in approximately 50% of 
all cancers including haematological malignancies.258 10% of primary AML and MDS 
patients have p53 mutations and 30% of patients who have MDS or AML secondary to 
radiation or chemotherapy have p53 mutations. P53 mutations are also commonly 
found in individuals with ARCH.259  
 
A p53 knock-out mouse has been developed. This mouse has a 450 base pair deletion 
of the Trp53 gene (mouse p53 gene), including the exon 5 splice acceptor site, this leads 
 
Figure 13 NPM1 HSCs have delayed cell division kinetics compared when with WT 
HSCs. 
When compared with WT HSCs (blue line, N=2), a smaller proportion of NPM1 mutant 
HSCs (pink line, N=3) have entered into cell cycle after 2 in culture (p=0.0002) or 
completed 2+ cell divisions after 3 day in culture (p=0.0001). After 10 days in culture 
NPM1 HSCs had given rise to a larger proportion of VS clones than WT HSC 
(p=0.0001). Error bars are SEM. 
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to complete knock-out of p53 protein.241 74% of mice homozygous for this mutation 
developed tumours by 6 months of age, most commonly malignant lymphomas. 
 
In HSCs, p53 has roles in maintaining quiescence and DNA damage response. P53 null 
mice have been reported to have an increased number of immunophenotypic HSCs 
(both LSKCD34- cells260 and CD150+Sca1+c-Kit+CD41-CD48-Lin- cells261), as p53 has 
roles in DNA damage response and apoptosis it has been suggested that this increase is 
due to decreased apoptosis from this population. However, Annexin-V staining of LSK 
fraction found no significant differences in levels of apoptosis compared with WT 
cells,261 suggesting that an increase in self-renewal may be responsible for the increase 
in phenotypic HSCs. This is supported by serial competitive transplantation data that 
has shown p53 null HSCs have an enhanced self-renewal potential.258  
 
The method by which loss of p53 achieves increased self-renewal has been 
hypothesised to be through its interaction with EZH2, the epigenetic 
regulator/polycomb protein commonly mutated in B-cell lymphomas, MDS, MPN, and 
T-cell ALL (see introduction section 1.10.2).216 Overexpression of EZH2 in HSCs 
increases their self-renewal capacity. Mutant p53 acts to enhance EZH2s association 
with the chromatin, thus increasing the levels of H3K27me3 methylation and thereby 
influencing the expression of self-renewal and differentiation genes.258  
 
When single p53 null HSCs were cultured in vitro they performed very similarly to WT 
HSCs in terms of entry into cell cycle (Figure 14 left, day 2 p=0.662), time to 
 
Figure 14 P53 HSCs behave similarly to WT HSCs in in vitro cultures 
P53 HSC (pink line, N=4) have similar cell division kinetics to WT HSC (blue line, 
N=4) in terms of their time to first and second division (no statistical difference between 
proportion completed first division at day 2, p=0.662, or second division at day 3, 
p=0.505). P53 HSCs gave rise to a similar proportion of VS (p=0.883), S (p=0.940), 
M (p=0.618), and L (p=0.524) clones to WT HSCs after 10 days in culture. Error bars 
are SEM. 
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subsequent cell division (Figure 14 middle, day 3 p=0.505), and clone size after 10 days 
in culture (Figure 14 right, VS p=0.883, S p=0.940, M p=0.618, L p=0.524).  
 
3.3 MPN patient JAK2 V617F and TET2 mutant HSPCs 
validate murine in vitro findings  
To validate the findings from the JAK2 V617F and TET2 knock-out mouse models in 
patient samples, data was utilised from isolated human Lin-CD34+CD38-
CD90+CD45RA- cells (hHSPCs) from MPN patients with JAK2 and TET2 
mutations.190 Single hHSPCs were cultured in stem cell maintenance conditions and 
divisional kinetics were tracked for 10 days. Individual clones were plated in a colony 
forming cell assay for a further 14 days before being harvested for genotyping (Figure 
15), allowing retrospective assignment of mutational status to the initial sorted cells.  
 
Like in the mouse model, hHSPCs with a JAK2 mutation alone had a shorter time to 
entry into cell cycle (Figure 17 left, after 3 days in culture 74% of JAK2 mutant hHSPCs 
had divided vs 51.85% of non-mutant cells, p=0.015), and reduced time to subsequent 
cell division (Figure 17 middle, after 4 days 77.45% JAK2 mutant completion 2+ 
divisions vs 50.88% of non-mutant cells, p<0.0001). However, unlike in the mouse 
model, this did not lead to significantly larger clones after 10 days in culture (Figure 17 
right, VS p=0.202, S p=0.786, M p=0.054, L p=0.674).  
 
Like the TET2 mouse model, hHSPCs with a TET2 mutation alone did not have 
division kinetics significantly different to WT HSPCs (Figure 16 left and middle, 1st 
division at day 3 p=0.582, 2nd division at day 4 p=1). However, unlike the mouse model, 
 
Figure 15 Schematic of in vitro cultures from patient samples 
Single Lin-CD34+CD38-CD90+CD45RA- cells (HSPCs) were sorted from MPN patient 
peripheral blood samples (3 essential thrombocythemia, 5 polycythemia vera, 4 
secondary myelofibrosis) into 96-well plates, and cell counts were performed daily for 
10 days. On day 10 clones were harvested and plated in a colony-forming cell assay, 
and the colonies produced were harvested for genotyping. 
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this did result in on average smaller colonies after 10 days in culture (Figure 16 right, 
65% of TET mutant colonies contain fewer than 50 cells, compared with 26.32% of 
non-mutant colonies, p<0.0001).  
 
Like in the mouse models, JAK2 TET2 double mutant cells from patients closely 
resembled JAK2 V617F alone. With accelerated time to first division (Figure 18 left, 
70.45% JAK2 TET2 double mutant cells divided by day 3 vs 51.85% of non-mutant 
cells, p=0.002) and second division (Figure 18 middle, 66.46% of JAK2 TET2 mutant 
cells completed 2+ divisions by day 4 vs 50.88% of non-mutant cells, p=0.013). Like 
with JAK2 mutation alone, no significant differences were observed in terms of day 10 
colony size (Figure 18 right, VS p=0.120, S p=0.332, M p=0.588, L=1). 
 
Figure 17 JAK2 V617F hHSPCs have accelerated cell division kinetics but do not 
make larger clones after 10 days in culture 
After 3 days in culture the proportion of JAK2 V617F HSPCs (JAK2, red line, N=11) that 
have entered into cell cycle is higher than that in non-mutant HSPCs (NM, blue line, N=11) 
(p=0.015), and after 4 days in culture a larger proportion have completed 2+ cell divisions 
(p<0.0001). This did not lead to a larger proportion of large clones after 10 days in culture 
(p=0.674). Error bars are SEM. 












































































































Figure 16 TET2 mutant hHSPCs have ‘normal’ cell division kinetics but make on 
average smaller clones after 10 days in culture 
After 3 days in culture a similar proportion of TET2 mutant (TET2, green, N=2) and non-
mutant hHSPCs (NM, blue, N=11) has entered into cell cycle (p=0.582), and after 4 days 
in culture a similar proportion had completed 2+ cell divisions (p=1). After 10 days in 
culture, compared with non-mutant clones, a larger proportion of TET2 mutant clones 
were very small (p<0.0001). Error bars are SEM. 
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Despite differences in the day 10 colony size, the human data mirrors the division 
kinetics seen in the mouse models; JAK2 V617F increases proliferation of primary 
HSCs, in the presence or absence of a TET2 mutation, and that TET2 loss on its own 
does not confer a proliferation advantage on HSCs in vitro. 
 
 
Figure 18 hHSPCs with JAK2 and TET2 mutations have accelerated cell division 
kinetics but do not make larger clones after 10 days in culture 
After 3 days in culture the proportion of JAK2 TET2 double mutant HSPCs (JAK2 
TET2, orange, N=8) that had entered into cell cycle was higher than that from non-
mutant HSPCs (NM, blue, N=11)(p=0.002), and after 4 days in culture a larger 
proportion had completed 2+ cell divisions (p=0.013). This did not lead to a larger 
proportion of large clones after 10 days in culture (p=1). Error bars are SEM.






















































































































In this chapter I explored the in vivo myeloproliferative and self-renewal capacity of 
JAK2 and TET2 mutant BM. Firstly I tested whether BM from JAK2 TET2 double 
mutant animals is able to impart an MPN-like phenotype in non-competitive serial 
transplantation recipients. Followed by establishing the minimum number of cells 
required to initiate this phenotype by limiting dilution. And finally, assessment of the 
self-renewal potential of JAK2 mutant, TET2 mutant, and double mutant BM by 
competitive serial transplantation. The additional transplantation data that was added 
for statistical comparison in section 4.2.2 was from an experiment performed by Juan 
Li.  
 
4.1 Non-competitive transplantation  
4.1.1 Primary recipients of JAK HOM TET HOM bone marrow 
display MPN-like phenotype in non-competitive transplantation 
setting 
To assess whether JAK HOM TET HOM BM cells are capable of imparting any 
haematopoietic phenotype upon recipients, non-competitive transplantation was 
performed. 5x105 whole BM cells from a pool of 2 JAK HOM TET HOM (CD45.2) 
or 3 WT (CD45.2) mice were transplanted into sub-lethally irradiated W41/CD45.1 
recipients. Mice were serially bled to assess chimerism and blood parameters (Figure 
19).  
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Throughout the experimental time course, primary recipients of JAK HOM TET HOM 
mutant BM displayed similar levels of chimerism to WT BM recipients (Figure 20). In 
WT recipients chimerism grew from 65.32% at 8 weeks to 88.38% at 24 weeks post-
transplantation, and in JAK HOM TET HOM recipients growing from 68.54% 
(p=0.257) at 8 weeks to 88.17% (p=0.949) at 24 weeks post-transplantation.  
 
Mice expressing homozygous human JAK2 V617F have previously been shown to 
have a myeloproliferative phenotype resembling that seen in MPN PV patients228 (PV 
 
Figure 19 Schematic of non-competitive transplantation 
Whole BM from JAK HOM TET HOM and WT donors (both CD45.2) was harvested 
and 5x105 cells transplanted into sub-lethally irradiated W41/CD45.1 recipients. 
Recipients were serially bled to assess for blood parameters and chimerism. 28 weeks 
after primary transplantation BM was harvest, a portion (1x107 cells) was secondarily 
transplanted into sub-lethally irradiated W41/CD45.1 recipients, while the remainder 
was analysed by flow cytometry for chimerism, mature lineage output, and HSC 
number. Secondary recipients were also serially bled and 18 weeks post-transplantation 
BM was harvested, and later analysed by flow cytometry. Donor chimerism was 
calculated as Donor/(Donor + Recipient).  
 
Figure 20 Donor chimerism in WT and JAK HOM TET HOM BM primary recipients 
in non-competitive transplantation 
Chimerism was comparable between WT (left) and JAK HOM TET HOM (right) 
recipients at all time points (8 weeks p=0.257, 16 weeks p=0.326, 24 weeks p=0.949). 
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covered in intro section 1.9.1); most simply defined by a strong erythrocytosis, 
measured by elevated haematocrit and haemoglobin. All blood parameters were 
measured in post-transplantation bleeds but only haematocrit and haemoglobin will be 
discussed in this thesis as these are the relevant parameters for establishing the PV-like 
phenotype. 
 
Compared with recipients of WT BM, mice receiving JAK HOM TET HOM BM had 
elevated haematocrit and haemoglobin throughout the experiment (Figure 21). WT 
haematocrit remained relatively stable (at 16 weeks average HCT 48.16%) whereas 
JAK HOM TET HOM recipient haematocrit was significantly higher (at 16 weeks 
average HCT of 92.62%, p=0.019). Similarly, the haemoglobin levels of WT recipients 
were largely stable (at 16 weeks, average HGB of 15.32g/dL), while the haemoglobin 
of JAK HOM TET HOM recipients was significantly elevated at all time points (at 16 
weeks average HGB of 26.60g/dL, p=0.026). 
 
 
Figure 21 Haematocrit and haemoglobin in primary non-competitive transplantation 
recipients of JAK HOM TET HOM bone marrow 
Recipients of WT BM in blue (left) and recipients of JAK HOM TET HOM in orange 
(right). JAK HOM TET HOM BM recipients display elevated HCT (p=0.019) and HGB 
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From the primary transplantation data, it can be concluded that JAK HOM TET HOM 
repopulation capacity is equivalent to that of WT animals, and JAK HOM TET HOM 
cells are able to impart a myeloproliferative phenotype, as evidenced by elevated 
haemoglobin, for at least 24 weeks.   
 
28 weeks after primary transplantation, recipient mice were sacrificed and 1x107 whole 
BM cells (containing recipient and donor-derived cells) were secondarily transplanted 
into sub-lethally irradiated W41/CD45.1 recipients. The remaining BM was analysed 
by flow cytometry. Fully differentiated erythrocytes do not read out in the chimerism 
measurement, as they lack the CD45 antigen, by also considering the chimerism within 
the BM this lineage is able to contribute to chimerism as erythroid progenitors still 
possess CD45. Although this does report the full extent of erythroid chimerism it allows 
the erythroid lineage to influence the chimerism to some extent. Like in the peripheral 
blood, WT and JAK HOM TET HOM BM recipients had comparatively high 
chimerism in the BM (WT 94.70%, JAK HOM TET HOM 97.30%, p=0.359) (Figure 
22 left).  
 
The lineage composition of the donor populations were assessed by flow cytometry, no 
significant differences were seen in the proportion of the graft made up of granulocytes 
and macrophages, B-cells, T-cells, or other cell types (Figure 22 middle, GM p=0.459, 
B-cells p=0.407, T-cells p=0.704, other p=0.678). The proportion of the donor 
population which are immunophenotypically defined as HSCs (ESLAM) was not 
significantly different between WT and JAK HOM TET HOM recipients (Figure 22 
 
Figure 22 Chimerism and bone marrow composition in bone marrow of non-
competitive primary transplantation recipients. 
JAK HOM TET HOM and WT BM recipients have eqivalent chimerism in primary BM 
(left), p=0.359, and no significant differences in donor graft lineage composition 
(centre) (GM (Mac1+, Gr1+/-) p=0.459, B-cells (B220+) p=0.407, T-cells (CD3+) 
p=0.704, other p=0.678 (Mac1-, Gr1-, CD3-, B220-)) or proportion of ESLAMs (right), 
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right, WT average 0.057, JAK HOM TET HOM average 0.085, p=0.098). While the 
assessment of ESLAM cells post-transplantation gives a representation of HSCs 
numbers, it should be noted that the ESLAM sorting strategy has not been fully 
validated in the post-transplantation setting, indeed single cell secondary 
transplantation of ESLAM cells has shown a HSC purity of ~30% in this population.262  
4.1.2 JAK HOM TET HOM BM recipients continue to display MPN-
like phenotype in secondary non-competitive transplantation  
In order to determine the longevity of the phenotype seen in primary transplantation, 
secondary transplantation was performed. As in the primary transplantation, the 
secondarily transplanted mice were serially bled to assess for chimerism and blood 
parameters.  
 
8 weeks post-secondary transplantation, chimerism remained comparable between WT 
and JAK HOM TET HOM recipients (Figure 23 top, 8 weeks WT 46.05%, JAK HOM 
TET HOM 41.73%, p=0.834) , and JAK HOM TET HOM recipients continuing to 
display elevated haematocrit (Figure 23 middle, at 8 weeks WT 57.30%, JAK HOM 
TET HOM 94.45%, p=0.053) and haemoglobin (Figure 23 bottom, 8 weeks WT 
14.85g/dL, JAK HOM TET HOM 23.99g/dL, p=0.048). Two recipients of JAK HOM 
TET HOM BM died of unrelated causes between the 8- and 16-weeks post-
transplantation, removing the power to draw statistically significant findings from this 
final timepoint, however the one remaining JAK HOM TET HOM recipient continued 
to display strong chimerism, which was accompanied by elevated haematocrit and 
haemoglobin (Figure 23).  
 
18 weeks after secondary transplantation mice were sacrificed, BM was frozen and later 
analysed by flow cytometry. As in the blood, chimerism levels were comparable 
between JAK HOM TET HOM and WT recipients (WT1 91.4%, WT2 94.1%, JAK 
HOM TET HOM 93.6%) (Figure 24 left). The proportion of the graft which is 
comprised of immunophenotypic HSCs (ESLAM) for both genotypes seems to be 
lower than after the primary transplantation (Figure 24 right), however it is difficult to 
conclusively state weather both genotypes have comparable proportions due to the 
unrelated animal deaths causing low replicate numbers for the JAK HOM TET HOM 
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arm. Likewise, no conclusive statements can be drawn about the balance of linages 
present in the BM (Figure 24 middle). The freezing of the BM before analysis may have 
also influenced the balance of cell types, as some types may be more sensitive to 
freezing and thawing than others. 
 
From this set of transplantations, it can be concluded that in the non-competitive setting 
JAK HOM TET HOM BM is able to engraft in recipient animals and impart a 
myeloproliferative phenotype in both primary and secondary transplantation recipients, 
 
Figure 23 Chimerism and blood parameters of secondary recipients of non-
competitively transplanted WT and JAK HOM TET HOM bone marrow 
At 8 weeks post-transplantation no difference in chimerism between WT and JAK HOM 
TET HOM recipients (p=0.834), and a strong erythrocytic phenotype in JAK HOM TET 
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as evidenced by elevated haematocrit and haemoglobin, indicating a significant 
expansion in the erythroid population.  
 
4.2 50,000 JAK HOM TET HOM cells or more are able to 
engraft and generate MPN-like phenotype upon 
transplantation  
In order to determine the minimum number of JAK HOM TET HOM cells required to 
initiate a myeloproliferative phenotype, a limiting dilution transplantation assay was 
performed by competing 100,000, 50,000 or 10,000 WT or JAK HOM TET HOM BM 
cells against 100,000 WT competitor cell. Recipients were serially bled to assess for an 
MPN-like phenotype (Figure 25). 
 
 
Figure 24 Chimerism and bone marrow composition in non-competitive secondary 
transplantation bone marrow 
Due to mouse numbers statistical test cannot be performed, however it seems that JAK 
HOM TET HOM and WT BM recipients have eqivalent chimerism in secondary BM 
(left), similar donor graft lineage composition (centre), and proportion of ESLAMs 























































Figure 25 Schematic of limiting dilution competitive transplantation 
100,000, 50,000 or 10,000 WT or JAK HOM TET HOM BM cells from CD45.2 donors 
were transplanted, alongside 100,000 WT competitor cell (CD45.1/.2), into 
W41/CD45.1 sub-lethally irradiated recipients. Recipients were serially bled to assess 
for blood parameters and chimerism. Donor chimerism was calculated as a proportion 
of transplanted cells (i.e. Donor/(Donor + Competitor)).  
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Peripheral blood (PB) chimerism levels were comparable between WT and JAK HOM 
TET HOM recipient, with both showing a cell dose dependent chimerism. 10,000 BM 
cells from either WT or JAK HOM TET HOM donors was insufficient to give sustained 
chimerism out to the final timepoint, with both falling to <1% by 24 weeks post-
transplantation (Figure 26 top, WT 0.94%, JAK HOM TET HOM 0.32%, no p as only 
1 animal per group). In the 50,000 cells group, both WT and JAK HOM TET HOM 
started with similar levels of chimerism, at 4 weeks WT average chimerism was 23.1% 
and JAK HOM TET HOM was 26.4%. However, WT chimerism expanded more 
through the subsequent time points with final average chimerism at 24 weeks for WT 
recipients was 59.5%, while JAK HOM TET HOM average chimerism was 35.8%. As 
there is only 1 mouse in each arm it is not possible to conclude if this is a consistent 
difference; however, it alludes to the possibility of a slight self-renewal disadvantage 
in JAK HOM TET HOM HSCs. For the highest dose, 100,000 cells, WT and JAK 
HOM TET HOM were once again similar in their levels of chimerism (starting at 41.6% 
for WT and 50.4% for JAK HOM TET HOM and rising to 71.3% for WT and 84.6% 
for JAK HOM TET HOM).    
 
Due to the low chimerism, 10,000 JAK HOM TET HOM cells did not cause a strong 
MPN-like phenotype in the recipient (Figure 26 middle and bottom, at 16 weeks post-
transplantation HCT 69.7%, HGB 16.2g/dL, average WT HCT 60.74%, HGB 
14.7g/dL). Higher doses of JAK HOM TET HOM BM (50,000 and 100,000) were able 
to impart a robust myeloproliferative phenotype upon recipients (at 16 weeks 50,000 
JAK HOM TET HOM HCT 80%, HGB 19.2g/dL, 100,000 JAK HOM TET HOM HCT 
81.92% HGB 19.8g/dL). Given that in JAK HOM TET HOM recipients chimerism 
between ~30 and 85% is accompanied with the same extent of HCT and HGB elevation, 
this could indicate that there is a maximum HCT and HGB able to develop in the 
recipient mice.  
 
In non-transplanted JAK HOM mice average haematocrit is 80%-90%, and 
haemoglobin is 22-25g/dL.228 The haematocrit from the limiting dilution 
transplantation is within the non-transplanted range (over 80%), however the HGB is 
lower (over 19g/dL). This difference in the maximum extent to which haemoglobin is 
elevated could be due to a number of reasons. Firstly, the non-transplanted mice JAK2 
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V617F is expressed from the foetal stage, whereas in the transplantation the mutation 
is introduced at time of transplantation, the earlier introduction might allow higher 
haemoglobin to develop over time. Secondly, in the steady state mouse the recombined 
allele is present in all cell types, not just haematopoietic cells, expression of JAK2 
V617F in other cells within the BM microenvironment might play a role in this increase 
 
Figure 26 Chimerism and blood parameters of WT and JAK HOM TET HOM 
limiting dilution transplantation 
Chimerism was not different between recipients of WT (left) and JAK HOM TET HOM 
BM (right). Transplantation of 50,000 or 100,000 JAK HOM TET HOM cells resulted 
in HCT and HGB above normal levels.  
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in HGB. The BM microenvironment also could be affected by a number of other 
factors, including irradiation and room cleanliness, which could play a role in feedback 
and consequently haemoglobin. Thirdly, loss of TET2 could be reducing the extent to 
which haemoglobin can be elevated (however this seems unlikely as HCT is elevated 
to same extent).  
 
From these findings it can be concluded at cell doses of 50,000 JAK HOM TET HOM 
cells or more able to engraft and generate MPN-like phenotype. Using limiting dilution 
analysis, an estimate of the disease-initiating cell frequency can be calculated for 
double-mutant whole BM (using WEHI eLDA); ~1 in 33 000 cells in the double mutant 
BM is a disease initiating cell, a number similar to the expected long-term HSC 
frequency in normal BM (1 in 20 000).  
 
4.3 Competitive whole bone marrow transplantation from 
JAK2 and TET2 mutant mice   
As mentioned in the introduction, serial competitive transplantation is the gold standard 
assay for determining the self-renewal capacity of HSCs (section 1.6.2). Competitive 
transplantation also represents a more disease-like state, where the leukaemic clone 
must compete against non-mutant cells to drive disease. To determine the relative 
ability of BM cells from TET2 mutant, JAK2 mutant, and double mutant mice to 
compete with non-mutant cells and initiate an MPN phenotype in recipients, and the 
 
Figure 27 Schematic of serial competitive transplantation 
5x105 WT or mutant BM cells from CD45.2 donors were transplanted, alongside 5x105 
WT competitor cell (CD45.1/.2), into W41/CD45.1 sub-lethally irradiated recipients. 
Recipients were serially bled to assess for blood parameters and chimerism. 28 weeks 
post-transplantation mice were sacrificed and BM harvested, 1x107 cells (containing 
donor, competitor and recipient cells) were secondarily transplanted and the remainder 
analysed by flow cytometry. Secondary transplantation recipients were serially bled to 
assess for MPN-like phenotype. Donor chimerism was calculated as a proportion of 
transplanted cells (i.e. donor/(donor + competitor)).  
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effect of each mutation on HSC self-renewal, serial competitive transplantation was 
undertaken. For this 5x105 whole BM cells from pools of mutant or WT mice (WT 3 
mice, TET HOM 3 mice, JAK HOM 3 mice, JAK HOM TET HET 2 mice, JAK HOM 
TET HOM 2 mice, all CD45.2) were transplanted, alongside 5x105 whole BM cells 
from CD45.1/2 WT mice, into sub-lethally irradiated W41/CD45.1 recipients (Figure 
27). Mice were serially bled to assess for MPN-like phenotype and chimerism. 28 
weeks after primary transplantation mice were sacrificed and BM secondarily 
transplanted. The results of primary transplantation for each genotype will be reported 
first, followed by the results of secondary transplantation.  
4.3.1 Loss of TET rescues JAK2 V617F self-renewal defect in 
primary transplantation 
Transplantation of WT BM acted as a control and was used for statistical comparison 
with the mutant models. The donor chimerism of WT BM recipients grew throughout 
the experimental time course (Figure 28 left) from an average of 52.7% at 4 weeks to 
73.5% at 24 weeks. These mice had normal blood parameters; at 16 weeks post 
transplantation haemoglobin of 14.7g/dL and haematocrit of 45.17% (Figure 28 right 
and middle). The WT recipients establish a normal range of haematocrit and 
haemoglobin for this experiment; HCT below 70, HGB below 18. Between the 16th and 
24th week post-transplantation 2 of 3 mice were culled owing to reasons unrelated to 
the transplantation, consequently statistical tests at the 24-week time point were not 
possible.  
 
Figure 28 Chimerism and blood parameters from primary recipients of competitively 
transplantation of WT BM 
Average chimerism (left), HCT (centre) and HGB (right) from recipient of WT BM. 
From this data the normal range of haematocrit and haemoglobin for transplantation 
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Primary recipients of TET HOM BM had an average donor chimerism similar to that 
of WT recipients (54.04% at 4 weeks to 58.94% at 24 weeks post-transplantation). 
Although the variability in TET HOM chimerism was much higher than in WT 
recipients, with 3 mice with rising chimerism throughout the time course (by 24 weeks 
over 75%), and the other 2 mice chimerism levels falling, (by 24 weeks below 25%) 
(Figure 29 far left).  
 
Recipients of JAK HOM BM had an initially high chimerism at (Figure 30 left, 4 weeks 
post transplantation average chimerism 84.72%, p=0.0006) however this dropped off 
steeply and remained significantly low for the remaining time points (8 weeks 8.168% 
 
Figure 29 Chimerism and blood parameters from recipients of competitively 
transplanted TET HOM BM 
Average chimerism of TET HOM recipients was similar to that of WT recipients 
(p=0.874 at 16 weeks post-transplantation). No changes in blood parameters were 
observed in TET HOM recipients; at 16 weeks HCT (p=0.077), HGB (p=0.225), and 
percentage monocytes (p=0.449) were all comparable to that of WT recipients. Error 
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Figure 30 Chimerism and blood parameters of primary recipients of competitively 
transplanted JAK HOM bone marrow 
Chimerism was initially high at 4 weeks post-transplantation (p=0.0006), and at 8 
weeks was sufficient to produce elevated HCT (p=0.029) and HGB (p=0.044), however 
by 16 weeks HCT and HGB were not significantly different to normal (HGB p=0.178, 
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p=0.001, 16 weeks 5.02% p=1.08x10-5, 24 weeks 3.34%). Due to these low levels of 
donor chimerism, an MPN-like phenotype was not observed in the JAK HOM 
recipients; haematocrit and haemoglobin were within the normal range (Figure 30 
middle and right, at 16 weeks average HCT 48%, p=0.154, and HGB 15.46g/dL, 
p=0.178). 
 
JAK HOM HSCs have been shown to be hyperproliferative in vitro (Chapter 3.1), this 
hyperproliferation is thought to lead to the initial burst in donor population size, but 
this hyperproliferation appears to come at the expense of HSC self-renewal, and the 
HSCs quickly exhaust, and donor population disappears as the cells differentiate and 
die.  
 
Recipients of JAK HOM TET HET BM had an initially strong chimerism (Figure 31 
left, 4 weeks average 58.42%) but this fell during the course of the primary 
transplantation to 20.72% at 24 weeks. Haematocrit and haemoglobin mirrored the 
level of chimerism; when chimerism was high in early time points HCT and HGB were 
elevated (Figure 31 middle and right, at 8 weeks when recipients had an average donor 
percentage of 33.54%, HGB 20.56g/dL p=0.002, HCT 64.56% p=0.011). As chimerism 
fell so did HCT and HGB; by 24 weeks, when chimerism was 20.716%, haemoglobin 
was 15.78g/dL, and haematocrit 57.80%. This is the upper cusp of the normal threshold.  
These results show that, while homozygous JAK2 V617F alone exhausts very quickly, 
combining a JAK2 mutation with heterozygous loss of TET2, in primary 
 
Figure 31 Chimerism and blood parameters of primary recipients of competitively 
transplanted JAK HOM TET HET bone marrow 
JAK HOM TET HET donor chimerism fell throughout the time course; by 16 weeks post 
transplantation chimerism was significantly low (p=0.003), however HCT and HGB 
remained significantly high (HCT p=0.004, HGB p=0.008), showing the strong 
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transplantation, slows exhaustion leading to higher chimerism and, when chimerism is 
robust, an increase in HCT and HGB. 
 
Unlike recipients of JAK HOM and JAK HOM TET HET BM, the chimerism of 
recipients of JAK HOM TET HOM BM did not fall but remained relatively stable 
throughout the primary transplantation (Figure 32 left, from 47.22% at 4 weeks, to 
28.9% at 24 weeks). As a consequence of this sustained higher chimerism, haematocrit 
and haemoglobin were elevated throughout the primary transplantation (Figure 32 
middle and right); at 16 weeks the average haemoglobin for JAK HOM TET HOM 
recipients was 25.52g/dL (p=0.003), and average haematocrit 84.26% (p=0.002).  
 
When the models with a JAK2 mutation are compared, it can be concluded that JAK2 
V617F alone has a strong self-renewal defect (leading to graft exhaustion), and while 
JAK HOM TET HET seems to slow the exhaustion of HSCs, JAK HOM TET HOM 
appears to, in primary recipients, rescue this exhaustion, with very little decrease in 
chimerism seen across the experimental time course. As a consequence of this robust 
chimerism HCT and HGB levels are very high across all time points. These data 
indicated a “dose” dependent response to loss of TET2, with loss of a single copy (JAK 
HOM TET HET) acting as a half-way response between no loss (JAK HOM alone) and 
complete loss of TET2 (JAK HOM TET HOM). 
 
At 28 weeks post-transplantation, recipients were sacrificed and secondary 
transplantation performed. At this time chimerism and cellular composition of the BM 
 
Figure 32 Chimerism and blood parameters of primary recipients of competitively 
transplanted JAK HOM TET HOM bone marrow 
Chimerism remained relatively stable in primary transplantation recipients, this was 
accompanied by significantly elevated HCT (p=0.002, at 16 weeks) and HGB 
(p=0.003, at 16 weeks) compared with WT recipients. Error bars are SEM.  
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was assessed by flow cytometry. In the BM the broad trends in chimerism are similar 
to the PB (Figure 33 left); JAK HOM chimerism is virtually absent, TET HOM has 
robust chimerism with an average similar to WT. JAK HOM TET HET chimerism is 
low (below 25%) but unlike JAK2 alone all mice have chimerism above 1% (the cut 
off for positive repopulation). And JAK HOM TET HOM is positively repopulated for 
all with a much higher average chimerism than JAK HOM alone.  
 
JAK HOM chimerism is very low in the BM of primary recipients (average 1.83%) 
only just over the cut off for positively repopulated, these grafts are comprised of a 
higher proportion of T- and B-cells than in WT/TET/JAK TET recipients (B cells 
comprise an average of 54.63% of the JAK HOM grafts vs 6.76% of JAK HOM TET 
HOM grafts, p=0.05) (Figure 33 middle). This is not representative of a “lymphoid 
bias” in JAK HOM HSCs, but is a result of the fact that these cell types have a longer 
half-life than myeloid cells and are therefore able to contribute to chimerism for longer, 
reading out even when the mutant stem and progenitor cells have stopped producing 
new cells.  
 
The small graft size means conclusions about the graft composition have to be 
interpreted carefully, as the small denominator can make population proportions less 
reliable. For example, the proportion of ESLAM cells within the JAK HOM donor 
 
Figure 33 Chimerism and composition of the bone marrow of primary competitive 
transplantation recipients 
Donor chimerism was significantly lower in JAK HOM (p=0.013) and JAK HOM TET 
HET (p=0.019) recipients relative to TET HOM recipients, JAK HOM TET HOM 
however was not significantly reduced (p=0.289). Comparison of the composition of 
donor grafts shows that JAK HOM has a significantly higher proportion on B-cells than 
JAK HOM TET HOM donor populations (p=0.05). The proportion of ESLAM HSCs 
within donor grafts was lower in JAK HOM TET HOM recipients than TET HOM 
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population (Figure 33 right) for 2/3 mice is 0, but for the third mouse the proportion of 
phenotypic HSCs within the graft appears normal, the actual number of ESLAM cells 
within this graft is small, but as the total number of donor cells is also small a few more 
or less cells in the gate makes a huge difference to the proportion read out.   
 
TET HOM recipients had higher chimerism in the BM than in the PB, this could be due 
to the BM timepoint being 4 weeks after the previous bleed, which could account for 
some of the difference, but as the chimerism had been fairly stable from 8 to 24 weeks 
this increase is more likely due to the difference in cellular composition of the BM. In 
agreement with literature, for all genotypes, the proportion of GM cells of donor origin 
was higher in the BM than the PB (Figure 34).263 TET2 knock-out animals have been 
reported to have a GM bias (Ko et al. 2011)210, this GM bias may account for the 
increased chimerism in the BM; if TET HOM HSCs produce proportionally more GM 
cells, are there are more GM cells resident in the BM than PB, it is reasonable that TET 
HOM would have a higher chimerism in the BM than the PB. 
 
 
Figure 34 Donor graft composition in primary recipient peripheral blood and bone 
marrow for each genotype 
In BM of all genotypes, granulocytes (Mac1+, Gr1+) and macrophages (Mac1+, Gr1-) 
made up a larger proportion of the donor population than in PB. In JAK HOM and 
JAK HOM TET HET recipients at 16 weeks post-transplantation the grafts had a 
reduced proportion of GM cells (JAK HOM p=0.0001, JAK HOM TET HET p=0.002), 
and increased proportion of lymphocytes (JAK HOM B-cells p=0.0146, JAK HOM TET 
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TET HOM has the highest average proportion of donor cells defined as ESLAM (Figure 
33 significantly higher than JAK HOM TET HOM recipients, p=0.013), this high 
number of phenotypically defined HSCs is in keeping with literature reports of 
expansion of the stem cell pool and enhanced self-renewal of HSCs from TET knock-
out mice.  
 
BM analysis of JAK HOM TET HET recipients showed they had low average 
chimerism (10.42%, Figure 33), however all recipients were still positively repopulated 
(above 1%). A lower proportion of JAK HOM TET HET grafts were comprised of GM 
cells (not significant), this may hint towards exhaustion of the graft as GM cells have a 
shorter life.  Of all the models with a JAK2 V617F mutation, JAK HOM TET HOM 
has the highest chimerism, and higher proportion of GM cells contributing to chimerism 
than JAK HOM TET HET, this implies that grafts are still actively contributing to 
production of shorter lived cell types. Expansion in ‘other’ cell types group, combined 
with low numbers of phenotypic HSCs, suggests a progenitor expansion in recipients 
of JAK HOM TET HOM BM. This progenitor expansion, in combination with mature 
cell expansion is thought to be the cause of the reduction in the proportion of phenotypic 
HSCs, not a reduction in the number of HSCs in these animals.  
4.3.2 Secondary transplantation reveals self-renewal properties of 
HSCs with JAK2 and TET2 mutations  
As the self-renewal defect in JAK2 HSCs is so strong, from the primary transplantation 
data it is clear loss of TET2 is able to at least partially rescue this defect, however self-
renewal potential can only be definitively tested in secondary transplantation. To 
investigate the self-renewal potential of each genotype BM from primary transplanted 
recipients was harvested and 1x107 cells (containing a mix of donor, competitor and 
recipient cells) was transplanted into sub-lethally irradiated W41/CD45.1 recipients. In 
the secondary transplantation many of the same effects were seen that were established 
in the primary transplantation recipients continue.  
 
By the end of the primary transplantation there was only one remaining WT recipient 
from this experiment (Figure 36), due to 2/3 mice having been culled due to non-
transplantation related health issues. In secondary transplantation this recipient 
continued to have HCT and HGB within the normal range.  
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In order to be more confident in the conclusions drawn from this experiment, and allow 
statistical comparison of mutant genotypes with WT, WT recipients from another set 
of transplants were combined with this data set. The additional data was from a 
transplantation that was set up in the same way as this experiment (5x105 donor whole 
BM cells alongside 5x105 competitor whole BM cells). The only common timepoint 
between these two experiments was the 16 week timepoint, this timepoint is therefore 
used for chimerism comparison. 
 
Comparison of the primary 16 week post-transplantation chimerism data showed that 
the two WT data sets were not different (p=0.141) (Figure 35), and addition of this data 
did not alter the significance of JAK HOM when compared with WT (without extra 
data p=0.005, with extra data p=0.006). However, addition did alter the degree of 
 
Figure 36 Chimerism and blood parameters of secondary recipient of competitively 
transplanted WT bone marrow 
Secondary transplantation of the one remaining WT BM recipient continued to have 
HCT and HGB within normal range.  
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Figure 35 Comparison of 16 week chimerism in primary and secondary recipients of 
WT bone marrow 
Previously presented data (light blue, as in Figure 28), and the additional data (dark 
blue) are not significantly different in primary transplantation (p=0.141). Error bars 
are SEM. 
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significance of JAK HOM TET HET (without extra data p=0.003, with extra data 
p=0.090). The additional data was therefore included for comparison of chimerism in 
the secondary transplantation. With the additional data secondary chimerism was 16 
weeks 33.2%. 
 
Recipients of secondary TET HOM BM follow the trends established in the primary 
recipients. Average chimerism at 16 weeks was similar to that of WT recipients (Figure 
37 left, 45.54%, p=0.610), however as in the primary, there was a wide variation with 
2/5 samples with very high chimerism (over 95%) and 3/5 with quite low chimerism 
(under 20%). Once again, the haemoglobin and haematocrit were within normal range 
(Figure 37 middle and right), as loss of TET2 does not result in a hyperproliferation of 
the erythrocyte lineage (at 16 weeks post-transplantation HGB 13.82g/dL, and HCT 
54.6%). As TET2 blood parameters have no erythrocytic phenotype, and blood 
parameter data was not available for the additional WT data set, TET HOM recipients 
were used for statistical comparison with JAK2 mutant models.   
 
Secondary recipients of JAK HOM BM continue to have very low chimerism in the 
secondary transplantation, with an average chimerism of 3.60% at 16 weeks post-
transplantation (p=0.030) (Figure 38 left). As in the primary animals, the lack of 
chimerism resulted in haematocrit and haemoglobin within the normal range as there 
were not a sufficient number of mutant cells to drive elevation of erythroid cell 
numbers; at 16 weeks post-transplantation average haematocrit of JAK HOM recipients 
was 56.8% (p=0.320), and average haemoglobin 13.4 g/dL (p=0.186) (Figure 38 middle 
and right).  
 
 
Figure 37 Chimerism and blood parameters of secondary recipients of TET HOM 
BM in competitively transplant setting 
Secondary recipients of TET HOM BM continued to have variable chimerism and HGB 
and HCT within the normal range. Error bars are SEM. 
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The chimerism in primary recipients of JAK HOM TET HET underwent a slow decline, 
much slower than the exhaustion seen in JAK HOM alone but a gradual decrease in 
chimerism with time. This continued into the secondary recipients and by 16 weeks 
post-transplantation average chimerism was 5.66% (p=0.036) (Figure 39 left). As in 
JAK HOM alone the chimerism in the secondary recipients of JAK HOM TET HET 
was insufficient to sustain elevated haematocrit and haemoglobin out to 16 weeks post-
secondary transplantation (Figure 39 middle and right, average HGB 13.275g/dL, 
p=0.242, and average HCT 50.65%, p=0.176). Indicating that although loss of a single 
copy of TET is able to slow the exhaustion of JAK HOM HSCs, it is not able to reverse 
the self-renewal defect entirely and consequently is not capable of imparting a serially 
transplantable MPN-like phenotype.  
 
 
Figure 38 Chimerism and blood parameters of secondary recipients of JAK HOM 
bone marrow in competitive transplant setting 
Secondary recipients of JAK HOM BM continued to exhibit the effects seen in primary 
recipients; significantly lower chimerism (16 weeks p=0.030) and no changes in HCT 
or HGB (relative to TET HOM, HCT p=0.320, HGB p=0.186 at 16 weeks). Error bars 
are SEM. 
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Figure 39 Chimerism and blood parameters of secondary recipients of JAK HOM 
TET HET bone marrow in competitive transplant setting 
Chimerism continued to decline in secondary recipients of JAK HOM TET HET BM, 
by 16 weeks chimerism was significantly lower than WT (p=0.036), this chimerism was 
insufficient to cause elevation in HCT (p=0.176) or HGB (p=0.242). Error bars are 
SEM. 
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The chimerism of JAK HOM TET HOM recipients resembles that of TET HOM alone, 
with a similar average chimerism to WT (Figure 40 left, at 16 weeks post-secondary 
transplantation 32.52%, p=0.974), but a large spread in the data within the chimerism 
of individual recipients at 16 weeks ranging from 2% to 80%. The primary recipients 
of JAK HOM TET HOM BM displayed striking increases in haematocrit and 
haemoglobin when compared with WT recipients; in the secondary transplantation this 
erythrocytic phenotype continues to be seen in the 8 week bleed (Figure 40 middle and 
right, average HGB 22.51g/dL, p=0.002, and average HCT 85.35%, p>0.001) and 16 
week bleed (average HGB 19.61g/dL, p=0.039, and average HCT 72.20, p=0.038).  
 
At 18 weeks post-secondary transplantation mice were sacrificed and BM analysed by 
flow cytometry. The BM from the secondarily transplanted recipients summarises the 
effects of each mutation upon self-renewal. TET2 loss alone recipients had a strong 
average chimerism with a normal distribution of cell types (Figure 41 left). JAK2 
V617F alone has a self-renewal defect, exhausting quickly, and was hence unable to 
sustain chimerism out to the end of the secondary transplant, by this point all recipients 
have donor chimerism of less than 1% - commonly accepted as the cut off for positive 
engraftment. By combining JAK2 V617F with loss of a single copy of TET2 self-
renewal improves slightly, with a more prolonged drop in donor chimerism over the 
course of the experiment, but by the end of the secondary transplantation 2/4 grafts has 
exhausted and other 2 were very low (1.13 and 3.44%). As in primary transplantation 
for JAK HOM the balance of cell types within these grafts are more weighted towards 
B and T lymphocytes (Figure 41 middle), this is not a lymphoid bias but a consequence 
 
Figure 40 Chimerism and blood parameters of secondary recipients of JAK HOM 
TET HOM bone marrow in competitive transplant setting 
Donor chimerism reveals JAK HOM TET HOM grafts have not exhausted by 16 weeks 
post-secondary transplantation. Elevated HCT and HGB continue to be seen in 
secondary recipients of JAK HOM TET HOM BM (at 16 weeks post-transplantation, 
HCT p=0.038, HGB p=0.039). Error bars are SEM.  
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of these cells having a longer life and therefore contributing to chimerism for longer. 
The loss of both copies of TET2 improves the self-renewal of JAK HOM mutant HSCs 
further, mice are able to sustain chimerism out to the end of the secondary 
transplantation, and these grafts contain the highest average proportion of phenotypic 
HSCs (although this was not significantly higher than other models) (Figure 41 right).  
 
 
4.4 JAK2 mutation reduces the proportion of ESLAM HSCs 
in steady state bone marrow   
To assess whether the restoration of the JAK2 V617F self-renewal defect, by 
combining with loss of TET2, impacts the number of phenotypic HSCs, the proportion 
of ESLAM and Sca1+ c-Kit+ (SK) progenitor cells from lineage depleted BM was 
calculated relative to WT control experiments (relative number, rather than absolute 
number, is reported to control for difference in lineage depletion/staining etc between 
experimental days). In agreement with previous studies228, JAK HOM animals had a 
reduced number of phenotypic HSCs (ESLAM) and an increase in the proportion of 
progenitor cells (SK) (Figure 42). Hyperproliferation of progenitors leads to increase 
in the progenitor population, and the increase in the number of progenitors and 




Figure 41 Assessment of the bone marrow chimerism and composition at the end of 
competitive secondary transplantation 
As in primary transplantation BM, chimerism was significantly lower in JAK HOM 
(p=0.023) and JAK HOM TET HET (p=0.025) than in TET HOM, but was not 
significantly lower in JAK HOM TET HOM than in TET HOM (p=0.577). No 
significant differences were observed in the proportion of different lineages within 
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TET mutant animals had a similar (slightly higher) proportion of ESLAM HSCs and 
SK HSPCs to WT animals (Figure 42). This is in agreement with previously published 
data on this mouse model; Ko et al. (2011)210 reported an increase in the absolute 
number of LK and LSK cells in TET2 knock-out animals. 
 
Combination JAK and TET mutant animals, like JAK2 mutation alone, had a reduced 
frequency of ESLAM HSCs (TET HOM vs JAK HOM TET HET p=0.045), this is 
presumably due to the increased proportion of mature progeny invoked by this 
hyperproliferating mutation. Double mutant mice contained a decreased frequency of 
SK cells, differing from JAK2 mutation alone (JAK HOM v JAK HOM TET HET 
p=0.029). 
 
Figure 42 Relative number of phenotypic stem and progenitor cells in mice with 
JAK2/TET2 mutation 
To mitigate the differences in lineage depletion/staining etc between experiments, 
values are relative to WT mice processed at the same time. JAK HOM TET HET mice 
had proportionally fewer ESLAM HSCs than TET HOM mice (p=0.045), and 






































































































In this chapter I explored the molecular mechanisms driving the self-renewal defect of 
JAK2 V617F HSCs, by using single cell multiplexed qPCR to examine the gene 
expression of 45 self-renewal regulators to attempt to identify individual genes driving 
the defect. Identified genes were then validated by over-expression using lentiviral 
vectors to determine whether these genes could restore the self-renewal defect. The 
expression of these genes was also investigated in bulk mouse cells post-transplantation 
and MPN patient samples. In section 5.1 the multiplexed qPCR was performed by 
Jiangbing Li and David Kent, and analysis performed by Nicola Wilson  
 
5.1 Single- and double-mutant HSCs have distinct molecular 
profiles of self-renewal regulators 
In order to understand the mechanisms by which a malignant clone can expand and 
drive disease, an appreciation needs to be gained of how malignant HSCs differs from 
normal HSCs; which molecular programmes they have employed to evade normal 
regulation and balance. Study of the genes expressed within mutant cells gives an 
insight into how mutations drive different functional characteristics and can provide 
potential targets for disease treatments.  
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5.1.1 Hierarchical clustering identifies subtypes within HSC 
population that are enriched in different genotypes  
The transplantation data in chapter 4 identifies a self-renewal defect in in JAK2 mutant 
HSCs, this defect is rescued by homozygous deletion of TET2. To determine whether 
expression of self-renewal genes is altered by these mutations, individually or in 
combination, single phenotypic HSCs from WT (N=3, n = 561), JAK HOM (N=3, n = 
376), TET HOM (N=1, n = 73) and JAK HOM TET HOM (N=1, n = 99) mice were 
analysed for the expression of 45 transcription factors and self-renewal regulators by 
multiplexed quantitative polymerase chain reaction. These 45 genes were selected from 
literature and are listed, and their roles in self-renewal discussed, in Table 1. 
Quantitative analysis of 48 genes (3 housekeeping genes plus 45 self-renewal 
implicated genes) was performed using Fluidigm 48.48 Dynamic Array chips, this 
allowed quantitative analysis of all genes in parallel at the single-cell level. For this, 
single ESLAM HSCs were sorted, followed by lysis, cDNA synthesis, and sequence-
specific preamplification all within the sorted well. Quantitation of gene expression was 
performed using TaqMan real-time PCR on the Fluidigm BioMark system.  
 
Hierarchical clustering shows 5 broad molecular clusters of cells (Figure 43). Clusters 
I and II are significantly enriched (p< 0.05 and p< 0.005) for JAK HOM HSCs, Cluster 
III is significantly enriched (p< 0.001) for TET HOM HSCs, and Cluster IV is 
significantly enriched for WT (p< 0.05) and double-mutant cells (p< 0.05). 
Interestingly, Cluster II does not have any TET single- or double-mutant HSCs. WT 
HSCs are present across all clusters; this exemplifies the heterogeneity of the normal 
HSC population. This spread likely represents a combination of informative and generic 
heterogeneity. As gene expression is measured at a snapshot in time, a degree of the 
differences between HSCs may correspond to the differences in cell state, like stage of 
cell cycle (generic heterogeneity), however as the genotypes with their different 
characteristics are enriched in distinct clusters the difference in their gene expression is 
most likely biologically driven, and the presence of WT cells in each cluster represents 
informative heterogeneity.  
 
Even from a visual inspection of the hierarchical clustering, some of the genes defining 
each cluster are clear, for example expression of Gfi1 is almost exclusively found in 
cluster V, lack of Tal1 expression is more common among cluster III cells, cluster IV 
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cells have on average higher expression of Vwf, and cluster II cells largely lack 
expression of Bmi1 (Figure 43).  This sets the stage for assessment of which genes are 
associated with each individual genotype by multidimensionality reduction.  
 
 
Figure 43 Hierarchical clustering of single cell gene expression data 
Five main clusters emerge when single HSCs from mice with each of the four genotypes 
(WT, JAK HOM, TET HOM, and JAK HOM TET HOM) are assessed. Individual HSCs 
and their expression for each self-renewal regulator with HSCs from each genotype 
are coloured accordingly: Blue (WT), Red (JAK HOM), Green (TET HOM) and Orange 
(double mutant). Each cluster was assessed for whether or not it contained an increased 
or decreased number of HSCs from each genotype compared to that expected by 
random chance by chi-squared analyses and these results are displayed in the table 
(yellow indicates p < 0.05 of a higher than expected observation and purple indicates 
p < 0.05 a lower than expected observation). 
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5.1.2 Principal component analysis reveals genes associated with each 
genotype  
Single HSCs of all genotypes were displayed on a single PCA plot to help visualise 
molecular clusters and identify the genes associated with each genotype (Figure 44). 
WT HSCs existed in all regions of the molecular landscape (Figure 44 top left), whereas 
JAK HOM HSCs were overrepresented in a specific region (Figure 44, top right), and 
this region was almost completely devoid of cells lacking TET2 expression, suggesting 
it is a unique molecular region exclusive to a minority of WT HSCs and a larger 
proportion of JAK HOM HSCs. The majority of these cells are also found in Cluster II 
described above. The single-mutant TET HOM HSCs (Figure 44 middle left) are 
predominantly found in a single area of the PCA plot, this region is enriched for cluster 
III cells. The double-mutant HSCs are enriched in another region (Figure 44, middle 
right), although a small fraction of double-mutant cells are also found with the single-
mutant TET HOM HSCs. The genes negatively associated with each of these regions 
are indicated in the loadings plot (Figure 44 bottom left), implicating genes such as 
Bmi1, Runx1, and Pbx1 as being involved in the self-renewal of HSCs (ie, associated 
with TET HOM and double-mutant genotypes), rather than proliferation (ie, associated 
with JAK HOM HSCs).  
 
When t-Distributed Stochastic Neighbour Embedding (t-SNE) analysis is used the same 
patterns can be seen as with PCA. WT cells occupy the entire molecular landscape 
(Figure 45 top left), JAK HOM cells are overrepresented in a region (Figure 45 top 
right), in which TET mutant cells are completely absent. TET HOM cells cluster in a 
separate region (Figure 45 bottom left), and JAK HOM TET HOM cluster in another 
region (Figure 45 bottom right) but are also found in the TET HOM enriched region. 
The same pattern of genotype separation in both the PCA and t-SNE gives confidence 











Figure 44 PCA of single-cell gene expression profiling shows distinct molecular 
regions of single and double-mutant HSCs 
Cells from all 4 genotypes were assessed by single-cell multiplexed quantitative 
polymerase chain reaction; each PCA plot displays all single cells analysed with 1 
population highlighted in each plot; HSCs from WT (n=561, blue circles), JAK HOM 
(n=376, red circles), TET HOM (n=73, green circles), and JAK HOM TET HOM 
(n=99, orange circles). Notably, WT cells are present across the entire molecular 
landscape, whereas single- and double-mutant HSCs are enriched in specific regions. 
Loadings plot for PCA, indicating the key defining molecular features of each region, 
with the distance from the centre indicating the negative correlation with a cell type 
(e.g., cells in the top right lack Vwf). Illustration depicting the different cell 
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Figure 45 T-SNE shows distinct molecular regions of single and double-mutant 
HSCs 
T-SNE analysis for the same dataset that appears in the PCA in Figure 44 Each t-SNE 
plot displays all single cells analysed with 1 population highlighted in each plot. T-SNE 
displays on a single plot, HSCs from WT (blue squares, n=561), JAK HOM (red 
diamonds, n=376), TET HOM (green triangles, n=73), and JAK HOM TET HOM 
(orange squares, n=99) mice.  
5.1.3 Identification of candidate genes to ‘rebalance’ HSC population 
in JAK HOM HSCs  
As the gene expression was performed on single HSCs, the clustering diagram and 
differential enrichment by genotype, in combination with the PCA loadings plot, can 
be used to ascertain which genes might define the molecular subtypes, and identify 
candidates for ‘rebalancing’ the HSC pool. For example, double-mutant cells (which 
have restored self-renewal but still proliferate rapidly) cluster away from JAK HOM 
single-mutant cells (which have high proliferation but lack durable self-renewal), 
allowing the uncoupling of individual characteristics, the genes driving this separation 
are only involved in self-renewal, not hyperproliferation. This permits the generation a 
list of candidate genes that might drive the self-renewal restoration observed in in vivo 
experiments; increased Bmi1, Pbx1, Runx1, and Meis1 and decreased Gfi1b and 
Dnmt3a.  
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It should be noted that Meis1 is included in this list despite being absent from the PCA 
loadings plot. This is because Meis1 was excluded from the PCA having failed the 
loading control (in the run with TET HOM and JAK HOM TET HOM), however Meis1 
was the strongest driver of ‘abnormal’ JAK2 cells in runs of JAK HOM and WT alone 
(Figure 46) and was therefore included for subsequent validation. 
 
The individual expression patterns of the identified genes, hypothesised to be driving 
self-renewal, across genotypes are displayed by violin plots (Figure 47). Bmi1 
expression is bimodal for all genotypes, but the proportion of cells in each group varies 
between genotypes; for JAK HOM and WT a larger proportion of cells have low/no 
expression of Bmi1 than for TET HOM and JAK HOM TET HOM.  
Like Bmi1, Pbx1 expression is bimodal for all genotypes and JAK HOM and WT have 
a larger population of cells with low Pbx1 expression than TET HOM and JAK HOM 
TET HOM. 
 
All TET HOM and the vast majority of JAK HOM TET HOM cells have high 
expression of Runx1. WT and JAK HOM cells have some cells with high Runx1 
expression but a larger population of cells with medium expression and another 
population of cells with low expression. Meis1 is expressed in all TET HOM and JAK 
HOM  TET  HOM  cells  but,  in  a  proportion  of  JAK HOM  and  WT  cells,  Meis1  
 
Figure 46 PCA of WT and JAK HOM HSCs 
JAK HOM HSCs are indicated by red circles, and WT HSCs are indicated by blue 
diamonds. A cluster of cells on the right hand side of the graph is enriched for JAK2 
V617F HOM HSCs and have reduced expression of several key HSC genes (Meis1, 
Pbx1, Bmi1, Sfpi1, Smarcc2, Runx1, Hoxb4, Myb, Lmo2). Axes are in arbitrary units. 
WT, n=465; JAK HOM, n=277. 




Figure 47 Violin plots for expression of each of the 45 self-renewal regulators in each 
genotype 
Top panel shows genes differentially regulated in JAK HOM HSCs; Bmi1, Pbx1, Meis1, 
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expression is very low/absent. However, Meis1 did fail its loading control for TET 
HOM and JAK HOM TET HOM so it is unknown if the presence of expression in these 
cells is real and no conclusion can be drawn from this.  
 
The genes for which decreased expression correlates with a self-renewal advantage, 
Dnmt3a and Gfi1b, both have bimodal expression patterns with a larger proportion of 
WT and JAK HOM HSCs having high expression of these genes than TET HOM and 
JAK HOM TET HOM HSCs. Between TET HOM and JAK HOM TET HOM HSCs 
Vwf, Gata3, Prdm16, and Tal1 have reduced expression in TET HOM HSCs (but not 
reduced expression in JAK HOM TET HOM) 
 
5.2 Candidate gene validation  
A reminder from above – the genes that drive the self-renewal restoration of JAK2 
V617F self-renewal defect; increased Bmi1, Pbx1, Runx1, and Meis1 and decreased 
Gfi1b and Dnmt3a. As loss of DNMT3A is a frequent mutation in MPNs, ARCH and 
other haematological malignancies, and frequently commutated with JAK2 V617F in 
MPNs, knock-down/out of DNMT3A does not seem like an appropriate means of 
validating the mode of action of TET2 mutation. This caused me to focus on the genes 
that are under-expressed in JAK HOM HSCs; Bmi1, Pbx1, Runx1, and Meis1, for which 
over-expression could restore the self-renewal defect of JAK HOM HSCs.  
 
Genes of interest were engineered into a pCCL-c-MNDUS-(X2)-PGK-EGFP 
backbone. The gene of interest was under the MND promoter (myeloproliferative 
sarcoma virus with the negative control region deleted), this is constitutively active in 
the haematopoietic system and commonly used for generating overexpression in this 
tissue; in a study to identify the most potent promoter in the haematopoietic system for 
gene editing for Wiskott–Aldrich syndrome, the MND promoter was found to be more 
effective than EF1a and WASp, driving higher expression in all lineages.264 The vector 
also contained eGFP, under the control of PGK promoter, this acted as a selection 
marker allowing transduced cells to be identified.  
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5.2.1 Overexpression of Bmi1, Pbx1, or Meis1 can help sustain JAK 
HOM chimerism in vivo 
To test which of the self-renewal genes identified as being under-expressed in JAK 
HOM HSCs (Bmi1, Pbx1, Runx1, and Meis1) might modulate the self-renewal of these 
cells, lentiviral overexpression and transplantation assays were performed. CD45+Lin-
CD150+CD48- HSPCs isolated from either JAK HOM or WT mice were transduced 
with a lentivirus containing a GFP reporter and the Bmi1, Pbx1, Runx1, or Meis1 genes 
or an empty vector (EV) control. Three days post-infection, cells were re-sorted for 
presence of GFP and transplanted into recipient mice to monitor for disease phenotype 
(Figure 48). 
 
For transplantation of cells over-expressing genes, the reporting of chimerism and 
blood parameters post-transplantation is slightly more complicated than for previous 
whole BM transplantation. This is because within each group there are mice which have 
not successfully repopulated (chimerism below 1%), the lack of repopulation could be 
the result of a number of factors. Firstly, the sorted population was transduced with 
lentivirus contained both stem and progenitor cells, it is not known which of these cells 
are successfully transduced and transplanted, should the population be mostly/entirely 
progenitors the graft may not able to be sustained. Secondly, the cells were kept in 
culture for three days before transplantation, during this time the cells divide, and to 
varying degrees differentiate. Even if many HSCs are successfully transduced, the 
 
Figure 48 Schematic of candidate gene overexpression transplants 
Bulk CD45+Lin-CD48-CD150+ (HSPC) cells were sorted from WT and JAK HOM mice 
and infected with lentivirus carrying no gene (empty vector) or lentivirus carrying genes 
to overexpress Bmi1, Pbx1, Runx1, or Meis1 (2 independent experiments). Three days 
after infection, GFP+ cells (300-2000) were isolated and transplanted into recipient 
mice. Serial analysis of peripheral blood was performed to assess chimerism and blood 
cell parameters. 
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culture conditions could drive them to differentiate and by transplantation the 
population may be too differentiated to sustain engraftment. Thirdly, the stress of the 
viral transduction can cause cells to die/differentiate. This combined with low cell 
numbers and a mixed starting population could mean no HSCs are left by 
transplantation injection. The repopulation success is still a measure of a given gene’s 
effect upon cells, however it also misleads the average chimerism by pulling down the 
average of successfully transplanted mice. Both the average chimerism, repopulation 
success rate, and chimerism of individual mice will be reported to try to give a more 
complete picture of the effect of each gene on WT and JAK HOM HSPCs. 
 
WT and JAK HOM HSPCs infected with an empty vector lentivirus had comparable 
repopulation success (WT 4/5, JAK 3/4 +1 dead) and, at early time points, similar 
average chimerism (8 weeks, Figure 49, WT average 24.85%, JAK2 average 20.00% 
p=0.747). This remained true out to 16 weeks post-transplantation, after this time JAK 
HOM EV average chimerism began to fall and by 24 weeks JAK HOM EV average 
chimerism was 6.00%, whereas WT was 23.65% (p=0.186)(Figure 49).  
 
This donor graft exhaustion parallels the effects seen in JAK HOM whole BM 
transplantation (section 4.3) but in this case exhaustion begins later (16 weeks post 
transplantation rather than 4 weeks). This difference in time to chimerism peak is likely 
due to the difference in the transplanted cell population. In this case HSPCs were 
 
Figure 49 Peripheral blood chimerism of recipients of WT and JAK HOM cells 
infected with EV lentivirus 
WT in blue, JAK HOM in red. Although chimerism between individual animals was 
variable, average chimerism in WT mice remained relatively stable throughout the 
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transplanted after 3 days in culture, this donor population differs in two important ways 
from whole BM. Firstly, this population most likely contains more stem and progenitor 
than 5x105 whole BM (long-term HSC frequency in normal WT WBM is 1 in 20 000, 
in 500 000 WBM cells would expect 25 HSCs). Secondly, this more primitive 
population, and smaller overall number of mutant cells transplanted, may differently 
impact the BM microenvironment. The large number of differentiated cells within JAK 
HOM BM will create a specific microenvironment, which could encourage the 
proliferation and differentiation of stem and progenitor cells thereby impacting self-
renewal.  
 
Overexpression of Runx1 resulted in a much lower rate of successful transplantation in 
recipients of both WT and JAK HOM cells (at 16 weeks post-transplantation 1/5 had 
chimerism over 1% for both WT and JAK HOM), and the successfully engrafted mice 
had very low chimerism, at 24 weeks post-transplantation average chimerism for WT 
Runx1 recipients was 2%, (WT EV 23.65%, p=0.118), and JAK HOM Runx1 recipients 
0.38% (JAK HOM EV 6.00%, p=0.240) (Figure 50). 
 
Recipients of Pbx1 overexpression cells also had a lower proportion of successful 
transplantation than EV recipients, WT 1/5 and JAK HOM 2/5. Of the successfully 
engrafted recipients, the WT recipient had very strong chimerism across all timepoints 
(Figure 51, at 16 weeks 60.50%), of the JAK HOM positive transplantation recipients 
 
Figure 50 Peripheral blood chimerism of recipients of WT and JAK HOM cells 
overexpressing Runx1 
Recipients of WT cells in blue and JAK HOM in red. Low chimerism for all recipients 
of WT and JAK HOM cells overexpressing Runx1 (although due to variability of EV not 
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one had continually low chimerism (at 16 weeks 6.63%), while the other had very high 
chimerism up to 16 weeks (chimerism 69.70%) when this animal had to be culled. The 
mouse displayed partial paralysis/jerky movements, a blood sample taken before death 
revealed extremely high HCT and HGB (HCT 96.02%, HGB 24.20g/dL), and it was 
therefore hypothesised that this mouse suffered a stroke due to the severely elevated 
erythrocytosis (unconfirmed as no analysis of brain performed). 
 
The varying effects of Pbx1 overexpression, in some instances not leading to any 
engraftment and in others very strong engraftment, could be due to a mixed starting 
population of stem and progenitor cells; for instance, Pbx1 expression in progenitors or 
primed/biased HSCs might results in differentiation (and thus reduced positive 
engraftment) while the same expression in a more primitive HSCs or an HSC with a 
different bias/priming might give an advantage, and when combined with JAK2 V617F 
this is able to give a myeloproliferative phenotype. 
 
All (5/5) recipients of WT cells overexpressing Meis1 were successfully repopulated 
and 4/5 recipients of Meis1 JAK HOM had chimerism over 1%, equivalent repopulation 
to EV (Figure 52). In WT Meis1 recipients average chimerism was similar to WT EV 
across all timepoints (at 16 weeks p=0.909). Compared to EV JAK HOM, Meis1 JAK 
HOM chimerism was lower at earlier time points (at 4 weeks EV 14.09%, Meis1 
 
Figure 51 Peripheral blood chimerism of recipients of WT and JAK HOM cells 
overexpressing Pbx1 
Recipients of WT cells in blue and JAK HOM in red. For both WT and JAK HOM, one 
mouse was able to generate high donor chimerism, while donor chimerism in the other 
recipients was low. Compared equivalent EV at 24 weeks, WT Pbx1 p=0.562, JAK 
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13.06%, p=0.923), but unlike JAK HOM EV where chimerism begins to fall after 16 
weeks post-transplantation, the chimerism in recipients of Meis1 JAK HOM remained 
relatively stable, although as this level was lower to begin with this is not significant. 
Unlike Runx1 and Pbx1 which, in many cases, seems to induce differentiation leading 
to reduced repopulation, over-expression of Meis1 does not appear to have a negative 
effect upon repopulation, and may have a slight positive effect, not resulting in 
increased chimerism but potentially dampening the fall in chimerism seen in JAK HOM 
alone. 
 
Overexpression of Bmi1 in WT cells resulted in successful engraftment in 3/5 
recipients, average chimerism was lower than for equivalent EV, although chimerism 
seemed to be climbing throughout time course in recipients of WT Bmi1 (Figure 53). 
All recipients of JAK HOM cells overexpressing Bmi1 were positively engrafted. Like 
JAK HOM EV, chimerism of these animals grew throughout early time points, after 
which the chimerism for most mice (3/4) begins to fall – although this is potentially at 
a slower rate than equivalent EV recipients – unlike EV the chimerism of one mouse 
continued to climb in the later timepoints, suggesting that under certain conditions Bmi1 
is capable of restoring JAK HOM self-renewal defect. One JAK HOM Bmi1 recipient 
was culled after 12 weeks, this mouse displayed the same jerky movement/paralysis as 
the JAK HOM Pbx1 recipient and is also suspected of having suffered a stroke.  
 
Figure 52 Peripheral blood chimerism of recipients of WT and JAK HOM cells 
overexpressing Meis1 
Recipients of WT cells in blue and JAK HOM in red. Both WT and JAK HOM recipients 
had chimerism similar to EV controls, compared equivalent EV at 24 weeks, WT Meis1 
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5.2.2 Sustained chimerism leads to MPN phenotype in JAK HOM 
HSCs overexpressing candidate genes in vivo 
As discussed earlier (limiting dilution section 4.2), in JAK HOM BM transplantation 
elevated HCT and HGB are reliant on elevated chimerism. This continues to stand true 
in the setting of HSPCs over-expressing self-renewal genes. In recipients of WT cells 
there is no myeloproliferative advantage and consequently no relationship between 
chimerism and blood parameters (Figure 54 top), the line of best fit not significantly 
deviated from the mean, R-squared of 0.28%, (0% indicates doesn’t explain any of the 
variation around the mean) (HGB p=0.821, Y = -0.003625*X + 14.69, Rsq 0.002282. 
HCT p=0.800, Y = 0.01807*X + 57.85, Rsq 0.002842). In recipients of JAK HOM 
cells elevated chimerism is associated with elevated HCT and HGB (Figure 54 bottom), 
linear regression shows a significant correlative relationship between chimerism and 
HCT/HGB (HGB p<0.0001, Y = 0.1188*X + 14.79, HCT p<0.0001, Y = 0.4703*X + 
60.04), with a R-squared values of 57.00%(HGB) and 51.04%(HCT), indicating that 
over 50% of the spread in the data set can be explained by the relationship between 
chimerism and HCT/HGB.  
 
This correlation combined with the individual gene effects on chimerism can be 
summarised with the haematocrit and haemoglobin at 20 weeks post transplantation 
(Figure 55). All WT recipients had average haematocrit and haemoglobin very similar 
 
Figure 53 Peripheral blood chimerism of recipients of WT and JAK HOM cells 
overexpressing Bmi1 
Recipients of WT cells in blue and JAK HOM in red. Bmi1 overexpression resulted in 
positive engraftment in all JAK HOM recipients. Chimerism compared with equivalent 
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to WT EV, regardless of repopulation status. JAK HOM EV had average HCT and 
HGB similar to WT. Likewise, no elevation in HCT or HGB was observed with 
overexpression of Runx1. Mirroring the effects on chimerism, the majority of Pbx1 
overexpressing have no elevation on HCT and HGB but the one mouse with raised 
chimerism was able to drive a myeloproliferative phenotype (this is the mouse that died 
of suspected stroke). All positively repopulated JAK HOM Meis1 animals had above 
average HCT and HGB; a comparison of repopulated animals showed significant 
elevation in JAK HOM Meis1 recipients compared to JAK HOM EV recipients (HGB 
p=0.049, HCT p=0.019). Overexpression of Bmi1 in JAK HOM cells, like Meis1, 
resulted in HCT and HGB above average in all recipients. Comparison of positively 
 
Figure 54 Correlation between chimerism and blood parameters in recipients of WT 
and JAK HOM cells 
In WT recipients (top) no causative relationship between chimerism and HGB 
(p=0.8206) or HCT (p=0.8002). In JAK HOM recipients (bottom), there is a significant 
correlative relationship between chimerism and HCT/HGB (HGB p<0.0001, HCT 
p=0.0001), R-squared values of 57%(HGB) and 51.04%(HCT). Solid line is line of best 
fit, horizonal dotted line shows average HCT/HGB for WT EV recipients, vertical 
dotted line at 1% represents the cut off for positive repopulation. Colours correspond 
with gene being overexpressed; EV=purple, Runx1=green, Meis1=red, Pbx1=blue 
and Bmi1=yellow.   
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repopulated JAK HOM EV mice with JAK HOM Bmi1 mice revealed this increase was 
significant (HGB p=0.050, HCT p=0.017). 
5.2.3 Transplantations of JAK HOM cells overexpressing key genes 
can result in splenomegaly 
Extramedullary haematopoiesis is a common feature of MPNs; the disease clone 
disrupts the BM microenvironment, disrupting trafficking and normal haematopoiesis, 
and driving haematopoiesis into secondary sites, like the spleen. This leads to an 
accumulation of cells in the spleen, resulting in enlargement of the spleen – 
 
Figure 55 Haematocrit and haemoglobin in recipients of WT or JAK HOM cells 
overexpressing candidate genes at 20 weeks post transplantation 
Filled circle represents chimerism over 1% i.e. successfully repopulated. Dark circle 
represents a mouse that died before 20-week time point (data from last available 
timepoint). Comparison of repopulated mice revealed significant elevation of HCT and 
HGB in recipients of JAK HOM cells overexpressing Meis1 (HGB p=0.049, HCT 
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splenomegaly.265 30-40% of PV patients develop splenomegaly during the course of 
their disease progression.266  
 
Some transplantation recipients developed splenomegaly, as determined by increased 
spleen length and weight (Figure 56 top). Of the mice with severely enlarged spleens 
(over 2cm), all were recipients of JAK HOM cells; one Pbx1, one Bmi1, and one EV.  
Only JAK HOM Meis1 recipients had statistically larger spleens than WT EV recipients 
(length, p=0.019, weight p=0.017) (Figure 56 bottom). 
 
5.3 JAK V617F gene expression in other settings  
One of the large unanswered questions in the MPN field is if JAK2 V617F confers a 
self-renewal disadvantage then why/how do patients with mutant JAK2 alone present 
with an MPN phenotype? Relatedly, in mice receiving high cell dose transplantation, 
how can JAK2 alone lead to an MPN phenotype?  
 
 
Figure 56 Assessment of spleen size in recipients of WT and JAK HOM cells 
overexpressing candidate genes 
Representative images of a normal and an enlarged spleen. Spleen weight and spleen 
length only significantly larger than WT EV recipients in recipients of JAK HOM cells 
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Gene expression analysis of the four self-renewal genes Bmi1, Meis1, Pbx1, and Runx1 
was performed to assess whether JAK mutant alone HSCs that are able to give an MPN 
phenotype, have achieved elevated Bmi1, Meis1, Pbx1, and/or Runx1 (thereby restoring 




Figure 57 Gene expression of Bmi1, Meis1, Pbx1, and Runx1 in bulk HSPC post-
transplantation samples 
HSPCs (CD45+CD48-CD150+) were sorted from the BM of WT and JAK HOM whole 
BM transplantation recipients. From these mRNA was isolated, cDNA synthesised, 
and gene expression assessed by qPCR using TaqMan probes. No significant 
differences were seen between WT and JAK HOM cells in their expression of 
Bmi1(p=0.705), Meis1(p=0.400), or Runx1(p=0.581) or Pbx1 (p=0.174). Relative 
expression calculated as 2-DCT. Below threshold samples are entered at 0.0001 in grey. 
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5.3.1 Bulk qPCR lacks power to detect changes in key genes in post-
transplantation murine HSPCs 
Donor HSPCs (SLAM) from 4 WT and 5 JAK HOM transplantation recipients were 
isolated, mRNA extracted, cDNA synthesised, and qPCR performed (Figure 57 top). 
No significant differences were seen between WT and JAK HOM cells in their 
expression of Bmi1(p=0.705), Meis1(p=0.400), Runx1(p=0.581) or Pbx1 (p=0.174) 
(Figure 57). This is unsurprising for two reasons; firstly, the qPCR was performed on 
bulk samples, and the assayed population encompassed both stem and progenitor cells. 
The proportion of stem cells in the assayed population is therefore small (especially in 
JAK HOM animals which have a progenitor expansion), it is therefore difficult to detect 
changes in self-renewal genes which are predominately involved at the stem cell level. 
Secondly, as the changes induced by JAK2 V617F are subtle, a shift in the balance of 
WT HSCs, they can only be seen at single cell level; bulk gene expression analysis by 
microarray between JAK HOM and WT HSCs only reveals changes in cell cycle.229  
5.3.2 Differences in expression of key genes seen in MPN patient 
samples   
To assess whether BMI1, MEIS1, PBX1, or RUNX1 expression is altered by JAK2 
V617F/TET2 mutation in patients, gene expression in HSC-enriched CD34+CD38- 
population (~1 in 617 HSCs267) was assessed by qPCR from primary patient samples 
bearing JAK2 V617F and/or TET2 mutations. (Figure 58 top) 
 
In agreement with the mouse model data, CD34+CD38- cells from patients with only a 
JAK2 mutation had significantly lower MEIS1 expression than non-mutant individuals 
(Figure 58 middle right, p=0.019), whereas in patients with both JAK and TET 
mutations MEIS1 expression was not significantly different from non-mutant 
individuals. BMI1 expression was significantly lower in patients with JAK2 and TET2 
mutation than in non-mutant individuals (Figure 58 middle left, p=0.046) and JAK2 
mutation alone patients (p=0.022), this is due to BMI1 expression being below detection 
threshold in JAK2 and TET2 double mutant patients. No significant differences were 
observed in PBX1 or RUNX1 expression between non-mutant individuals and those 
with JAK2 or JAK2 and TET2 mutations (Figure 58 bottom). However, in agreement 
with mouse data, PBX1 expression was higher in individuals with JAK2 and TET2 
mutations than in individuals with a JAK2 mutation alone (p=0.026). 
  Results 
 126 
 
There are a number of reasons why differences might not be seen in the expression of 
self-renewal genes in patient samples. Firstly, these are bulk samples, as in the mouse 
it is expected that the changes evoked by JAK2 mutation would be fairly subtle, 
affecting changes in the balances of types of stem cell within the stem cell pool, this 
 
Figure 58 Gene expression of BMI1, MEIS1, PBX1, and RUNX1 in bulk 
CD34+CD38- human samples 
Schematic of experimental procedure; bulk CD34+CD38- cells were sorted from normal 
individual or MPN patients with a JAK2 V617F mutation alone, or a JAK2 V617F in 
combination with a TET2 mutation. From these samples’ mRNA was isolated, cDNA 
synthesised, and gene expression assessed by qPCR using TaqMan probes. MEIS1 
expression was lower in JAK alone patients than normal individuals (p=0.019). BMI1 
expression was lower in JAK2/TET2 mutant patients than JAK2 alone (p=0.022) and 
normal individuals (p=0.046) PBX1 expression was higher in double mutant patients 
than in JAK alone patients (p=0.026). No significant changes were seen in Runx1 
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kind of subtle change cannot be detected at the bulk level. Secondly, the CD34+CD38- 
population is far from a pure population of stem cells (approximately 1 in 600), making 
it very difficult to gain a meaningful insight into expression of self-renewal associated 
genes which are only expressed at the very top of the haematopoietic hierarchy. Thirdly, 
the different mutations will also cause shifts in the ratios of different cell types within 
the CD34+CD38- population, as in the bulk post-transplantation gene expression above 
the disruption in the balance of cell types can cause changes in the expression levels of 
genes in a bulk population. Fourthly, unlike mouse models, patients are not 100% 
mutant. A patient with mutations in both JAK2 and TET2 genes will have cells with no 
mutations, cells with a JAK2 or TET2 mutation alone, and cells with both mutations. 
A bulk assay is an average of all cell types presented, the relative proportions of each 
population and their contribution to the gene expression is unknown.  
 
Due to these reasons this experiment lacked the necessary power to assess the effects 
of JAK and TET mutations on the self-renewal regulators of HSCs in settings like 
patients and post-transplantation. These findings highlight power of single cell 
approaches in unpicking the molecular networks of haematological malignancies 
(unable to see changes in bulk but are able in single cell), and sets the stage for the 
advent of new techniques combining single cell transcriptomics with targeted 
sequencing to overcome the problems connected with assessing gene expression 










In order for a cancer to develop and maintain itself from a single HSC, the HSC and its 
progeny must be able to thrive relative to the endogenous population of non-malignant 
HSCs. Understanding the relative self-renewal and proliferative capacity of HSCs in 
malignant and non-malignant populations is therefore crucial if malignant HSCs are to 
be effectively targeted.  
 
As many leukaemias are complex and have many mutations, simplified disease models 
like MPNs are a useful starting point from which to study the effect of combinations of 
mutations. Where combinations of mutations are common, it becomes increasingly 
important to study both the mutations individually and in combination in order to gain 
a full appreciation of how the mutations interact to influence self-renewal and 
proliferation, and how the cancer develops though the sequential acquisition of a series 
of mutations. Combining the latest advances in single cell techniques with recently 
developed mouse models, it is now possible to understand more deeply the precise 
mechanisms involved in malignant HSC self-renewal.  
 
In this thesis I establish the in vitro proliferative capacity, and in vivo self-renewal 
potential of HSCs from JAK2 V617F, TET2 knock-out and double mutant animals. I 
then identify the distinct molecular profiles that correlate with the observed HSC 
functional properties in mouse models where JAK2 V617F drives hyperproliferation, 
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TET2 loss increases self-renewal and double mutant HSCs have increased self-renewal 
and hyperproliferation. This is followed by genetic rescue experiments to identify 
which self-renewal regulators are critically involved in partnering with JAK2 V617F 
to drive a myeloid malignancy. Together, these single-cell approaches refine the 
molecules involved in clonal expansion of MPNs and have broad implications for 
deconstructing the molecular network of normal and malignant stem cells.  
 
In chapter 3 I utilised single cell in vitro culture of HSCs to investigate the effect of 
common myeloid malignancy mutations on the cell cycle kinetics of HSCs. 
Comparison of WT HSC and HSCs with loss of TET2 revealed that this mutation does 
not affect the proliferation kinetics of HSCs. On the other hand, JAK2 V617F mutation 
alone caused a significant acceleration of cell cycle kinetics. When these two 
commonly co-mutated mutations were combined (homozygous JAK V617F with either 
heterozygous or homozygous loss of TET2) it was revealed that double mutant HSCs 
have cell cycle kinetics accelerated to the same extent as JAK2 V617F alone. This 
finding establishes for the first time that loss of TET2 does not restrict (or amplify) the 
hyperproliferative properties of JAK2 V617F in culture.  
 
A selection of mouse models of myeloid malignancy mutations (p53, NPM1, CBP, 
CALR) were then assessed to determine the commonality of these effects across types 
of mutations. While many of these mutations have been reported to affect the cell cycle 
properties of cells, the study of HSCs at the single cell level still remains relatively rare 
and this represents the first direct comparison of this number of myeloid malignancy 
mutation models HSCs in vitro. From these data we are able to conclude that while 
CALR mutation affects the same pathway as JAK2 V617F and both mutations 
accelerate cell division kinetics, they do not have identical effects on HSCs in culture 
(JAK2 HSCs have quicker entry into cell cycle than CALR mutant, and CALR 
producing larger clones after 10 days in culture than JAK2 mutant). CBP and NPM1 
mutations imposed delayed cell division kinetics upon HSCs. P53, the most common 
oncogenic mutation, did not cause any deviation from WT cell division kinetics. The 
assessment of these mutations established that the speeds exhibited by JAK and TET 
mutant HSCs did not represent the extents of the assay (i.e. both fast and slower cell 
division kinetics are possible) and established that myeloid malignancy mutation 
cannot be ‘grouped’ by their in vitro characteristics.  
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The effects of JAK2 V617F and loss of TET2 function were then validated in the human 
setting using data from MPN patient samples. The human data supported the mouse 
findings that JAK2 V617F drives an acceleration in cell cycle kinetics, an effect that is 
not hampered by the loss of TET2. These conclusions in patient data add conviction to 
the strength of the mouse models in recapitulating this disease.  
 
In chapter 4, I explored the in vivo myeloproliferative and self-renewal capacity of 
JAK2 and TET2 mutant murine bone marrow. As the double mutant model had not 
been tested in the transplantation setting previously, it was first established that this 
model is capable of imparting an MPN-like phenotype upon transplantation. This was 
established by non-competitive transplantation of whole BM from JAK2 TET2 double 
mutant animals. Recipient mice displayed elevated haematocrit and haemoglobin, 
representative of a PV-like MPN phenotype.  
 
Through competitive limiting dilution, it was determined that transplantation of 50,000 
JAK HOM TET HOM cells or more are capable of initiating this MPN-like phenotype. 
This transplantation also established that (in the primary setting) that double mutant 
BM has equivalent repopulation and short-term self-renewal capacity to WT BM.  
 
The gold standard for determining the self-renewal potential of a cell population is 
competitive serial transplantation. Competitive BM transplantation from JAK2 V617F 
donors confirmed previous reports that JAK2 V617F alone has a self-renewal defect 
resulting in the exhaustion of the donor population. Loss of TET2 had chimerism, on 
average, similar to WT donors. Combining JAK2 V617F with heterozygous loss of 
TET2 partially rescued the self-renewal defect imparted by JAK2 V617F, slowing the 
exhaustion of the donor population. Homozygous loss of TET2 combined with JAK2 
V617F lead to rescue of the JAK2 V617F self-renewal defect, allowing serially 
transplantable sustained chimerism and the accompanying elevation of haematocrit and 
haemoglobin.  
 
These findings, combined with the in vitro findings of chapter 3, allows proliferative 
and self-renewal characteristics to be assigned to HSCs of each mutational status; JAK2 
HOM HSCs have a proliferative advantage leading to erythrocytic expansion, however 
this comes at the expense of reduced self-renewal, JAK HOM HSCs are less 
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competitive than their WT counterparts and exhaust upon competitive transplantation. 
Loss of TET2 does not affect the speed of HSCs proliferation nor does it have a 
substantial effect on self-renewal when compared with WT cells. JAK HOM TET 
HOM HSCs have the proliferative advantage of JAK2 V617F alone, but with self-
renewal restored to WT levels by the loss of TET2.  
 
In chapter 5, I coupled these proliferative and self-renewal characteristics with 
expression of genes known to be involved in HSC self-renewal, in order to define the 
molecular mechanisms behind the JAK2 V617F self-renewal defect. For this single 
HSCs from WT, JAK HOM, TET HOM and JAK HOM TET HOM mice were analysed 
for their expression of 45 self-renewal regulators by multiplexed qPCR. The single-cell 
gene expression profiling provided molecular evidence of distinct HSC states, and these 
profiles parallel the unique functional features of HSCs with different genotypes. As 
each distinct molecular profile could be identified in WT HSCs, although sometimes at 
a low frequency, these data suggest that WT HSCs are a heterogeneous mix of cells in 
distinct proliferative and self-renewing states. JAK2 and TET2 mutations disrupt the 
balance of HSC molecular subtypes by restricting the number of HSC states and, 
subsequently, via their downstream progeny, lead to an MPN phenotype. Comparison 
of gene expression between JAK HOM and JAK HOM TET HOM HSCs, which both 
share hyperproliferative properties but differ in self-renewal potential, allowed 
identification of key self-renewal genes under in JAK HOM HSCs; namely Bmi1, Pbx1, 
Runx1, and Meis1. The involvement of these genes in the self-renewal of MPN HSCs 
was then validated by genetic rescue experiments by lentiviral overexpression of each 
gene in JAK HOM HSPCs. Transplantation of these cells was met with variable 
engraftment success. When able to engraft, overexpression of Meis1, Pbx1, or Bmi1 in 
JAK2 V617F HSPCs were able to, in some cases, elicit a myeloproliferative phenotype, 
and in 2 cases resulted in premature death of recipients and splenomegaly.  
 
The expression of these four key self-renewal genes were assessed in post-
transplantation JAK HOM HSPCs and MPN-patient HSPCs, however as stem and 
progenitor cells were assessed at the bulk level no changes in expression of these genes 
was able to be seen; highlighting the power of single cell approaches in uncovering the 
molecular networks governing self-renewal in malignant HSCs.  
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6.2 Discission and remaining questions  
6.2.1 Driver mutations and proliferation  
In this thesis the proliferation of HSCs from a number of myeloid malignancy mutation 
models was explored at the single cell level. Cell cycle kinetics from some of these 
models have previously been studied at the bulk level, however this is the first 
assessment of these models at the single cell level. The benefits of performing this assay 
at the single cell level include the guaranteed clonality of growth, and ability to see the 
heterogeneity in the population. As this is an in vitro system, this assay also has the 
benefit of being relatively fast; within 11 days you can compare key HSC properties 
such as cell cycle kinetics, survival and differentiation. How the single cell function 
data from each model fits into the previously published reports is discussed below. 
 
JAK2  
The data in this thesis shows that homozygous JAK2 V617F confers a proliferative 
advantage onto ESLAM HSCs in culture, resulting in shorter time between cell 
divisions and larger colony size after 10 days in culture.  Previous in vitro reports on 
homozygous JAK2 V617F have established that bulk populations of lineage negative 
FL cells have a proliferative advantage compared to WT cells.228 However, as this assay 
was performed on a bulk population it cannot be determined if the stem cells or the 
progenitors are hyperproliferating, and, if the HSCs are hyperproliferative, if all the 
HSCs are hyperproliferative or if only a subset have enhanced cell cycle properties.  
 
In the heterozygous setting this question had been answered by Kent et al. (2013)230 in 
their study of single cell division kinetics of ESLAM HSCs from heterozygous JAK2 
V617F mice. This study showed that these cells have accelerated cell division kinetics 
when compared with their WT counterparts, and give rise to larger, more differentiated, 
clones after 10 days in culture.230  
 
In contrast with Li et al. (2010)227 where JAK HET had only a modest effect upon 
division kinetics, Kent et al. (2013)230 show a striking effect evoked by this mutation. 
This disparity is likely due to the difference in the Cre drivers of these mouse models; 
the homozygous JAK2 V617F model (used in Li et al. 2010) is activated from foetal 
development (Stella-Cre), whereas the heterozygous JAK2 V617F model (used in Kent 
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et al.) is inducible by pIpC treatment (Mx1-Cre). pIpC treatment is an inflammatory 
stimulus and consequently has broad effects on the haematopoietic system, including 
potentially enhancing proliferation of HSPCs in vivo (also shown to be very leaky in 
same paper).268 Due to this, induction by Stella-Cre may represent a more 
physiologically relevant model, and also allows for generation of homozygous 
mutation, which is more prominent in PV patients, although the deficiency is that it is 
expressed in all cells of the body rather than specifically in the haematopoietic system.  
 
The data in this thesis uses the Stella-Cre homozygous JAK2 V617F model to confirm 
the conclusions of Kent at al.; at the single cell level JAK2 V617F accelerates the cell 
division kinetics of HSCs.  
 
CALR 
Unlike JAK HOM HSCs which have accelerated cell cycling from the first cell division, 
CALR HOM HSCs do not have faster entry into cell cycle, but do have a shorter time 
to second division, and after 10 days in culture produce a larger proportion of large 
colonies than even JAK HOM HSCs. This coupled with the reported normal self-
renewal of CALR HSCs (neither increased nor decreased self-renewal potential as 
determined by serial transplant)201 implies that the speed of exiting the stem cell state 
(i.e. time to first division) is not changed in CALR HOM HSCs but once cycling they 
have substantially elevated proliferative potential.  
 
While JAK2 V617F and CALR del52 mutations both affect the same cellular pathway 
(i.e. the JAK/STAT signalling pathway) and have broadly similar effects in that they 
both cause hyperproliferation, they do not perform identically in culture (or in vivo). 
This could be due to differences in mouse models –  the JAK2 model uses the entire 
human JAK2 gene whereas the CALR model combines the human mutant c-terminus 
with the murine gene, JAK is Stella-Cre (activation from embryo) while CALR is Mx1-
Cre (induced by pIpC treatment, which as mention previously has been proposed to 
accelerate HSPC cycling kinetics)268 – or it may be due to the differences in their mode 
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CBP 
The CBP mutant mouse used in this thesis has been reported to have a myeloid (GM) 
differentiations bias and self-renewal defect, as determined by serial competitive 
transplantation.239 This model has been reported to have a decrease in LSK number 
(progressive over time) and increase in downstream myeloid progenitors (Lin- IL-7- c-
Kithi Sca1-). CBP null HSCs share a number of characteristics with JAK2 V617F HSCs; 
a self-renewal defect, expansion of downstream progenitors, and a myeloid cell bias. 
Despite these similarities, CBP mutant HSCs behave in the opposite manner to JAK2 
mutant HSCs in culture; CBP mutant HSCs have delayed cell division kinetics and 
smaller average clone size after 10 days in culture. 
 
There are several possible explanations for this difference. While in JAK2 mutant HSCs 
the self-renewal defect is suggested to be due to increased proliferation and 
differentiation of these cells (prioritised over slow-dividing quiescent HSCs), this is by 
no means the only way of achieving a reduced stem cell number and activity. HSCs 
could also be lost due to death or direct differentiation, or reduced division frequency 
meaning the stem cell population size is not maintained. In CBP null animals the 
progressive loss of stem and progenitor cells with impeded division kinetics could be 
due to any of these reasons. The myeloid skewing reported in CBP null animals239 
might not represent a myeloid bias of progenitor cells but instead a reduction in 
population sizes of other cell types as stem and progenitor cells exhaust. 
 
TET2 
TET2 has established roles in self-renewal, however few studies (one) look at the 
proliferation of TET2 stem and progenitor cell in culture, instead many focus on 
transplantation and CFCs which can be used to study self-renewal. TET2 knock-out 
LSK cell have been reported to hyperproliferate in vitro211; when 500 LSK cells were 
cultured for 7 days (liquid culture with 4 growth factors - mSCF, mIL-3, IL-6 and EPO) 
they generated more total cells than WT, and when replated in CFCs, TET2 knock-out 
cells were able to generate more colonies. As this is a bulk culture it cannot be known 
if HSCs or progenitors are responsible for this enhanced proliferation.  
 
The data in this thesis shows that TET2 knock-out alone does not impact division 
kinetics of ESLAM HSCs in culture compared to WT HSCs, when cultured with the 
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cytokines SCF and IL-11. The different cell types (ESLAM vs LSK) could be 
responsible for this difference (i.e. in the LSK culture, HSCs might be proliferating at 
normal speed but progenitors hyperproliferating), or the difference in the supplemented 
cytokines might be responsible.  A potential future experiment would be to compare 
the division kinetics of single cell ESLAM HSCs and MPP1 progenitors (Lin-Sca1+c-




NPM1 mutant HSCs have been reported to have increased self-renewal, like TET2 
knock-out HSCs, and a myeloid bias. Despite this myeloid bias, when cultured in 
conditions supporting myeloid differentiation NPM1 mutant HSCs had slower cell 
division kinetics and consequently gave rise to on average smaller colonies that WT 
HSCs. However, these mice also have a reported enhancement of HSC self-renewal,240 
and since accelerated cycling is associated with exiting the stem cell state and 
differentiating,269 it may be that NPM1 HSCs retain their self-renewal state by dividing 
more slowly and that downstream progenitors give rise to the myeloid expansion.  
 
P53 
In this thesis no difference in cell division kinetics was seen in vitro when compared 
with WT HSCs. As P53 is known to affect self-renewal, rather than proliferation, 
through its interaction with EZH2 and subsequent effect on epigenetic regulation (and 
self-renewal potential is not reported in this assay), it is therefore not surprising that 
P53 knock-out HSCs act similarly to TET2 knock-out HSCs (which also have increased 
self-renewal with no proliferative change). However, loss of P53 has been reported to 
accelerate cycling of HSCs in vivo; BrdU (bromodeoxyuridine) staining has shown that 
in vivo an increased proportion of p53-/- HSCs are cycling relative to WT cells, two 
days after administration of BrdU 60% of CD34-LSK cells from p53-/- animals 
contained the stain, vs 30% in WT animals.261 This disparity between in vitro and in 
vivo data could be the consequence of a lack of microenvironmental factors in vitro, 
which may be required for hyperproliferation of P53 knock-out cells. It could also be 
that it is not the HSCs with accelerated kinetics but a downstream progenitor; the cells 
assessed for BrdU staining in vivo were CD34-LSK cells which are reportedly 21% 
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HSCs10, however we might still expect to see this hyperproliferation in culture in the 
day 10 colony size read out.  
 
This model confirms that not all oncogenic mutations affect HSC characteristics in vitro 
and highlights the importance of combining in vitro assays with in vivo experiments to 
validate the observed effects are applied in the complex network/environment of the 
haematopoietic system. Nonetheless, this set of experiments exemplify that valuable 
insight can be gained from studying HSCs in vitro, for example the finding that CALR 
and JAK2 mutations do not cause the same affect on HSC proliferation despite effecting 
the same pathway. These experiments have the additional benefits of being much higher 
throughput than in vivo assays and can therefore be a quicker and easier way to identify 
biological features associated with mutations.  
6.2.2 Differences between effects of JAK2 and TET2 mutation in 
mouse and human  
When the results in mouse models were compared with those from human patient 
samples, some findings were borne out, others were not. In terms of proliferation, JAK 
V617F hHSPC behaved similarly to murine HSCs, with faster entry into cell cycle and 
reduced time to subsequent divisions. However, this hyperproliferative effect did not 
extend to day 10 colony size, with no significant increase in proportion of large colonies 
from JAK2 V617F hHSPCs. The difference in effect of JAK2 V617F on day 10 colony 
size between human and mouse samples could be due to the more mixed starting 
population in the human samples (i.e. hHSPC rather than mouse HSC) having 
lower/finite proliferative capacity. Moreover, the lack of effect of hyperproliferation on 
day 10 clone size could be a consequence of the culture conditions for human HSPCs 
being less well optimised than those for mouse. The reduced efficiency of human 
culture is evident in a number of ways; firstly compared with mouse, a higher 
proportion of sorted hHSPCs do not give rise to a colony which could be due to the 
mixed starting population, more committed progenitors lacking the capacity to form a 
colony under these restricted cytokines/environmental stimuli. Secondly, the cells 
which are able to give rise to colonies grow more slowly than in mouse colonies269 and 
a much smaller proportion are able to reach medium or large size, this is compounded 
by the fact that some human colonies can begin dying after 9-14 days in liquid culture. 
While the culture conditions are not as well optimised for hHSPCs the early division 
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kinetics (i.e., the time to first and second division) are recapitulated in the human JAK2 
V617F cells in line with the mouse data, demonstrating that cells with a JAK2 
activating mutation have faster cell cycle kinetics than those without. 
 
Human HSPCs with a TET2 mutation proliferate in a similar manner to WT cells, but 
unlike TET2 knock-out mouse HSCs, after 10 days in culture a larger proportion of the 
clones from TET2 mutant hHSPCs contain fewer than 50 cells compared to non-mutant 
clones. While the human assay does not commonly produce medium and large colonies 
(due to the slower initial cycling of hHSPCs), the change in the ratio of very small to 
small colonies seems to represent a real change in proliferative capacity of TET2 
mutant HSPCs. This could be a function of the change in the ratio of stem to progenitor 
cells in the HSPC population; TET2 give a self-renewal advantage giving an increase 
in the HSC population, HSCs being quiescent are likely to divide more slowly/exit 
quiescence slower and consequently give rise to smaller colonies. Alternatively, the 
difference could be the result of the fact that in the MPN patients TET2 mutations are 
commonly on a single allele, whereas in the mouse model TET2 is completely knocked 
out. Comparison of TET2 mutant mice (loss of catalytic activity, not whole protein) 
with complete TET2 knock-out mice has revealed that TET2 has non-catalytic roles in 
haematopoiesis.270 TET2 mutation (loss of catalytic activity) leads to an expansion of 
HSPCs and enhanced colony formation compared to WT, but neither the HSPC 
expansion nor colony forming capacity is enhanced to the same degree as in TET2 
complete knock-out. The mice also differ in the diseases they develop with TET2 
mutant animals developing myeloid malignancies while complete loss develop both 
myeloid and lymphoid malignancies.  
 
It is also formally possible that as humans and mice diverged evolutionarily a very long 
time ago, not all protein functions have been entirely conserved, TET2 could have roles 
in human that are absent in mouse. However, this would be unlikely to affect its role in 
leukaemogenesis since in both cases loss of function mutations are associated with 
myeloid malignancies. 
 
As mentioned above, neither the starting cell population nor the culture conditions for 
human cells used here are as well optimised as they are for murine HSCs. This is an 
area of ongoing improvement, with recent advances including the combining of 
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coculture methods (on MS5 stromal cells) with addition of various growth factors and 
cytokines.28 However even if human HSC culture were fully optimised, HSC isolation 
from PB is far from ideal. Using the current best sorting strategy from cord blood, only 
~1 in 10 sorted cells is an HSC,29 and this is much lower in peripheral blood or bone 
marrow obtained from patient samples. Until there are advances in the isolation of 
human HSCs, the study of HSCs will remain largely clouded by non-HSC 
contaminants, making interpretation of single cell data extremely challenging. Using 
current methods, studying HSPC fractions permits large effects (that effect both stem 
and progenitor cells) to be seen, like that of JAK2 on proliferation, however more subtle 
changes, such as affecting HSC self-renewal at a modest level, are not resolvable. 
Therefore, until this technical barrier is surmounted, the study of HSC mechanisms will 
continue to rely on mouse models. 
6.2.3 Order of mutation acquisition  
Like in mouse, human JAK TET double mutant cells act similarly in vitro to cells 
carrying a JAK2 V617F mutant alone, with accelerated cell division kinetics and 
increased proliferation. This allows the same conclusion to be drawn in the human 
setting as in mouse; namely that JAK2 V617F hyperproliferation is not restricted by a 
concomitant loss of function TET2 mutation. It should be noted that in the patients the 
mutations are acquired sequentially, either JAK2 first or TET2 first, whereas in the 
mouse models used in this thesis, both mutations are germline. This could have some 
consequences, since the order of mutation acquisition has been shown to influence both 
the clinical features of disease (e.g. disease subtype and risk of thrombosis), as well as 
aspects of HSPC biology (e.g. CFC generation capacity and balance of progenitors).190  
 
The order of mutation acquisition represents an important and understudied aspect of 
combining mutations. A proposed future experiment is to model the order of JAK2 and 
TET2 mutation acquisition in mice. Modelling the order of mutation acquisition in 
mouse rather than human has a number of advantages; firstly, it is possible to isolate 
HSCs at a much higher frequency in mouse than in human. Secondly, reporters can be 
introduced alongside mutations, allowing for easy prospective isolation of cells with 
different genetic alterations (in humans the mutations present can only be 
retrospectively identified). This also widens the scope of assays which can be 
performed on HSCs of different mutational status as the assays no longer need to result 
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in the growth of a colony for retrospective genotyping. Thirdly, patients are influenced 
by a huge number of external factors (differences in lifestyle, smoking, diet, etc) which 
cannot be controlled for, in mouse it is possible to control for these factors as well as 
others, such as time of acquisition of first mutation and length of time to acquisition of 
second mutation.  
 
Even more practically, the order of mutation acquisition could be modelled by lentiviral 
overexpression of JAK2 V617F in TET2 knock-out HSCs, and by shRNA (short 
hairpin RNA) knock-down, or CRISPR knock-out of TET2 in JAK2 V617F HSCs. 
Alternatively, the order of mutation acquisition could be modelled by crossing the 
current models with inducible models. The crossing of  TET2 knock-out mice with an 
inducible JAK2 V617F model (e.g. pIpC inducible 271) would allow the modelling of 
‘TET first’ order, and crossing the JAK V617F mouse with an inducible TET2 knock-
down model,272 would act as the ‘JAK first’ model. The resultant HSPCs could be 
assessed in many of the same ways as the mouse models in this thesis; in vitro for their 
time between cell divisions and subsequent day 10 clone size and composition, and in 
transplantation for their myeloproliferative phenotype (order affects PV vs ET) and 
self-renewal capacity, and for differences in gene expression between the orders (and 
similarity to single mutant HSCs). 
6.2.4 Transplantation variability in recipients of TET2 bone marrow 
In competitive transplantation, it was seen that recipients of TET2 knock-out BM had 
highly variable chimerism (section 4.3). From published literature TET2 knock-out 
HSCs have a self-renewal advantage,135,210,211 resulting in high chimerism when 
competitively transplanted. The low chimerism in some of the recipients in this thesis 
is therefore somewhat perplexing. One potential technical cause of this could be sub-
optimal transplantation injection resulting in a lower dose of cells being transplanted 
but there are a few reasons why this is unlikely to be the cause. Firstly, the number of 
donor and competitor cells is within the normal range, implying that transplantation 
itself was performed adequately. Secondly, the same variability in chimerism is seen in 
TET HOM alone and JAK HOM TET HOM recipients but not in WT recipients, 
consequently it seems to be a phenotype associated with loss of TET2 and not one of 
the experiment in general.   
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A further potential explanation for the difference between this thesis and previous 
studies might lie in the different transplantation recipient strains used. Previous 
transplantation of TET2 knock-out cells have used lethally irradiated Bl6 mice as 
recipients,135,210,211 whereas in this thesis the recipients were sub-lethally irradiated 
W41 mice. W41 mice have a partial loss of function in the SCF receptor c-Kit, this 
mutation results in an HSC defect.95,273 This defect allows these mice to act as 
transplantation recipients after receiving a sub-lethal dose of irradiation as the 
recipients own HSCs are less competitive and therefore outcompeted by transplanted 
donor cells. As W41 mice only receive sublethal irradiation they have reduced 
morbidity and mortality compared with other models that require lethal irradiation and 
are consequently ethically preferable. A potential reason why transplantation of TET2 
knock-out cells into W41 recipients might differ from Bl6 recipients could be due to 
differences in extramedullary haematopoiesis. TET2 knock-out animals have been 
reported to have an increase in extramedullary haematopoiesis, and the increase in self-
renewal seen in TET2 knock-out mice could be the result of, not of an increased 
intrinsic self-renewal capacity, but an extension of the niches in which an HSC is able 
to self-renew. While sublethal irradiation of W41 mice is sufficient to allow 
engraftment of transplanted donor cells in the BM, it may be that sub-lethal irradiation 
is insufficient for evacuation of extramedullary haematopoietic sites, meaning TET2 
knock-out HSCs would be unable to occupy all the same sites in W41 recipients as in 
Bl6 resulting in reduced self-renewal and consequently lower chimerism. Supporting 
the hypothesis that splenic sites may be occupied in sub-lethally irradiated W41 mice, 
it has been reported that other c-Kit mutations (KitW-sh) cause extramedullary 
haematopoiesis in the spleen.274 Alternatively, it may be that the difference between 
lethal and sub-lethal results in other microenvironmental and inflammatory changes 
that effect TET2 knock-out HSCs. A potential future experiment would be to do an 
assessment of the impact of different recipient strain and irradiation doses on TET2 
self-renewal capacity.  
6.2.5 Functional assessment of combinatorial mutations  
While combinations of mutations are common in patients, and the number of double 
mutant mouse models is increasing, there are limited reports on the functional effect on 
HSCs of co-mutation of JAK2 and TET2. Primary competitive transplantation has been 
performed on the only other published JAK2 V617F/TET2 knock-out mouse model.225 
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This group transplanted LSK cells from each genotype alongside WT LSK and 
reported, in agreement with the data in this thesis, that loss of TET2 in combination 
with JAK2 V617F improved chimerism when compared with JAK2 V617F alone. This 
study did not include secondary transplantation so robust conclusions could not be 
drawn about the long-term self-renewal of double mutant HSCs, but the data in this 
thesis would support it being robust in serial transplantations. 
 
The findings of this thesis and Chen et al., that loss of TET2 function improves JAK2 
V617F HSC function in transplantation, is also supported by xenotransplantation 
findings. When CD34+ cells from JAK2 V671F MPN patients low allele burden (less 
than 50% in granulocytes) were transplanted into nonobese diabetic/severe combined 
immunodeficiency (NOD/SCID) mice, cells were unable to engraft in recipients.275 
However when xenotransplantation was performed from patients with both JAK2 and 
TET2 mutations, donor CD34+ cells showed enhanced repopulating capacity compared 
with JAK2 mutation alone.276 This would suggest that patient JAK2 V671F HSCs do 
not display a robust proliferative advantage but instead have reduced engraftment and 
limited self-renewal capacity,277 in agreement with some mouse models.228 This also 
supports mouse model findings that loss of TET2 improves the ability of JAK2 V617F 
HSC to sustain long-term engraftment in transplantation recipients. The inability of 
JAK2 V617F patient samples to reliably engraft in mice is also one of the key reasons 
why mouse models have been so heavily used to study this mutation. 
 
While this thesis focused on the effect of combinations of mutations on HSCs, this is 
by no means the only cell population likely to be affected by the mutations. It has 
previously been reported that both JAK V617F and TET knock-out mutant mice have 
expansion in their progenitor compartments.135,210–212,228 Meanwhile JAK V617F/TET2 
knock-out have not been reported to have an expansion in progenitors in BM (but do 
have expansion in spleen225). The data in this thesis agrees with these reports. 
Unpublished 10X transcriptomic data has further suggested that both JAK2 V617F and 
TET2 knock-out mice have increased cell cycle kinetics in multipotent progenitors (S 
Watcham, personal communication) which could explain these expanded population 
sizes. A potential future experiment would be to determine if immature progenitors 
(MPP1, Lin-Sca1+c-Kit+CD48-CD150+CD34+FLK2-) from JAK HOM alone, TET 
HOM alone and double mutant animals have different cell cycle kinetic in vitro. This 
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would be assessed by single cell sorting of MPP1s into erythroid permissive media (and 
the standard media used in in vitro experiments in this thesis), and tracking the cell 
division kinetics, and assessing the clone size and composition after 14 days by flow 
cytometry.  
6.2.6 Unpicking the molecular states of HSCs – molecular drivers of 
cellular properties  
In the assessment of HSC gene expression, approximately 25% of the JAK HOM HSCs 
had reduced expression of the key self-renewal regulators Bmi1, Meis1, Pbx1, and 
Runx1. One potential explanation for the increased proportion of cells lacking HSC 
self-renewal regulators in the JAK2 homozygous mouse is that the phenotypic HSC 
gate (ESLAM) captures a different proportion of HSCs compared with contaminating 
progenitors than its wildtype littermates (e.g. there are more contaminating non-HSCs).  
Several lines of evidence suggest this would not be the case, including the similar 
reduction in HSC number using an alternative sorting gates (Lin-Sca1+c-Kit+CD34-
Flk2- 164) and the observation that HSCs with similar molecular programs are present 
in WT mice (albeit at a lower frequency), but not in the TET knock-out or double-
mutant cells. In either case, as this molecular study represents a static picture taken at 
a single developmental stage (3-4 months) and does not give any information regarding 
the dynamics of the HSC compartment, it is not currently possible to resolve the 
relationship of impaired to unimpaired HSCs, and we cannot yet ask questions of 
primacy or relatedness. 
 
The molecular signature of TET HOM HSCs partially overlaps with JAK HOM TET 
HOM HSCs but neither overlap with JAK HOM HSCs. The genes with reduced 
expression in TET HOM HSCs (that are not reduced in JAK HOM TET HOM) are Vwf, 
Gata3, Prdm16, and Tal1. Previous gene expression profiling of TET2 knock-out cells 
have reported significantly downregulation of Hoxa9 in LSK cells and Gata2 in Lin- 
cells.270 This study agrees that Gata2 expression is reduced in cells with loss of TET2 
(with or without JAK2 V617F), but reduction in Hoxa9 is not observed. Interestingly, 
many of the genes with reduced expression in models with loss of TET2 (TET HOM 
and JAK HOM TET HOM) are associated with higher expression in ‘true’ HSCs (gene 
expression signature of overlapping region of different HSC gating strategies27), i.e. 
Gata2, Gata3, Gfi1b, Itga2b, Prdm16, Procr, Tal1, and Vwf. There are many processes 
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central to maintenance of an HSC “state”, including self-renewal, quiescence, avoiding 
apoptosis, maintaining multilineage capacity, and avoiding differentiation. Loss of 
TET2 has been linked to increased self-renewal, but this may not represent an increase 
in total ‘stem-ness’. The difference in gene expression between TET mutant HSCs and 
‘true’ HSCs might be related to some of these other processes. Indeed, Vwf, Itga2b 
(CD41), and Gfi1b have been linked with megakaryopoiesis, Tal1 has been implicated 
in formation, but not maintenance, of HSCs, and Prdm16 has been implicated in 
avoiding apoptosis and division (deletion enhances apoptosis and cycling of HSCs).  
 
Gene expression profiling has previously been performed on bulk LSK populations 
from JAK2 mutant, TET2 knock-out and double mutant mice by Chen et al. (2015)225 
by whole genome Illumina MouseRef-8 v2.0 gene expression arrays (microarray). This 
yielded identification of 17 differentially expressed genes between the 3 groups. The 
authors then employed gene set enrichment analysis to look for more subtle changes in 
the transcriptome evoked by these mutations and found that targets of STAT5 signalling 
were differentially expressed in JAK2 mutant and double mutant LSK cells (but not 
TET2 alone), and an HSC self-renewal signature was significantly enriched in TET2 
knock-out and double mutant (but not JAK2 alone). While this is supportive of the 
increased self-renewal of HSCs with a TET2 mutation, the lack of detection of 
individual differentially regulated genes means that the individual genes responsible 
for the defect cannot be identified and validated without using single cell approaches. 
 
None of the differentially regulated genes identified in this study are implicated in self-
renewal and the lack of differential expression of self-renewal genes between the JAK2 
and double mutant cells is unsurprising for three reasons. Firstly, the assayed cell 
population, LSK, is a very broad population, while this gating encompasses all HSCs 
it also includes many other cell types and HSCs are at a very low frequency (~10% 278). 
Changes affecting gene expression in HSCs are therefore unlikely to be observed in 
this population. Secondly, even if a more purified population of stem cells was assayed, 
changes in self-renewal regulators might not be seen as in this case since a bulk gene 
expression assay was performed. From the single-cell gene expression data in this 
thesis, the majority of JAK2 V617F have ‘normal’ expression of self-renewal regulators 
and only a subset of JAK2 mutant HSCs that have reduced expression of key self-
renewal genes drive the differences observed. Subtle changes in the relative balance of 
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‘types’ of HSC therefore cannot be detected at the bulk level and are further supported 
by the presence of WT cells across the entire molecular landscape (i.e., all molecular 
subtypes are possible, but a mutation selectively enriches/depletes one type over 
another). Thirdly, this paper uses a ‘whole genome’ microarray approach, where 
amplification occurs prior to hybridisation and could result in biases in genome 
coverage and representation bias,279 in the presence of mutations like JAK2 V617F 
which have such a large effect on proliferation. This takes over the gene signature and 
it cannot be determined if the absence of self-renewal genes in the gene expression 
profile is due to down regulation of these genes, or if the transcriptome is being flooded 
with proliferating genes, obscuring the presence of lowly expressed self-renewal genes.  
 
With new technologies improving the depth of sequencing and reducing the cost, 
unbiased approaches are becoming more popular while targeted approaches fall out of 
fashion. In contrast to this, the data in this thesis rather demonstrates the power of 
targeted approaches for unravelling molecular networks associated with individual 
properties. 
6.2.7 Implications for other genetic drivers 
From the clustering and PCA, key self-renewal genes under-expressed in JAK HOM 
HSCs were identified; Bmi1, Pbx1, Runx1, and Meis1. The other change in gene 
expression between JAK HOM HSCS and JAK HOM TET HOM HSCs is the reduced 
expression of Gfi1b and Dnmt3a in double mutant HSCs. DNMT3A, like TET2, is 
involved in DNA methylation (as discussed in section 1.10.2) and loss of function 
DNMT3A mutations are common in patients with MPN, AML and ARCH. Knock-out 
of DNMT3A in mice leads to expansion of the HSC compartment and increased self-
renewal of HSCs.64 The finding of reduced expression of Dnmt3a in TET2 knock-out 
HSCs implicates DNMT3A in the mechanism of TET2s impact on self-renewal. A 
potential future experiment is to validate this interaction. As Dnmt3a is itself a 
commonly co-mutation with JAK2, knock-down of Dnmt3a in JAK HOM HSC is not 
an appropriate means of validating the effects of TET2 mutation. DNMT3A could also 
be overexpressed in JAK HOM TET HOM HSCs, potentially reversing the self-renewal 
advantage, this is a potential future experiment. This experiment could be complicated 
by the fact that JAK HOM TET HOM, like TET HOM alone, has highly variable 
chimerism (either very high or very low) making changes in self-renewal difficult to 
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confirm unless they are very striking. Another potential future experiment would be to 
cross JAK2 V617F mice with a DNMT3A knock-out model, and to repeat the gene 
expression with another combination of mutations, to see if the same genes lead to the 
restoration of the JAK2 self-renewal defect, or if a variety of self-renewal genes are 
able to restore the defect.  
6.2.8 A role for the Meis-Hox axis in MPNs  
MEIS1 and PBX1 control gene expression through their interaction with HOXA9.  
HOX proteins are best known for their involvement in anterior-posterior patterning in 
drosophila,280 and during development play a fundamental role in the regional identity 
of a wide range of tissue types across diverse taxa. HOX proteins are DNA binding 
proteins, able to bind hundreds to thousands of target genes, the specificity of HOX 
protein binding is assisted by co-factors, and consequently these proteins have an 
important role in gene expression. Hoxa9 is the most highly expressed HOX gene in 
the haematopoietic compartment. MEIS1 and PBX1 are HOXA9 cofactors; HOXA9 
can form a dimer with PBX1 or a trimer with PBX1 and MEIS1.281  
 
Hoxa9, Meis1 and Pbx1 have all been implicated in myeloid malignancies, especially 
AML. HOXA9 overexpression is the strongest predictor or poor prognosis in AML.88 
PBX1 fusion (E2A-PBX1) is a common initiating mutation in ALL.282 MEIS1 has been 
implicated in AML, both as a transcriptional target of MLL-fusion proteins,103 and in 
cytogenetically normal AML, MEIS1 expression is associated with poor prognosis.102  
 
MEIS1, PBX1 and HOXA9 have all been associated with maintenance of self-renewal 
in HSCs. Inactivation of PBX1 leads to progressive loss of HSCs, reduced quiescence, 
and defective self-renewal as determined by serial transplantation. Likewise, loss of 
MEIS1 leads to a reduction in HSC numbers, reduced quiescence, and reduced colony 
formation capacity, and loss of MEIS1 in combination with MLL oncogenes removes 
self-renewal advantage required for myeloid transformation.283 Overexpression of 
HOXA9 results in expansion of HSCs and early progenitors, leading to 
myeloproliferative phenotypes in mice.88 
 
From the overexpression of Pbx1 and Meis1 in this thesis, neither gene drives a strong 
self-renewal advantage. As these gene products form a complex with HOXA9, it may 
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be that Hoxa9 must also be overexpressed for any effect to be visible. This is a potential 
future experiment; overexpressing Meis1 or Pbx1 in combination with Hoxa9 in JAK 
HOM HSCs and assessing for restoration of self-renewal defect. Combining 
overexpression of Hoxa9 and Meis1 has previously been shown to induce AML; 
retroviral over-expression of Hoxa9, Meis1 or Pbx1 alone failed to transform mouse 
BM cells, but combining overexpression of Hoxa9 and Meis1 (but not Hoxa9 and Pbx1) 
was able to induce AML in transplantation recipients, resulting in premature death.284 
As MPNs can transform to AML, it stands to reason that they share some molecular 
characteristics with this more aggressive disease, it might be that high level 
overexpression of Hoxa9 and Meis1 drives AML, but that lower level increases of the 
same genes plays a role in MPNs.  
 
Another potential future experiment could be to disrupt the interaction between PBX1 
and MEIS1 in double mutant cells; Pbx-regulating protein-1 (PREP1) and MEIS1 
compete for binding of PBX1,285 PREP1 has been reported to reduce Meis1 
transcriptional activity and inhibit tumorigenicity.286 Over-expression of Prep1 in JAK 
HOM TET HOM HSCs would determine if disruption of the MEIS1/PBX1 complex is 
sufficient to disrupt self-renewal, potentially identifying a druggable pathway for the 
treatment of MPN patients.  
6.2.9 Resolution of the impact of Runx1 on self-renewal  
The effect of RUNX1 on self-renewal has been the subject of numerous contradictory 
reports. RUNX1 forms the DNA binding subunit for the RUNX1/CBFβ transcription 
factor complex and is essential for haematopoiesis.287 RUNX1 chromosome 
abnormalities are common in AML and ALL (e.g. RUNX1-CBFA2T1, ETV6-RUNX1, 
RUNX1-MECOM (MDS1-EVI1)). Non-translocation mutations in RUNX1 have been 
reported in ALL, AML, MDS, CMML. RUNX1 is one of the most commonly mutated 
genes in MDS, mutated in 10% of patients. In general, RUNX1 mutations are loss of 
function.287  
 
There have been numerous opposing reports on the effect of loss of RUNX1 on HSC 
self-renewal and stem and progenitor cell number. Some stating that loss of RUNX1 
increases self-renewal and stem cell number (limiting dilution288), some that loss of 
RUNX1 decreases self-renewal capacity (in primary transplantation288), and others still 
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that RUNX1 has little effect on self-renewal (as determined by serial 
transplantation115). The results of this thesis show that overexpression of Runx1 has a 
negative effect upon engraftment capacity in both WT and JAK HOM cells. This 
accords with a previous study of Runx1 overexpression, which reports that 
transplantation of BM cells overexpression of Runx1 could not engraft mice,288 
allowing the conclusion that RUNX1 negatively regulates HSCs. 
 
The lack of engraftment from Runx1 overexpressing cells could be a result of 
differentiation or death of the transplanted cells. As loss of function RUNX1 mutations 
cause a differentiation block,289 it could be hypothesised that Runx1 overexpression 
could promote differentiation. RUNX1 has been reported to have roles in 
erythropoiesis; during early erythropoiesis Runx1 levels decline290 and mutant RUNX1 
reduces Burst-Forming Unit erythrocytes (BFUe) formation in CFC (from CD34+ cord 
blood cells).289 Expression of Runx1 in BFUe prevents Pu.1 down-regulation and 
blocks terminal erythroid differentiation.290 Therefore, reduced Runx1 expression in 
JAK HOM HSCs is suspected to be related to erythroid differentiation rather than 
related to self-renewal properties.  
 
This raises another question of why reduced Runx1 expression associated with JAK 
HOM alone rather than JAK HOM TET HOM which shares the pro-erythroid 
phenotype? As just mentioned RUNX1 is involved in the control of PU.1 (gene Sfpi1). 
Sfpi1 was one of the genes identified as being under expressed in JAK HOM cells when 
compared with WT cells (Figure 46) but was not associated with any induvial genotype 
when the four genotypes were compared together (Figure 44). This allows the 
conclusion that Sfpi1 is not responsible for the JAK HOM self-renewal defect and likely 
plays a role in erythroid differentiation. Double mutant cells have found a means of 
achieving low Sfpi1 expression without low Runx1 expression therefore permitting 
erythroid differentiation. These finding in the role of Runx1 shows the importance of 
functional validation of gene expression data.  
6.2.10 Bmi1; a therapeutic target for MPNs? 
Polycomb group proteins form two classes of complex that repress gene transcription; 
polycomb repressive complex 1 (PRC1) and 2. PRC1 ubiquitinates the c-terminus of 
histone H2A and thereby represses target genes. BMI1 is a component of PRC1. A 
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number of the components of PRC2 have been reported as being mutated in myeloid 
malignancies such as EZH2, as well as interacting protein such as ASXL, however the 
subunits of PRC1, including BMI1, have not been reported to be mutated in 
haematological malignancies. Although not mutated in haematological malignancies, 
BMI1 has been suggested as a biomarker in haematological malignancies with higher 
levels of Bmi1 transcript correlating poor prognosis and more severe disease in myeloid 
malignancies (MDS, AML, CML) and lymphoid malignancies (ALL, CLL, mantle cell 
lymphoma).291  
 
Both loss-of-function and gain-of-function studies have revealed a central role for 
BMI1 in the self-renewal of HSCs (loss of Bmi1 gene induces a defect in self-renewal, 
while over-expression promotes self-renewal).50 The strong effect of BMI1 on self-
renewal accords with the results of this thesis where Bmi1 overexpression had the most 
success at restoring the JAK2 V617F stem cell defect (as determined by number of 
positively repopulated mice).  
 
In breast epithelial and breast cancer cell lines histone deacetylase (HDAC) inhibitors 
have been shown to downregulate BMI1 expression.292 HDAC inhibitors have shown 
potential as a cancer treatment across many cancer and tissue types (now combination 
therapy looking more appropriate due to the extensive effects of HDAC inhibitors on 
many biological processes in non-cancerous cells). A potential future experiment is to 
perform preliminary experiments to determine the feasibility of HDAC inhibitors as a 
differentiation therapy for MPNs. This would involve treating JAK HOM TET HOM 
double mutant cells with HDAC inhibitors to determine if this is sufficient to reduce 
Bmi1 expression and consequently disrupt the self-renewal potential of these cells and 
cause graft exhaustion.  
6.2.11 Emerging areas in the study of gene expression and clonal 
expansion for MPN patients  
Assessment of the expression of BMI1, MEIS1, PBX1 and RUNX1 in human HSPCs 
from MPN patients, did not reveal any changes in these genes. As mentioned in the 
results there are a number of reasons why these changes might not be visible by 
profiling human samples in this way (bulk samples, very few HSCs in population, 
mixed genotypes, etc). The goal of dissecting the molecular networks governing 
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malignant HSC self-renewal is to apply the findings to treatment of patients with 
cancer. It is therefore desirable to find a more appropriate and reliable means of 
validating findings, such as those in this thesis, on patient samples. In recent years two 
new approaches have been published which are certain to have large impacts upon the 
study of haematological malignancies in patient samples.  
 
Giustacchini et al. (2017)293 developed a new protocol coupling single cell 
transcriptomics with detection of the BCR-ABL transgene in CML patients by 
multi-plexing BCR-ABL-specific primers at the reverse transcription and amplification 
steps of the scRNAseq protocol. This technology allows sensitive and specific detection 
of the BCR-ABL mutation simultaneously with unbiased whole transcriptome analysis 
of the same HSC, thereby permitting a molecular comparison of mutant to non-mutant 
HSCs in the same individual. After validating the nested priming approach for 
genotyping cells from the transcriptome, this study compared HSCs from normal 
individuals to BCR-ABL+ HSCs and BCR-ABL- HSCs from CML patients.   
 
Perhaps the most interesting aspect of the Giustacchini et al. study was their comparison 
of normal HSCs to non-mutant HSCs in the CML patient which showed striking 
differences in the gene signatures; non-mutant HSCs from CML patients had higher 
expression of genes associated with microenvironmental factors IL-6, STAT5, 
transforming growth factor (TGF)-β and tumour necrosis factor (TNF)-α. As 
inflammation is a suspected suppressor of HSC function,294,295  this suggests that in 
humans, leukaemic stem cells and their progeny might be creating their own self-
supporting niche296 that suppresses normal non-mutant HSCs.  Moreover, response of 
patients to TKI treatment could be predicted by the inflammatory signalling changes 
observed in non-mutant HSCs – again something that could only be detected by being 
able to study these HSCs separately. 
 
However, BCR-ABL, unlike other mutations, only requires a single genotyping assay 
to be developed for all patients, loss-of-function mutations would be less 
straightforward to genotype via the transcriptome in a robust and scalable manner. 
Efforts to scale this to more mutations have nevertheless begun in diseases such as 
AML297 but the efficiencies are not yet at a point where there is a high confidence in 
calling the absence of a mutation. To address this issue Rodriguez-Meira et al. (2019)298 
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have developed a technique combining scRNAseq with targeted mutation sequencing 
from genomic (g)DNA and cDNA, allowing much more accurate calling of mutations 
for which cDNA expression is undetectable or highly allelic-biased.  
 
Using this technique, the group analysed HSPCs from MPN patients with a JAK2 
V617F mutation (either alone or in combination with collaborating mutations such as 
in TET2, EZH2, and ASXL1). The group was able to accurately determine mutation 
burden, order of mutation acquisition, and distinguish heterozygous and homozygous 
JAK2 mutations. As in CML patients, the group determined that non-mutant cells in 
patients are transcriptionally distinct from normal controls with patient cells having 
enrichment of inflammatory pathways (TNF-a, and IFN signalling), MPN 
microenvironments effect on WT cells from same patient.  
 
In agreement with the mouse model data in this thesis, Rodriguez-Meira et al. reported 
distinct and biologically relevant molecular signatures of HSPC subclones with 
different mutational profiles. They also reported that cells with mutations in epigenetic 
regulators had a distinct transcriptional signature whereas the cells with JAK HET more 
closely resembled WT cells. This agrees with the data in this thesis which shows a more 
subtle difference between JAK2 mutant and WT cell than WT cells and cells with a 
TET mutation.  
 
As the approach taken by Rodriguez-Meira et al. was a whole genome scRNAseq 
method, whereas in this thesis a targeted multiplex qPCR approach focusing only on 
stem cell and self-renewal associated genes was used, it is not surprising that 
Rodriguez-Meira et al. report a greater separation between mutant and WT cells, as 
other pathways involved in processes such as differentiation can also contribute to the 
transcriptome. As a consequence of scRNAseq reporting an unbiased but shallow 
transcriptome, the key self-renewal genes identified in this study were not identified in 
the patient data, this does not necessarily mean that these genes do not play a role in 
the self-renewal of patient MPN HSCs, but that technical limitations preclude our 
ability to see their expression. It may be that a future technical development will allow 
addition of targeted gene expression on top the techniques developed by Giustacchini 
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et al. and Rodriguez-Meira et al., however until then the expression of stem cell genes 
in human HSCs with different mutational profiles will remain somewhat unknown.  
 
The second major development turns away from investigation into the molecular nature 
of malignancy, towards the monitoring and understanding of HSC clonal dynamics in 
humans, to understand how a single clone can emerge to drive a leukaemia. This was a 
project I was involved with alongside of my primary project, where we used somatic 
mutation acquisition as an endogenous barcode to study the relative contribution of 
clones over the lifetime of an individual.299 This study was based on the fact that 
somatic mutations are acquired in a linear fashion throughout life, and are stably passed 
down, marking the clonal history of a cell.   
 
We isolated stem and progenitor cells from the peripheral blood and BM of a healthy 
59-year-old individual, and clonally grew 140 colonies which were then whole genome 
sequenced. Subsequently, at time points, we isolated mature cells from the same 
individual, which were subject to targeted bait set sequencing allowing their 
‘relatedness’ to the original HSPCs to be determined. The whole genome sequencing 
of HSPC derived colonies allowed the construction of a phylogenetic tree of the 
haematopoietic system of this individual, and revealed that all blood cells were derived 
from a common ancestor that predated gastrulation (common ancestor with buckle 
epithelium), that in early life the stem cell population grew at a steady rate, and reached 
a plateau by adolescence. Based on the branching pattern of the hierarchy, 
computational simulations estimated of the absolute number of HSCs in this 
unperturbed human individual as in the range of 50,000–200,000, with an average self-
renewal division rate of 2-20 months. From the follow-up time points it was observed 
that many HSCs were contributing to blood production and identified multilineage 
clones, contributing to both granulocyte and B lymphocyte lineages.  
 
In this paper we reported that mature cell contribution was stable across the months 
assessed, we are continuing to collect material from this individual, this will allow 
investigation into the stability of clonal contribution across years and shed light of the 
effects of aging in the haematopoietic system. A potential future experiment is to repeat 
this experiment with MPN patient samples; investigating how acquisition of MPN 
associated mutations affects the dynamics of clonal growth, both on the mutant clone 
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and the surrounding non-mutant clones. This could shed light upon the relative effects 
of different mutations on clonal expansion, and the length of time between an individual 
acquiring a mutation and the presentation of disease. 
 
At present, such techniques are not possible in large numbers of humans, but if similar 
approaches could be devised, studying how clonal dynamics change upon acquisition 
of oncogenic mutations and exposure to environmental or endogenous stresses may 
well become a fruitful line of enquiry.  Until then, in vitro approaches and mouse 
models will be heavily relied upon. The emergence of these new single cell and clonal 
technologies has generated significant enthusiasm amongst researchers and clinicians 
trying to understand the molecular differences between malignant and non-malignant 
cells, including a more complete understanding of clonal competition during disease 
establishment, maintenance and progression.  As mentioned above, the first studies are 
only now starting to emerge as technologies converge; the next few years promise to 
deliver an increasingly detailed understanding of the molecules governing fate choice 
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